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Liver disease is characterised by ongoing inflammation and regeneration the mechanism of
which is incompletely understood, although the Fn14/TWEAK receptor-ligand system may play
a role in cholangiopathies. Currently, the only treatment for end stage disease is transplantation.
This thesis describes the development of ex vivo Normothermic Machine Liver Perfusion of dis-
carded human livers for viability testing, before validation by transplantation and assessment
as a novel model of ischaemia-reperfusion injury. Biliary epithelial cells were isolated, Fn14
expression determined and functional activity of Fn14 stimulation by TWEAK established us-
ing existing in vitro modelling. Ex vivo Normothermic Machine Liver Perfusion was evaluated
as a model of Fn14 expression. Perfusate lactate <2.0mmol/L after 2 hours of normothermic
perfusion and delta lactate concentrations were key determinants in the viability of discarded
human livers. Viability could be predicted earlier using proteomics at commencement of perfu-
sion. Evolution of this model included using a bovine haemoglobin-based oxygen carrier as the
perfusate and successful liver splitting with concurrent perfusion. This ex vivo human system
then investigated the potential role of Fn14 in this newly established, validated model.
Normothermic Machine Liver Perfusion has a significant role in determining viability of dis-
carded human livers and establishing the Machine Criteria Donor.
This thesis is dedicated to my Mum and Dad
(1931-2012). Only with your sustained
presence in body, mind and spirit has this been
achieved.
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1.1 Liver Anatomy and Physiology
To investigate liver disease it is important to understand the fundamentals of liver anatomy and
pathophysiology. Below is a summary to enable an understanding of the data presented later in
this thesis.
1.1.1 Gross Anatomy and Physiology
The liver weighs approximaetly 1500 grammes and is located in the upper quadrants of the
abdomen, mainly on the right side, where is is protected by the spine posteriorly, diaphragm
superiorly and abdominal musculature and ribs anteriorly.[1, 2] The diaphragmatic surface of
the liver is covered with visceral peritoneum except posteriorly where it lies in direct contact
with the diaphragm, known as the bare area, that is demarcated by the reflection of teh peri-
toneum from the diaphragm forming the upper and lower layers of the coronary ligament.[2]
The liver is suspended from the aorta and Inferior Vena Cava (IVC) by the left and right tri-
angular ligaments as well as the falciform ligament.[1] The liver is enveloped by the capsule
made of connective tissue and is largely surrounded by the peritoneum on its visceral surface,
except in the gallbaldder fossa.[2] The liver consists of four non-functional anatomical lobes,
the left lobe, right lobe, quadrate and caudate lobes. The left and right lobes are separated
by the falciform ligament, whilst the caudate lobe lies superoposteriorly and the quadrate lobe
inferoposteriorly.[2] The liver receives its dual blood supply predominantly from the nutrient
rich but oxygen deplete portal vein, itself the confluence of the splenic and superior mesenteric
veins that drain the spleen and bowel respectively.[3] This accounts for approximately 70% of
the blood flow. The remaining 30% is supplied by the oxygenated hepatic artery, itself a branch
of the coeliac artery arising from the aorta superior to the superior mesenteric and two renal
arteries.[1, 3] Of surgical importance is the variation in the vascular anatomy, itself a result of
the emryological origins of the midgut that undergoes a 270o in utero. The liver itself can be
divided functionally into eight segments, originally described by Couinaud, with segments II,III
and IV in the functional left lobe and segments V-VIII in the functional right lobe, demarcated
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by Cantlie’s line running through the gallbladder fossa to the IVC.[4, 5] Segment I is largely
counted as an independent functioning segment. Each of these segments receives blood supply
from branches of the portal vein and hepatic arteries whilst venous drainage is to the hepatic
veins that drain directly in to the IVC and onto the right atrium.[2] Drainage of bile from each
segment converges into the left and right hepatic ducts form the common hepatic duct and, after
storage in the gallbladder, passes into the common bile duct subsequently the duodenum.[2]
The bile duct, hepatic artery and portal vein together form the portal triad that extends from the
porta hepatis to the duodenum encased within the lesser omentum, known as the hepatoduode-
nal ligament.[2] The discovery of this segmental anatomy was pivotal in allowing the planning
and execution of radical resections of liver lesions so permitting onocological clearance whilst
minimising haemorrhage .[6]
The liver performs a number of complex tasks but overall they can be divided into three main
categories. These comprise resorption the storage as well as synthesis and secretion of carbo-
hydrates, lipids, amino acids and proteins.[7] Such proteins include albumin, ceruloplasmin,
acute phase proteins and clotting factors.[7] Additionally, the liver detoxifies bilirubin, alcohol
and ammonium as well as excreting primary bile acids cholic acid and chenodeoxycholic acid
as components of bile.[7] The liver produces approxiamtely 600-750ml of bile per day that is
stored in the gallbladder before being excreted in to the duodenum to facilitate digestion and
subsequent absorption of dietary fat by micelle formation.[7]
1.1.2 Microarchitecture and Function
The functional unit of the liver parenchyma is the hexagonal liver lobule which has the hepatic
vein at its centre with the portal triad of a bile ductule, terminal branch of the heptic artery
and terminal branch of the portal vein at each of its six corners.[7, 8] Heptic arterial and portal
venous mix as it enters the lobule before draining in to the central hepatic vein, whilst bile travels
through the bile canniculus before entering the bile ductules and eventually bile duct.[9] The
most fucntioanly relevant unit of the liver is the liver acinus, composed of the two portal triads
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Figure 1.1: Segmental anatomy of the liver. The functional left lobe of the liver contains seg-
ments II, III (left lateral), IV (medial) whilst the functional right lobe contains segments V &
VIII (anterior), VI & VII (posterior). Segment I is an independent functioning segment.[5]
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and their neighbouring central veins in a diamond shape and reflects metabolic activity.[7, 8]
Split in to three zones, each zone receives differently oxygenated blood with periportal zone I
exposed to the highest oxygen concentrations and zone III the lowest oxygen concentraion.[10]
Each lobule contains all of the cells described below.
Hepatocytes
Hepatocytes are the functioning unit of each lobule and form more than 75% of the weight of
the liver. They are arranged in plates around a hepatic sinusoid. Their primary function is the
detoxification of blood that has drained from the portal venous system from the gut as well as
critical liver function including protein synthesis, coagulation factor production and immune
responses. They have a high metabolic rate with hepatocytes in zone I specialising in oxidative
energy metabolism, amino acid catabolism and fatty acid oxidation. Conversely, lipogenesis,
ketogenesis and metabolism of xenobiotics mainly occurs in zone III, where hepatocytes are
more prone to hypoxic damage.[10] Hepatocytes are derived from foregut hepatic progenitor
cells on exposure to fibroblast growth factors 1 & 2, bone morphogenic proteins 2 & 4 and the
Wnt signalling pathway.[11, 12] It is thought that transforming growth factor β limits the extent
of differenitation.[13] These progenitor cells appear to bipotent with the abilty to differenitate
into either hepatocytes or cholangiocytes btu is dependent on the complex interplay of six tran-
scription factors HNF1a, HNF1β , FoxA2, HNF4a1, HNF6 and LRH-1.[14] Once matured, hep-
atocytes are some fo the largest cells in the body, rich in organelles, can contain two and more
nuclei that reach polyploidy with increasing age and reduced nutrient supply.[7] Hepatocytes
are polarized with the basolateral domain facing the sinusoid, the apical domain facing the same
domain from the opposite heaptcyte forming the bile canniculus containing the ATP-dependent
excretion pump ABC transporter superfamily and the lateral domain containing a series of tight
junctions and cell adhesion molecules used in direct cell to cell communication.[15, 16, 17]
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Figure 1.2: Representation of the structure of the liver lobule. The portal veins and hepatic
arteries terminate in the intrahepatic portal tracts, which contain bile ducts that transport bile
from the canaliculus through the extrahepatic biliary system.[9]
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Hepatic Sinusoidal Endothelial Cells
Human Sinusoidal Epithelial Cells (HSEC) are a morphologically distinct popuation of cells
that line the sinuoids and have multiple fenestrae and lack a basement membrane.[18] They
are separated from the hepatocytes by the perisinusoidal Space of Disse and are often the first
cells to come into contact with blood from the portal triad. One of their cellular functions
is filtration using the fenestrae that have a diameter of approximately 100nm and so serve as
a mechanical sieve.[19, 20] HSEC have an important role in the attraction of leukocytes that
bind to the adhesion molecules on HSEC, such as Vascular Adhesion Protein-1 (VAP-1) that
promotes adhesion and transmigration of leukocytes, particularly as the sinusoid is a low blood
flow environment.[21] Other adhesion molecules such as Vascular Cell Adhesion Molecule
1 (VCAM-1) and Intercellular Adhesion Molecule 1 (ICAM-1) are upregulated during liver
injury.[22] HSEC also have a role in nitric oxide signalling for the autoregulation of blood flow,
endocytosis, bacterial processing and liver regeneration.[7]
Cholangiocytes
Biliary epithelial cells, also known as cholangiocytes constitute approxiamately 5% of the mass
of the liver. They line the lumen of the biliary tree and are polarized with apical and basolateral
domains but are largely mitotically dormant.[23, 24] They play an important role in the forma-
tion of bile by altering the contents of the primary cannicular bile via secretion and absorption
in addition to the detoxification of xenobiotics.[23] Cholangiocytes express numerous G and
non-G protein-coupled receptors including the tyrosine kinase receptors in addition to com-
ponents of the Notch and Hedgehog signialling pathways.[7] Development of cholangiocytes
stems from the differentiation of bipotent hepatoblasts under the influence of the six transcrip-
tion factors above.[14] Ductal plate formation necessary for cholangiogyte expansion appears
to be dependent on the TGF-β gradient and possibly the Notch pathway.[25] The expression of
Sox-9, starting in the periportal region, is an early marker for cholangiocyte differentiation.[26]
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Hepatic Stellate Cells
Hepatic Stellate Cells (HSC) are located in the Space of Disse and store retinyl esters and are
important in the metabolism and storage of retinoids.[27] Activated HSC display a number of
phenotypes including proliferation, migration, contraction, chemoattraction and cross-talk with
the immune system, cancer cells and biliary cells. However, much attention has been paid
to the myofibroblast-like phenotype that produces excessive amounts of collagen types I and
III over the predominant synthesis of collagen IV and the different sources of activation are
being studied to distinguish between differential activated phenotypes.[28] The stiffness of the
extracellular matrix may influence activation as suspension or culturing on matrix similar to
basement membrane inhibits proliferation and collagen deposition.[29]
Kupffer Cells
Kuppfer cells are the resident liver macrophages that reside in the hepatic sinusoids and are
the first immune cells to encounter the antigens and microbe-derived toxins from the portal
vein.[7] Lipolysaccharide, IL-12 and Interferon Gamma (IFN-γ) polarizes Kupffer cells to pro-
duce proinflammatory cytokines such as CCL2 that recruit Ly6C positive monocytes to the liver
as well as Reactive Oxygen Species (ROS) and Tumour Necrosis Factor-alpha (TNF-α) to result
in anti-microbial and tumourocidal activity. The effect of these recruited monocytes is to poten-
tiate the initial response of the Kupffer cells by producing TNF-α , IL-1β , IL-12 and IL-6. These
are known as Classic M1 type Kupffer cells. The alternaitvely activated M2 type Kupffer cells
produce antiinflammatory cytokines such as IL-10, arginase-1 and CD206 and are involved with
tissue repair and modelling, tumour progression and resolution of inflammation.[30, 31, 32]
Extracellular Matrix
The Extracellular Matrix (ECM) is not only an important structural scaffold but also dynami-
cally reguates cell and organ function using signals that are transduced via cellular receptors, the
most widely studied being the integrin family. ECM is composed of a large number of collagens,
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non-collagenous glycoproteins such as laminin and fibronectin, glycoaminoglycans, proteogly-
cans and matricellular proteins that may be released by the degrading matrix proteases.[33]
There is evidence to suggest that the ECM plays a role in the directing teh stem cell niche
during liver regeneration.[34]
1.2 Principles of Inflammation and Its Relationship to Liver
Disease
Chronic inflammation of the liver leads to end stage liver disease and cirrhosis, resulting in
over 1 million deaths worldwide each year.[35] Risk factors are the chronic pathological liver
diseases such as chronic viral infection, in particular hepatitis B and C, Alcoholic Liver Disease
(ALD), Non-Alcoholic Steato-Hepatitis (NASH), autoimmune disease and cholangiopathies,
diseases of the bile ducts, such as Primary Biliary Cirrhosis (PBC) and Primary Sclerosing
Cholangitis (PSC), characterised by destruction of the intrahepatic bile ducts.[36, 37, 38, 39]
Different liver injuries elicit several mechanisms that trigger potentially chronic immune reac-
tions and subsequent fibrosis. These are highly conserved with all diseases involving cell death
but ultimately lead to activation of HSCs producing myofibroblasts, contributing to the produc-
tion of ECM and inflammatory signalling pathways.[40, 41] The HSC interact with other liver
resident cells, such as hepatocytes, HSEC and cholangiocytes, as wel as infiltrating immune
cells to control the development and regression of fibrosis.[42] During extensive hepatocellular
death, fibrosis can be seen to be beneficial by providing mechanical stability, the inflammatory
cells removing cellular debris and inflammatory cells promoting liver regeneration with the aim
of creating normal liver architecture.[43] However, if left unchecked, extensive hepatocellular
deaths results in progressive fibrosis and cirrhosis.
1.2.1 Cell Types That Link Inflammation and Fibrosis
As described previously, HSC are the main effector of fibrosis and interact with hepatocytes,
HSEC, cholangiocytes and Kupffer cells to promote fibrosis, although termination of the re-
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sponse can be achieved when HSCinteract with natural killer cells.[44, 45] The HSC are re-
sponsive to lipopolysaccharide and, once activated via the Nuclear Factor-kappa B (NF-κB)
pathway and AP-1, signal in either an autocrine fashion or recieve signals form immune cells
to maintain their activation.[46] The expression of Toll-Like Receptor (TLR)s provides a link
between the gut either using the portal venous system or lymphatics and the liver.[44, 47]
Hepatocellular death is significantly promotes chromic liver inflammation with necrotic hepa-
tocytes and apoptotic bodies releasing pro-inflammatory and profibrogenic cytokines to activate
HSCs. Cytokine release from hepatocytes under oxidative stress in addition to Damage Asso-
ciated Molecular Patterns (DAMPs) are aso implicated[48, 49] Cholangiopathies, such as PBC
and PSC are strongly associated with inflammation and fibrosis but the relationship between
cholangiocytes and HSCs is not clear.Cholangiocytes are a source of cytokine and chemokines
that interact in particular with T lypmhocytes as well as being responsive to TLRs.[50] The
ductular reaction seen in many cholangiopathies might be related to cholangiocyte proliferation
resulting from the activation of the hyaluronan receptor Cluster of Differentiation (CD)44 fol-
lowing deposition of hylauronan.[51] There is a close relationship between HSEC and HSCs,
with suppression of HSCs by HSEC during normal liver function, but the inability to sup-
press HSC activity following liver injury.[52] This might be mediated by CXCR4, FGFR-1 and
TLR.[42]
In addition to the large number of Kupffer cells, the resident liver macrophages, liver injury
promotes the recruitment of macrophages from the bone marrow that subsequently promote
liver fibrosis by releasing profibrogenic cytokines and maintain activation of HSCs. Polari-
sation of these macrophages to M2 macrophages can promote resolution of fibrosis via the
degradation of of ECM via increased matrix metalloprotease expression.[41] It is reported that
M2 macrophages can also promote resolution by the deactivation and removal of HSCs via
TRAIL.[53]
Natural killer cells and natural killer T cells constitute a high proportion of liver lymphocytes
and are important in exerting an anti-firotic effect.[45, 54] This is mediated via IFN-γ and
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the destruction of HSC via TRAIL and FasL, but this effect is suppressed through elevated
TGF-β concentrations.[55, 56] There does not appear to be a clear role for neutrophils in the
fibrogenesis although they are recruited to the liver.[57] A subset of Innate Lymphoid Cell
(ILC), the ILC2 appear to have a role in fibrosis and epand in response to secretion of IL-33
from hepatocytes that results in activation of HSCs in a IL-13 and STAT6 dependent fashion but
independent of the TGFβ pathway.[58] Although microthrombi are seen in the hypercoaguable
injured liver, suggesting the release of growth factors such as PDGF resulting in the activation
of profibrotic coagulation cascasdes, there are potentially antifibrotic effects exerted by platelets
that is an ongoing active area of research.[59]
1.2.2 Pathways Modulating Hepatic Inflammation
There are a number of different pathways that modulate hepatic inflammation. Triggers of
inflammatory signalling include the gut microbiota-TLR pathway, the inflammatory cytokines,
chemokines, interferons, inflammatory and fibrogenic signals from dead cells.[60]
The gut microbiota-TLR pathway is mediated by bacterial molecules Pathogen-Associated
Molecuar Pattern (PAMP)s via the activation of TLR4. Induction of TLR4, particularly on
HSCs induces expression of chemokines and adhesion molecules to recruit macrophages.[44]
Stimulation of HSEC by TLR4 can induce portal hypertension via fibronectin production from
HSCs.[61] when acting on Kupffer cells, TLR4 elicits expression of pro-inflammatory cytokines
such as TNF-α , IL-β1, CCL2 and CCL20.[62]
Inflammatory cytokines implicated in fibrosis include IL-1β , produced by macrophages and is
of particular relevance in toxic alcohol and NASH induced fibrosis.[63] The cytokine TNF-α
has diverse effects but may contribute to fibrosis preventig HSC apoptosis in addition to pro-
moting hepatocyte apoptosis, immune cell activation and HSC activation.[64] IL-17, produced
from CD4+ Th17 T cells stimulate Kupffer cells and HSCs via activation of NF-κB and STAT3,
inducing HSC activation.[65] In the liver IL-22 suppresses fibrosis by inducing HSC senescence
in a STAT3-p53-p21 dependent manner and can be used clinically as a biomarker to predict the
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prognosis of cirrhosis.[66, 67] TGF-β , produced hepatic macrophages but needing to be ac-
tivated by fr example ROS plays an important role in fibrosis and induces the transcripton of
collagen types I and III in HSC[68]
The function of chemokines and their receptors is the recruitment of immune and non-immune
cells in to the inflammed areas. In particular, CCL2 which is mainly produced by Kupffer cells
and HSCs receruits monocytes and macrophages to the liver and promotes HSC activation.[69]
CCL5 and its receptors CCR1 and CCR5 promote liver fibrosis via mcrophage and HSC respectively.[70]
In comparison, interaction of CX3CL1 with its receptor CX3CR1 on macrophages enhances
macrophage survival, with CX3CL1 expressed on HSC suggesting its anti-inflammatory properties.[71]
Both type I (IFNα and IFNβ ) interferon and type II (IFNγ) interferon are increased in chronic
liver disease.[60] The latter suppresses HSCproliferation directly whilst IFNα reduces collagen
gene transcription in HSCs.[55]
1.2.3 Downstream Signalling Pathways Linking Inflammation and Fibro-
sis
The transcription factor NF-κB acts as a key regulator of inflammation and cell death and is of
importance in chronic liver diseases.[60] It is activated by TLRs, IL-1β and TNF-α and whilst
physiological activation of NF-κB is protective by preventing hepatocyte apoptosis, overacti-
vation in hepatocytes or inflammatory cells induces production of pro-inflammatory cytokines
such as TNF-α , IL-1β and IL-6.[60] Activation of NF-κB in HSCs promotes HSC survival and
thus continuing fibrogenesis that is mediated by IL-1β and TNF-α from Kupffer cells.[72] Fur-
thermore, activation of NF-κB in HSCs initiates chemokine secretion to promote recruitment
and interaction with inflammatory cells, so perpetuating fibrosis.[73]
The c-Jun-N-terminal Kinases (JNK)s are Mitogen-Activated Protein Kinases (MAPKs) acti-
vated by stimuli including TLR, IL-1β , TNF-α , ROS and saturated free fatty acids.[60] In the
liver, substrates for JNK1 and JNK2 are components for the transcription factor AP-1 that in-
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clude c-Jun, Jun B, Jun D and Fos.[60] The JNKs promote fibrogensis by HSC proliferation
via PDGF, TGF-β and angiotensin II as well as collagen production.[74] JNK also modulates
hepatic fibrosis by regulating hepatic steatosis, hepatocyte cell death and inflammatory gene
expression, consolidating its role in liver fibrosis.[75]
1.3 The Tumour Necrosis Factor Receptor Superfamily
The Tumour Necrosis Factor (TNF) receptor cytokines form a superfamily that bind with their
cognate receptors, the TNF Receptor Superfamily (TNFRSF), that are found on the cell surface
of a variety of cells including those involved with immune function.[76] The TNF superfamily
is composed of 19 structurally related ligands that bind to one or more molecules from the
TNF receptor superfamily, a total of 29 structurally similar receptors.[77, 78] A number of
these ligands can be grouped according to chromosomal loci.[76] However, there is complexity
to this receptor-ligand signalling system. Although each ligand, acting in its trimeric form,
was initially thought to bind to its cognate receptor there is considerable crossover between
ligands interacting with various receptors, as summarised in Figure 1.3.[76, 79] Additionally,
ligands are either membrane-anchored or soluble trimers that cluster their cognate receptors to
iniate signal transduction.[80] Activation of the intracellular signalling pathway is initiated via
receptor clustering of the extracellular cysteine-rich domains that utilises a series of adapter
mechanisms that subsequently activates a number of intracellular enzymatic complexes (Figure
1.4).[76, 80]
Generally, the Tumour Necrosis Factor Superfamily (TNFSF) promote either survival or inflam-
matory signalling, for example TNF, lymphotoxin, nerve growth factor, CD40 ligand, OX40
ligand and B cell activating factor.[80] Alternatively, they can induce apoptotic cell death, such
as FAS ligand and TNF-Related Apoptosis-Inducing Ligand (TRAIL).[80] The functional out-
come of TNF ligand engaging with its receptor can include cellular proliferation, death and
differentiation although the mechanisms that determine which fates cells take are yet to be fully
characterised and is dependent on the specific receptor-ligand interaction.[76] The transcription
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Figure 1.3: Summary of the TNF Superfamily. Members of the TNF cytokine superfamily are
represented on the outer aspects (amber ring) and grouped according to chromosomal location
(mauve segments). Members of the TNF receptor superfamily are represented on the inner
aspect (blue ring) and vary in size according to the number of cysteine domains. The blue
arrows represent the specific ligand and cognate receptor interaction, which may include cross-
over as shown.[79]
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Figure 1.4: Inflammatory and death inducing activity of TNFSF. Left, pro-inflammatory activa-
tion by receptor trimerisation allowing the recruitment of TNFR-associated factors that activate
serine/threonine kinase dependent pathways. Right, apoptotic activation by organising TNFRSF
members containing a death domain into timeric configurations to recruit adapter molecules
containing death effeector domains.[80]
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factor NF-κB is thought to play a pivotal role.[76]
Predicting the cellular functional effect following the binding of a TNF superfamily member
with its corresponding receptor is difficult and is further complicated by the ablility of the lig-
ands to act as cosignals.[81] For example, TNFR2 binds its cognate ligand TNF-α and the
secreted ligand lymphotoxin-α , both of which also bind to TNFR1.[82] Other members of the
TNFSF and TNFRSF that are similar include glucocorticoid-induced tumour necrosis factor,
Death receptor 3, TNFRSF9, OX40, CD30.[81] This is further complicated by the interactions
of immediate TNF superfamily members and Herpesvirus Entry Mediator, resulting in a diver-
sity of cellular regulation.[83]
1.3.1 The Fn14/TWEAK Receptor-Ligand System in Organ Inflamma-
tion and Repair
A novel member of the TNF superfamily of ligands called Tumour Necrosis Factor Weak In-
ducer of Apoptosis (TWEAK) and its cognate receptor the type 2 transmembrane protein Fn14
(Fn14) have been implicated in the regulation of hepatic inflammation and tissue remodelling
as part of a broader role for Fn14/TWEAK in progenitor differentiation.[84, 85] TWEAK is
mainly secreted as a soluble cytokine, having been cleaved by the furin proteases, by cells
of myelomonocytic lineage including macrophages.[86, 87, 88] Fn14 is the smallest mem-
ber of the TNF receptor superfamily, has only a single cysteine-rich domain and is the cog-
nate receptor for TWEAK.[79, 88] It is expressed throughout the body and although expres-
sion is generally low in healthy tissues, it is up-regulated in diseased ones.[79, 88] CD163
has been described as a competing scavenger receptor for TWEAK that may have implica-
tions in cardiovascular mortality.[89, 90, 91] Activation of the Fn14/TWEAK receptor-ligand
pathway is involved in myocyte progenitor differentiation and cardiac remodelling and has
been implicated in regeneration, angiogenesis and stromal cell remodelling in response to in-
flammation in rheumatoid arthritis, lupus nephritis, renal tubular injury and graft versus host
disease.[92, 93, 94, 95, 96, 97, 98, 99, 100] Interaction of Fn14 and TWEAK promotes cell
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growth, apoptosis and autophagy through activation of intracellular signalling pathways includ-
ing differential activation of the classical and non-canonical nuclear-factor kB pathways and
the Activator Protein-1 (AP-1) pathway via TNF Receptor Associated Factors (TRAFs) and the
MAPKs respectively (Figure 1.5).[88, 101, 102] The regulation of this incompletely charac-
terised pathway is yet to be fully elucidated.
1.4 Mortality from Liver Disease
Mortality from chronic liver disease has increased in the United Kingdom since 1970 rising
by 50% between 1990 and 2000 resulting in significant morbidity, mortality and healthcare
costs (Figure 1.6).[103, 104, 105, 106] This has been despite significant reductions in the stan-
dardised UK mortality rate for circulatory, ischaemic heart, cerebrovascular, neoplasm, respira-
tory, endocrine diseases and diabetes throughout the same period (Figure 1.6).[106] Mortality
from chronic liver disease can be clustered in to two age demographics (Figure 1.7). Those
aged 45-64 years have had a higher age standardised death rate compared to those aged 25-44
years across all years since 1970.[103] The older demographic started with an age standard-
ised mortality from liver disease of 4-6 per 100,000 population per year, increasing to 8-13
per 100,000 population in 1993 before accelerating to 14-22 per 100,000 population by 2000.
[103] The younger demographic commenced with a age standardised mortality rate of 1-2 per
100,000 population in 1970, before steadily increasing to 4-6 per 100,000 population by the
year 2000.[103] For both age clusters and across all years the rate of age standardised death
rate for males has been at the higher end of each range.[103] Comparing mortality in the UK
with Europe reveals startling differences since 1970. Whilst the age standardised mortality rate
initially increased in Europe between 1970 and 1976 from 13 per 100,00 population to 15 per
100,000 population, there was subsequently a steady reduction to 9 per 100,000 population per
year in 1998, the year data collection was completed (Figure 1.8).[103] In comparison, the age
standarised death rate in the UK between 1970 and 1976 increased from 2 per 100,000 popu-
lation per year to 3 per 100,000 population per year.[103] This gradual increase continued to
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Figure 1.5: The Signalling Pathway after Fn14/TWEAK Interaction. TWEAK binds to its
cognate receptor Fn14 mainly in its soluble form, although it can be cell-bound. Interaction of
TWEAK and Fn14 results in the intracellular domain of Fn14 binding to various TRAFs that
results in the functional activation of canonical and non-canonical NF-κB pathways, as well as
the AP-1 pathway via MAPKs.[88]
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just over 4 per 100,000 population per year by 1993, following which there has been a faster
rate of increase. This has culminated to an age standarised death rate of 7 per 100,000 popu-
lation per year for the UK in 1998.[103] Since 2000, there has been a progressive increase in
liver mortality attributable to alcohol and obesity or diabetes, whilst death from viral hepatitis
and autoimmune or metabolic diseases have remained relatively static, despite an increasing
population (Figure 1.9).
1.5 Liver Transplantation and Meeting the Demand for Or-
gans
1.5.1 Outcome on the Liver Transplant Waiting List
Despite scientific and medical advances, the only treatment for end-stage liver disease is trans-
plantation. Until 2010, the number of patients on the transplant waiting list for all organs had
increased to 8012 before decreasing to 6388 in 2017.[107] The number of patients on the active
liver transplant waiting list demonstrated an increase from 268 in 2008 to 611 in 2015 before
reducing to 530 in 2017, a decrease of 8% compared to the previous 12 months but almost dou-
bling in 9 years.[107, 108] The outcome for patients following registration on the waiting list
varies dependent on time since listing. After 6 months, 51% will have been transplated, 38% are
still waiting, 3% have been removed due to their condition deteriorating and 8% have died.[108]
At 2 years following addition to the waiting list 74% of patients will have been transplanted,
only 5% will still be waiting whilst 8% will have been removed due deterioration and 13% will
have died.[108, 109]
1.5.2 Organ Donation Rates and Changes to Donors
Overall deceased donor rates have continued to increase with an additional 4% in 2016-2017
compared to the previous year although a 3% decrease in living donor rates, a source of organs
not routinely used in liver transplantation.[107] Cadaveric organ donation can be divided into
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Figure 1.6: Liver mortality rates compared to other diseases in the UK since 1970 until
2010.[106]. This demonstrates a clear increase in mortality from liver disease just over dou-
bling between 1970 to 1993, before accelerating to almost six times the standardised mortality
by 2010.
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Figure 1.7: Age standardised death rates for chronic liver disease between 1970 and 2000.[103]
This demonstrates two age clusters of 23-44 years and 45-64 years. Males have a higher mor-
tality rate compared to females in both clusters across all years. There was an acceleration in
mortality, particularly in males from 1993, most noticeable in the older demographic.
21
Figure 1.8: Age standarised mortality from chronic liver disease in the UK and Europe between
1970 and 1998.[103] Between 1970 and 1976 there was an increase in the age standardised
mortality from liver disease in Europe from 13 to 15 per 100,000 popoulation per year, following
which it has decreased to 9 per 100,000 population per year to 1998. In comparison, the UK
has experienced an increase in age standardised mortality from 2 per 100,000 population per
year to 7 per 100,000 per year in 1998, most notably since 1993.
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Figure 1.9: Mortality in the UK by type of liver disease between 1980 and 2013.[105]. From
1993, when there were approximately overall 3000 deaths per year attributable to liver disease,
to 2013, when almost 8000 people died as a result of liver disease per year, the increase was
primarily a result of alcohol or obesity or diabetes deaths. During the same period, deaths from
viral hepatitis, autoimmune or cause not recorded remained static.
23
Donation after Brainstem Death (DBD), where the donor is neurologically tested and found to
have absent brainstem function in the presence of a functioning circulatory system, and Dona-
tion after Circulatory Death (DCD) in which donation occurs after the support of life support-
ing treatment and the donor dies following cessation of cardiorespiratory function. The DCD
donors can be further subdivided into uncontrolled and controlled DCD according to the cate-
gories defined at the first DCD worskhop held in Maastricht in 1995.[110, 111] Uncontrolled
DCD donors include: donation from patients who are dead on arrival (Maastricht Category I),
donation after unsuccessful ressucitation (Maastricht Category II) and donation following un-
expected cardiac arrest in a critcally ill patient (Maastricht Category V).[111] Controlled DCD
donors include: donation whilst awaiting cardiac arrest (Maastricht Category III) and donation
following cardiac arrest in a brainstem dead donor (Maastricht Category IV).[110, 111] The
number of DBD donors increased by 6% to 829 with a concomitant increase in DCD donors of
1% to 584 during the same period.[107] Specifically, the number of liver DBD donors increased
by 4% (total 747) with a 10% increase in transplatation (total 738), whilst the number of DCD
liver donors decreased by 1% (total 294) although there was a 1% increase in transplatantion
(total 208).[107, 108] Over the ten years to March 2017, the number of donors older than 60
years increased from 20% to 36% with the largest decrease in the 18-49 year age bracket.[107]
A greater proportion of DBD donors were 18-49 years (41%) compared to DCD donors (28%).
Despite the reported increase in BMI for the UK population, the distribution of donor BMI
has remained static with between 69-75% having a BMI between 20-29 Kg/m2 in the 10 years
to March 2017.[107] The distribution between DBD and DCD donors was almost the same.
In both groups of donors, the cause of death was intracranial (DBD 86%, DCD 81%) rather
than trauma (DBD and DCD 3% each).[107] Of note, the vast majority of both DBD and DCD
donors were of white ethnicity (92% and 95% respectively).[107] With the expansion of the
DCD liver transplant programme, it might be expected that it has contributed to any decline in
the DBD however, analysis of the UK Transplant Registry does not support this.[112]
Of the 34,369 audited deaths between March 2016-2017 the proportion of potential donors
who actually go on to donated could be improved. For the 1775 patients meeting the organ
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donation referral crieria as potential DBD donors, 97.4% were referred formally for donation,
85.7% were tested for neurological death, of that subset the family was approached in 87.3%,
consent gained in 69.0% and donation proceeded in 89.3% of those where consent gained.[113]
In contrast, of the 6204 patients meeting the organ donation referral criteria as potential DCD
donors where imminent death was expected, the formal referral rate for donation was 85.6%,
the family approached in 29.3% and consent gained in only 58.1% of families approached with
donation proceeding in 53.6% of those where consent gained.[113] Overall, whilst 81-86% of
DBD livers are transplanted, only 28-36% of DCD livers are transplanted.[107, 114] The drop-
off in successful donation in DBD donors is largely due to clinical unsuitability, whilst in DCD
donors, livers are not retrieved or transplanted due to being clinically unsuitable, donor age,
poor function that includes the degree of warm ischaemic damage secondary to a prolonged
agonal phase greater than 30 minutes, rendering the organs beyond the accepted criteria for
donation.[107] As a result these donors are deemed too high risk for use of their organs and
those organs are subsequently discarded.
1.5.3 Selection and Outcome From Liver Transplantation
In the ten years to March 2017, there have been a total of 8042 liver transplants, increasing
almost annually and most notably in the number of DCD liver transplants performed (Figure
1.10).[108]. Of these, 6831 have been deceased donor first liver only transplants, the remainder
composed of re-transplants, atypical and multiorgan transplants. In first only liver transplants,
6170 have been performed in adults, 1303 DCD transplants, whilst 660 in paediatric patients,
660 DCD transplants. Both adult and paediatric liver transplants can be categorised accord-
ing to whether they are elective (routine) or super-urgent (emergency), with between 10-18%
performed on a super-urgently (Figure 1.11).[108] The selection criteria between elective and
super-urgent liver transplantation reflects the different aetiologies and thus the markedly differ-
ent short-term prognoses of these two groups.
In the UK, adult elective selection criteria is primarily based on projected 1-year mortality >9%
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using the predicted United Kingdom Model for End-Stage Liver Disease (UKELD) score ≥49
risk of death without a liver transplant and have a projected 5 year survival of greater than 50%
as well as the ability to improve the quality of the recipient’s life.[115] For patients with Hepa-
tocellular Carcinoma (HCC) to be transplanted, a single tumour ≤5cm diameter, upto 5 tumours
all ≤3cm or a single tumour between 5cm and upto 7cm diameter where there is no evidence
of tumour progression or extraheptic spread over a 6 month period is required using both Com-
puted Tomography (CT) and Magenetic Resonance Imaging (MRI) and in which there is no ab-
solute contraindication, that includes ruptured tumour, Alpha-feto Protein (AFP) >1000iu/ml or
extra-hepatic spread.[115] A list of other variant syndromes eligible for transplantation can be
found at National Health Service Blood and Transplant (NHSBT).[115] In paediatric patients,
chronic liver disease with a life expectancy of <18 months, an unacceptable quality of life,
growth failure, reversible neuro-developmental impairment from liver disease or the likliehood
of irreversible end organ damage are the most common indications, although rarer indications
include organic acidaemia, unresectablehepatic malignancies and hepatoblastoma.[115]
The indications for super-urgent liver transplantation in adult and paediatric patients is based
on the King’s College Criteria that identified factors depending on whether the aetiology of ful-
minant hepatic failure was paracetamol or non-paracetamol induced.[116] These criteria have
since been modified for paracetamol-induced liver failure (Categories 1-4), favourable (Cat-
egory 5) and unfavourable (Category 6) non-paracetamol aetiologies, acute Wilson’s disease
or Budd-Chiari syndrome (Category 7), post liver transplant hepatic aerty thrombosis, spe-
cial cases of early graft dysfunction after liver transplantation (Category 9), total absence of
liver function (Category 10), a previous live liver donor developing acute liver failure post-
operatively (Category 11) and acute liver failure in children under two years of age.[115]
Outcomes after liver transplantation are reported by NHSBT in terms of patient and graft sur-
vival. Overall undajusted one and five year survival for adult elective deceased donor first
transplant is 93.9% and 81.2% respectively. Risk-adjusted one, five and ten year survival for
the same group but between January 2005 and December 2016 is 83%, 70% and 57% respec-
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Figure 1.10: Number of liver transplants in the UK 2007-2017.[108] The numbers shown are
by donor type, either DBD, DCD, living or domino transplantation.
Figure 1.11: Liver tranplants 2007-2017 by urgency.[108] Adult and paediatric liver transplants
can be categorised according to whther they are elective or super-urgent.
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tively. Overall unadjusted one and five year survival for adult super-urgent deceased donor
first transplant is 88.9% and 80.1% respectively for the period April 2012 to March 2016.[108]
Paediatric elective first transplant outcomes are even better and are comparable to adults in the
super-urgent group.
Differences are apparent when comparing outcome parameters between DBD and all categories
of DCD liver transplantation. Studies have shown that graft survival after DCD liver trans-
plantation is inferior compared to DBD, in particular Primary Non-Function (PNF) has been
reported between 0-5.5% for DCD whislt biliary complications such as non-anastomotic stric-
tures 13-37% compared to 1-20% of DBD liver transpants.[117, 118, 119, 120] When restrict-
ing DCD liver transplantation to Maastricht Category III with donors aged <55 years with a
BMI <29 kg/m2, a donor Warm Ischaemic Time (WIT) <30 mintes and hypotension <15 min-
utes, it was demonstrated in a multicentre study that 1 and 3 year patient (DCD 85% and 80%,
DBD 86.3% and 80.8%) and graft (DCD 74% and 68%, DBD 80.4.3% and 74.5%) survival
rates were similiar.[121] Nevertheless, the 3-year cumulative non-anastomotic biliary stricture
rate was 31% in the DCD recipients whilst only 9.7% in the DBD cohort.[121] Consequently,
identifying risks factors for poor outcome, especially biliary complications, in DCD liver trans-
plantation is paramount. A meta-analysis of risk factors in 489 DCD and 4455 DBD recipi-
ents identifed that DCD recipients had a 10.8 times increased risk of ischaemic cholangiopathy
(DBD 3% recipients compared to 15% DCD recipients) with a higher 1 year patient mortlaity
or graft failure.[122]
Consequently, the concept of the ‘Ideal’ DCD donor has been proposed that provides favourable
outcome after transplantation. An ‘Ideal’ donor is one who is: (1) <50 years old, has a WIT <30
minutes, a Cold Ischaemic Time (CIT) <10 hours and <15% steatosis.[123, 124, 119, 125, 126]
A modification of this has been incorporated in to UK guidelines, in which the age is <50 years,
weight <100 kg, Intensive Therapy Unit (ITU) stay < 5 days functional WIT, defined as the
time between a systolic blood pressure of <50 mmHg or oxygen saturations <70% to asys-
tole, is <20 minutes, steatosis <10% and CIT <8 hours.[111] These livers are recommended
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to be used. In contrast, a ‘Marginal’ liver, defined as age >50 years, weight >100kg, ITU
stay >5 days, a WIT 20-30 minutes, a CIT 8-12 hours and >% steatosis, should only be used
selectively.[111] Furthermore, recipient factors that have been associated with graft failure in-
culde: age >55 years, male sex, African-American race, hepatitis C positivity, a metabolic
liver disorder, transplant Model of End Stage Liver Disease (MELD) >35, hospitalisation at
transplant and re-transplntation and have been recommended in UK guidelines.[111, 124, 127]
Prediction models that aim to provide an indvidual risk for the particular donor, recipient and
donor recipient combination have been devised. Until recently, the most commonly utilised
in liver transplantation were the MELD and UKELD scores that predict transplant recipi-
ent mortality. The MELD stratefies the severity of end stage liver disease, the model based
on creatinine, bilirubin and sodium concentrations as well as Internationalised Normal Ratio
(INR).[128, 129] Of more relevance to the United Kingdom is the UKELD score that uses
the same parameters but a different formula to predict mortality in the potential transplant
receipient.[130, 131] Models predicting risk from using a particular donor have been devised
with the oringal being the Donor Risk Index (DRI), an American model that accounts for age,
cause of death, race, donor type, donor height, geographical sharing and CIT.[132, 133] The
Eurotransplant Donor Risk Index (ET-DRI) is more specific for donors in Europe and incor-
porates laboratory gamma-glutamyl transpeptidase and rescue allocation.[134] A UK specific
score the Donor Liver Index (DLI) has been devised using data from all 7929 liver transplants
on the UK transplant Registry that incorporates donor age, sex, height, donor type, bilirubin,
smoking history and whether the donor liver was split.[135] However, this model still needs
further independent validation using a prospective cohort. Models to optimise donor recipient
matching include the Donor Age and Recipient Model for End stage Liver Disease (D-MELD),
that is the product of donor age and MELD but does not account for older donors accurately, and
Balance of Risk (BAR) score, that includes recipient MELD score, CIT, recipient age, donor
age, previous liver transplant and life support dependence.[136, 137, 138] To date these scores
do not provide an indication of the benefit of liver transplantation accounting for donor and
recipient factors compared to remaining on the transplant waiting list. A recent liver allocation
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score based on transplant benefit devised in Germany could not be validated on a UK cohort
of patients, demonstrating that perhaps the future relies on national transplant benefit scores
applicable to an individual country.[139] This is due to be designed for the UK in the imminent
future.
1.5.4 Strategies to Reduce Demand for Liver Transplantation in the UK
In response for the demand of organs to match supply there have been different approaches
by both European and UK government. These measures have included considering the intro-
duction of Minimum Unit Price (MUP) for alcohol to reduce the burden of ALD, improved
food labelling and public health awareness with repsect to Non-Alcoholic Fatty Liver Disease
(NAFLD). MUP of alcohol has been proposed for a number of years with evidence indicat-
ing that patients with ALD are consuming high amounts of cheap alcohol (33p/unit) compared
to low risk drinkers (£1.10/unit).[140, 141] Furthermore, it has been predicted that the impact
of a minimum unit price of 50p/unit would be 200 times higher in patients with liver disease
copared to low risk drinkers.[141] The Sheffield Alcohol Policy Model, that accounts for alco-
hol purchasing and consumption across various socioeconomic groups, has predicted that the
greatest impact of a MUP of 45p/unit leads to an immediate reduction in consumption, particu-
lary in the harmful drinkers on low incomes that conincides with substantial increases (87.1%)
in quality-adjusted life-years.[142] This has been confirmed by a similar analysis of Scottish
harmful drinkers as well as by systematic review.[143, 144] Although legislation is due to come
in to effect in 2018 for Scotland, the rest of the UK awaits its impact before reassessing hte need
for the introduction of MUP for alcohol.
In an attempt to combat the rise of obesity and the increasing impact that obesity and type
2 diabetes has on NASH related liver mortality, the introduction of a levy on sugar sweetened
beverages to reduce the intake of free sugars is soon to be enacted. Qualitative thematic analysis
of major UK news websites demonstrated three themes incuding the mistrust of the intention of
the proposed tax, varying perceptions of the relationship between sugar, obesity and appropriate
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interventions as well as the balance between responsibility and autonomy.[145] Modelling to
predict the reduction in weight form a 20% sugar tax results in the reduction in obesity of 1.3%
or 180,000 people and largest effect on younger adults.[146] Other modelling has predicted
that the largest effect scenario would be for the reformulation of sugar sweetened beverages to
reduce obesity, type 2 diabetes and dental caries.[147] the actual effect remains to elicited.
The early identification and treatment of groups at risk of being exposed to hepatitis B and C
virus and the longer term implications of developing hepatocellular carcinoma currently is lim-
ited to the screening of donated blood (Hepatitis B and C) and for women during pregnancy
(Hepatitis B) only.[148] Due to the natural course of hepatitis C, the safety and effectiveness of
new directly acting antivirals and the cost implications fo screening, a programme for Hepatitis
C appears unjustified.[149] However, the NHS vaccination schedule includes Hepatitis B vac-
cination to all infants as well as those at higher risk of contracting the virus, both via vertical
and horizontal transmission.[150] to date, there is no vaccine for hepatitis C.
1.5.5 Strategies to Increase Supply of Donated Livers in the UK
To increase the supply of organs available for transpantation, a collaborative strategy between
the Department of Health UK, The Scottish Government, the Welsh Assembly, the Department
for Health, Social Services and Public Safety as well as NHSBT and various interested parties,
both within the UK and internationally, has been proposed titled ‘Taking Organ Transplantation
to 2020 - A UK strategy’.[151, 152] This has identified four main outcomes and builds on
previous recommendations for increasing the UK donor rate.
The first outcome is increasing the organ donation rate and is hoped to be achieved by changing
behaviour and attitudes towards organ donation, such as education materials and increasing the
opportunities for consenting to donation, for example when an individual renews their driving
licence or the introduction of organ donation in to the school curriculum. Of particular impor-
tance is honouring the wishes of individual at time of donation who have already pledged to
be on the organ donor register. Approximately 100 families overide the wishes of their relative
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who is on the donor register and prevents them from proceeding with donation. As discssed
above, the donation rate of the Black, Asian and Minority Ethnic community is significantly
lower than for the white population yet they are relatively overpresented on the transplant wait-
ing list. Increasing the donation rate in this population by increasing awareness of the need to
donate and the benefits its brings to their community need to be highlighted. Another option is
promoting those individuals already on the organ donor register to be of higher priority should
they need a transplant themselves. Finally looking to Spain and Wales, there has been a change
in legislation to an opt-out organ donation system that has been evaluated and will come into
effect for England from 2020. This will change the burden of registering to be an organ donor
to that of presumed consent. Whilst some in the transplant community and public are strong
advocates for this system, it remains to be seen whether it actually increases the number of
organs available for transplantation based on the results from Spain and Wales.[153, 154]
The second outcome is providing excellent care to donors around the time of donation which
should directly impact the care provided to recipients. This can be achieved by adhering to the
clinical guidelines for donation, increasing the opportunity of more DCD organs by approach-
ing more families earlier, improving the training provided to clinical staff either employed by
NHSBT or by the donor hopitals to emphasise the need to provide excellent care. This has led to
the introduction of Clinical Lead for Organ Donation (CLOD)s, a clinician in every hospital in
the UK who takes responsibility for and facilitates the identification of potential donors, mainly
on ITU. They are supported by a network of Specialist Nurse in Organ donation (SNOD)s, spe-
cialist nurses who cover an area of the country within which there are a number of hospitals
and who liaise with NHSBT to facilitate the actual organ donation process. They also provide
invaluable support directly to donors and their families during a very emotive time. Specifically
creating a National Referral Service to support hospitals and working with the Coroner and
Procurator Fiscal to facilitate organ donation is of great importance. Additionally, the National
Organ Retrieval Service (NORS) was created to provide a network of travelling surgical teams
containing a surgeon, an assistant, a theatre practition and, more recently, a perfusionist. The
abdominal oragan retrieval teams are provided mainly by the seven liver transplant centres, with
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support from number of kidney/panreas transplant centres. The organs, once retrieved from a
DBD liver donor will be placed into the national allocation system to permit equality of access
to transplantation around the country for potential recipients. The DCD livers are still trans-
planted by the retrieving NORS teams to minimise the CIT so maintain outcomes. There is a
move to commence a national allocation system for DCD livers tht will take into account such
particular considerations. Another future avenue is increasing the live donor liver transplant
programme, taking left lateral segments of the liver from an adult donor and transplanting it
into a child or small adult. Whilst splitting of livers into these components as part of the cadav-
eric transplant programme, live donor transplantation is largely limited to a few of the largeer
liver transpant centres due to the perceived risk of the donor. Expansion of this programme may
prove fruitful and eventually become established a in the Far East, where cadaveric programmes
are in their infancy.
Increasing the organ utilisation rate is the thrid outcome and can be achieved by increasing the
number of DBD and DCD retrievals as well as using novel assessment and therapeutic technolo-
gies to stratify organs appropriately, which help in decision making by surgeons in conjunction
with the potential recipient around suitability of organs for transplantation. Ante-mortem donor
interventions in DCD donors is another area for exploration but may introduce ethical concerns
regarding the intention of the intervention. However, of less dispute is the establishing the
place of withdrawal for DCD donors, providing named organ recipients and investigating the
length of the offering process. Analysis of data surrounding organs that are delcined for trans-
plantation, information sharing and monitoring damage rates is imperative as is exploring novel
methods of perfusion and preservation. Improving the transplant community’s understanding of
compatibility in organ donation and transplantation will hopefully improve organ utilisation and
reduce the discard rate of organs. This might incorporate the use different immunosuppression
strategies or exchange programmes to permit transplantation between previously considered
incompatible donors and recipients.[152]
The final outcome is improving the process of organ donation and transplantation. This in-
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corporates creating and expanding regional collaboratives to improve practice, reviewing the
worksforce, IT systems and administrative processes to facilitate and maximise on donation
and transplantation opportunities. Building a sustainable training and development programme
has also been highlighted as has ensuring future capacity in transplant centres as the numbers
increase. The creation of an expert histopathology service available 24 hours per day is also
being investigated.[152]
The success of the above programme can be measured when: (1) Consent for organ donation
is >80%; (2) There are 26 deceased donors per million population; (3) Organ utiliation has
increased by 5%, which translated into 85% for abdominal organs; (4) The deceased donor
transplantation rate is 74 per million population. The midpoint review as of May 2017 highlights
that progress has been made in each of the outcome domains with more of the population joining
the organ donor register, increasing rates of referral to the organ donation service, the presence
of SNOD at a higher proportion of donations and an increased number of transplants as a result
of this action.[155] Nevertheless further action is required to achieve the original outcomes.
1.6 Mechanisms of Ischaemia Reperfusion Injury
Liver preservation is one of the most important steps in the transplantation process as its effi-
cacy influences organ utilisation and outcome. In DBD donors, preservation injury to the liver
can occur prior to preservation, during cold preservation, during rewarming and at reperfusion.
For DCD donors, an additional injury occurs between when the blood pressure drops below
50mmHg or oxygen saturations are less than 70% to the time of cold flushing a retrieval.[156]
Prepreservation injury includes the effects of any underlying liver disease at the time of organ
retrieval, injury associated with cardiac arrest or hypotension from either trauma or intoxica-
tion, injury during organ retrieval resulting in hypotension as well as the aforementioned warm
ischaemia injury during DCD retrieval.
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1.6.1 Cold Preservation Injury
Cold preservation injury affects all types of cells within the liver, but it is recognised that HSEC
are particularly vunerable to this type of injury, with increasing length of CIT associated with
inferior outcomes.[157] Although it is accepted that during cold preservation hepatic core tem-
perature is approaching 0oC, enzymatic activity is still variable, with the sodium-potassium AT-
Pase being completely inhibited whilst lactate dehydrogenase is active at approximately 10%
compared to when at 37oC.[158]
One consequence of inhibition of the sodium-potassium ATPase is hypothermia injuced cel-
lular swelling due to the inhibition of the Adenosine Tri-Phosphate (ATP) pump to excrete
intracellular sodium and maintain a cellular membrane electrochemical gradient. Once the AT-
Pase activity is significantly reduced during cold preservation due to enzymatic inactivity and
the relative lack of ATP, osmotic equilibrium occurs between the intracelluar and extracellu-
lar space with the influx of sodium ions also bringing negatively charged proteins, resulting in
intracellular hyperosmolality, water uptake, swelling and cell lysis.[156]
Although the cooling of organs the metabolic demand, some metabolic reactions are not stopped
but continue despite the insufficient generation of ATP The consequence of this is the production
of xanthine oxidase that ultimately results in ROS generation as well as increased glycolysis,
lactate and hydrogen ion production and influx of calcium ions. With the addition of increased
lipolysis, there is cellular membrane injury, receptor-channel impairment and altered cell per-
meability, all of which contribute to cell death by either apoptosis or necrosis.[159] It appears
that HSEC are the most vulnerable hepatic cell type from cold preservation injury.[160]
1.6.2 Reperfusion Injury
There are two distinct phases to reperfusion injury, the early phase which is characterised by
rapid Kupffer cell activation that releases ROS including superoxide and hydrogen peroxide.[161]
This induces oxidative stress and although modest initially, it triggers a cascade of events that
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results in the recruitment of activated leukocytes followed by significant liver injury. Oxidant
stress induced by Ischaemia Reperfusion Injury (IRI) results in the release of complement,
TLR, high-mobility group box 1 and IL-23.[162, 163] These activate Kupffer cells and induce
their production of TNF-α that propagates the inflammatory response by upregulating adhesion
molecules on endothelial cells. CD4 T cells are transiently recruited to the liver and, with the
previous events, facilitates neutrophil recruitment into the liver parenchyma.[164] Neutrophils
directly injure hepatocytes resulting in necrotic cell death, although activation of NF-κB by
ROS in hepatocytes leads to the upregulation of protective cytoprotective proteins in an attempt
to promote hepatocyte survival and function but concurrently releases proinflammatory TNF-α
that propagates the inflammatory injury.[165]
The late phase of IRI is characterised by neutrophil recruitment and their subsequent damage
to the hepatocytes via oxidants and proteases. This is dependent on the expression of CXC
chemokines that are chemotactic and activating for neutrophils which interact with their recep-
tors CXCR2.[166, 167] The capture and transmigration of neurophils across the space of Disse
is dependent on the expression of adhesions molecules P-selectin on the HSEC and L-selectin
expressed on neutorphils which slow the neutrophils and allow stronger biding to occur, fa-
cilitated by integrins on the neutrophils as well as ICAM-1 and VCAM-1 on the endothelial
cells.[168] The release of ROS from the neutrophils causes the greatest hepatocyte damage
with the production of superoxide anion that is catalysed by superoxide dismutase to hydrogen
peroxide that is reduced to the highly reactive hydroxyl radical. The result is mitochondrial dys-
function, calcium accumulation and mitochondrial permeability, followed by cell death.[169]
This has significant impact on organ function and disruption to whole body physiology for
patients undergoing liver transplantation that can result in death from myocardial instability
following the release of potassium, known as reperfusion syndrome.
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1.7 Bench-to-Bedside Research and Emerging Tools for Liver
Disease and Transplantation
1.7.1 Bench-to-Bedside Research in Liver Disease and Transplantation
There are a number of different research approaches to improving outcomes in liver disease and
organ donation leading on to transplantation. There is a preclinical research strategy, that can be
broadly divided into understanding contributors towards inflammation such as the role of VAP-
1 in T-cell recruitment, the role of bile acid salts, genetic and environmental factors towards
cholangiopathy.[170, 171] Other investigators are approaching T- and B-cell infiltration as their
primary focus.[172, 173, 174] A further approach is investigating the effects of reactive oxygen
species and their differential role in endothelial, hepatocyte and cholangiocyte damage.[175]
A second strategy is to investigate how the liver regenerates. In particular great emphasis has
been placed on mesenchymal stem cells, whether they are recruited from the bone marrow or
naturally resident in the liver and their potential immunomodulatory effect.[176] Other groups
have approached this problem by considering a resident group of liver progenitor cells. Utilis-
ing mouse models to attempt to understand liver progenitor lineage tracking is being actively
investigated.[177] Isolating the peri-biliary gland stem cells resident in the biliary tract is being
studied as an alternative source of cells available following cholecystectomy.[178] Liver regen-
eration from a pluripotent stem cell perspective by the transformation of skin fibroblasts into
a variety of different liver cells is of significant importance, potentially allowing organs to be
regenerated from any other cell type.[179]
Another preclinical strategy is to try and prevent chronic rejection. This has largely been reliant
on medical therapy but does also have a reliance on mouse models. New in vitro modelling
techniques have been developed including an ex vitro system as well as organoids.[180, 181]
Even these techniques have disadvantages, mainly surrounding the need for the correct environ-
ment for cell culture environment that does not necessarily represent the microenvironment that
cells are exposed to in vivo.
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1.7.2 Emerging Tools for Liver Disease and Transplantation
As important as the research themes are for investigating specific diseases from bench to bed-
side, are the cross-cutting tools that can answer the questions from a systems biology approach.
Pertinent methods are metabolomics, proteomics and organ machine perfusion.
Metabolomics
The definition of the metabolome is the quantitative collection of endogenous and exogenous
metabolites present in a cell or organism, whether synthesised and catabolised within the bio-
logical system or absorbed from its external environment (pharmaceuticals, food nutrients or the
components of a growth medium or of symbiotic or passenger organisms).[182] Metabolomics
is the study of the metabolome. Although no single technique can capture the complete metabolome,
advances in sample preparation and analytical platforms based around mass-spectrometry can
increase the yield. Proteomics is the large scale interrogation of biological phenomena at the
protein level using mass spectrometry based techniques.[183] Advances in technology and un-
derstanding the importance of sample preparation to select the proteome of interest has led to
the rapid development and integration of proteomics into pre-clinical, translational and clinical
research, including biomarker discovery.[183]
The use of metabolomics in liver disease and transplantation is documented. The drug rifax-
imin is used to treat hepatic encephalopathy in patients with cirrhotic liver disease however,
its mechanisms are not clearly understood but might involved modulation of the gut micro-
biota and its subsequent influence on the gut-liver-brain axis.[184] The use of serum and uri-
nary metabolomics in conjunction with clinical cognitive testing and microbiome assessment
demonstrated that rifaximin significantly improves cognition, increases in serum saturated and
unsaturated fatty acids whilst having a significant reduction on gut bacterial linkage in this inte-
grated study.[184] The use of metabolomics has expanded to the assessment of oxidative stress
markers, including lipid peroxidation, and metabolic parameters in patients with NASH.[185]
These were monitored at intervals during treatment to produce a timecourse of an individual’s
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metabolomic profile. Expansion of that pilot study involved urinary metabolomics to compare
biomarkers across the spectrum of non-alcoholic fatty NAFLD, in which healthy age matched
controls were compared to non-diabetic subjects with steatosis but normal liver function and
sujects with NASH and abnormal liver function.[186] Not only could metabolomic analysis
distinguish between controls and diseased subjects but also identified lower cholinesterase and
higher indoleacetic acid in the NASH compared to the NAFLD cohort.[186] Metabolomics can
help identify unique signatures assocaited with hepatorenal dyfunction and mortality in patients
with cirrhosis which can potentially inform the need for transplantation more accurately than
current modelling permits, whic hcould reduce the burden of demand and mortality on the liver
transplant waiting list.[187]
Proteomics
To date, there has been a over 40 studies that have implemented proteomics as part of clin-
ical trials to varying extents.[188] These studies can be broadly categorised into those that
are attempting to identify stratification or diagnostic biomarkers and can be traced back to the
mid 1990s.[188] Stratification of patients to identify those who are higher risk of more severe
or more rapidly progressing disease is of particular importance to patient with chronic kid-
ney disease that might necessitate haemodialysis or trasnplantation. High resolution urinary
proteomics has been of value in these patients, in which a urinary proteomics-based classifer
CKD276 has been quantified to predict the likelihood of a particular patient experiencing an
adverse outcome and could separate patients according to their renal function.[189] Urinary
proteomics has been able to identify 85 proteins that could discriminate between asymptomatic
hypertensive patients with left ventricular diastolic dysfunction from healthy controls.[190] As
a diagnostic tool, multiple reaction monitoring-mass spectrometry has been utilised in a prop-
sective clinical study to identify a plasma biomarker protein panel that can differeniate between
a transient ischaemic attack and non-cerebrovascular conditions in patients presenting to an
accident and emergency department.[191] Nine proteins were demonstrated to be significant
uniariate predictors of transient ischaemic attack which could be potentially translated to a
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bedsde test.[191]
Proteomics has been translated in to clinical studies investigating potential diagnositic mark-
ers in liver disease. These have included identifying proteins that help establish the diagnosis
of HCC as the aetiology of malignant ascites using a quantitative proteomics approach with
iTRAQ and serum analysis of patients with HCC that has demonstrated galectin-1 as a possi-
ble biomarker for the reponse of patients to treatment with sorafenib.[192, 193] Importantly,
for a disease with late presentation, difficulty in diagnosis and poor outcome, a prospective
proteomic-based study of patients with cholangiocarcinoma identified 25 candidate proteins
of which two were validated using other methods, albeit in only five cases compared to five
healthy controls.[194] More promisingly, mass spectrometry has been used to assess the reponse
of patients to gemcitabine treatment for cholangiocarcinoma and concluded that macrophage-
capping protein was assocaited with overall survival.[195] Hepatitis C virus has been the target
of serum proteomics that has profiled 25 infected individuals using SELDI-TOF mass spectrom-
etry to assess their response to pegylated interferon and ribavarin.[196] This is of particular use
when trying to reduce the burden of hepatitis C on the transplant waiting lists.
1.7.3 The Role of Machine Perfusion
From a translational research perspective, a number of groups have tried to increase the donor
pool by understanding the DCD process and outcomes and this has extended to early work us-
ing machine perfusion.[197, 198] Here there are three main approaches. Initially hypothermic
machine perfusion was approached and successfully translated by a group in America.[199]
Within Europe, Clavien and Dutkowski have made substantial progress in the understanding of
energy metabolism during Hypothermic oxygenated machine perfusion (HOPE).[200] Another
reported approach is by normothermic machine perfusion. To date, the main proponents have
been the Oxford group that have developed and translated the Organox device which is now
being used as part of an International randomised control trial in which normothermic machine
perfusion commences at the donor hospital soon after organ retrieval.[201] The Netherlands
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have taken a slightly different approach by returning the donor organ on static cold storage to
a perfusion centre for subsequent assessment.[202] There still remain open avenues of explo-
ration to define the correct strategy, for the correct donor to maximise the chance of successful
transplantation.
1.8 Aims of the Project
I will test the hypotheses that:
1. Human ex vivo normothermic machine liver perfusion can be developed and perfusate
lactate concentration evaluated for viability testing in discarded human livers.
2. Human ex vivo normothermic machine liver perfusion can be used as a model of is-
chaemia reperfusion injury that could be translated in to early clinical applications.
3. The Fn14/TWEAK receptor-ligand systems plays a role in intra-hepatic biliary epithelial
cell biology using established in vitro modelling. Normothermic Machine Liver Perfusion
(NMLP) could be used to investigate the role of the Fn14/TWEAK receptor ligand system
in an ex vivo human model.
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CHAPTER 2
DEVELOPMENT & VALIDATION OF AN EX VIVO
HUMAN MODEL OF THE LIVER USING
NORMOTHERMIC MACHINE LIVER PERFUSION
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2.1 Introduction
The demand for donor organs in Orthotopic Liver Transplantation (OLT) greatly exceeds supply.
As the global incidence of end-stage liver disease continues to rise, there is disparity between
the availability of livers and the pressures of increasing demand. In the UK, the number of ac-
tive patients on the waiting list increased by 11%. However, approaching 20% of patients listed
for OLT have either died or been removed from the transplant waiting list within one year of
listing.[203] Despite the increasing utilisation of grafts from DCD and marginal DBD, together
known as Extended Criteria Donors (ECD), the cadaveric liver transplant waiting list mortality
has not decreased. ECD livers are associated with a higher incidence of early post-transplant
complications such as PNF, Early Allograft Dysfunction (EAD) or renal failure . Utilisation of
high-risk organs remains low with 168 out of 1011 livers procured in the UK during 2015-16
being discarded. Only 35% of all potential DCD livers were transplanted which can be ex-
plained by variation in interpretation of donor history, laboratory parameters, macroscopic or
histological assessment, personal experience and the transplanting centre’s expertise in the util-
isation of marginal organs. This semi-subjective assessment impacts on the selection process,
potentially compromising patient safety by acceptance of a high-risk marginal graft that does
not function or discarding potentially usable organs due to a perceived fear of PNF.
The hypoxic environment of conventional Static Cold Storage (SCS) triggers a cascade of is-
chaemic injury. Continuing anaerobic metabolism depletes ATP leading to a loss of transcellular
electrolyte gradients, influx of free calcium, activation of phospholipases and, on reperfusion,
production of ROS. This results in IRI and may lead to graft PNF and Ischaemic Cholangiopa-
thy (IC). However, ECD livers are at increased risk of graft primary non-function, dysfunction,
and increased susceptibility to IRI. These remain major obstacles for the utilisation of ECD in
transplantation.
One strategy to increase the number of available livers is the progressive expansion of the accep-
tance criteria for donated organs. There is an increasing reliance on marginal ECD livers from
older donors, with higher body mass indices or longer WIT and CIT. However, not only has
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mortality on the liver transplant waiting list remained stagnant, but also the potential benefits
have been offset by post-transplant complications. Especially seen in recipients of DCD livers,
complications include graft PNF, Delayed Graft Function (DGF) and ischaemic type biliary
strictures. IRI is a fundamental cause of organ damage following static cold storage leading to
complications and is exacerbated by steatosis, particularly in DCD livers. The potentially fatal
consequence of PNF remains the main obstacle for the further utilisation of extremely marginal
donor livers.[120, 203, 204].
Recipient and graft outcomes after transplantation of ECD livers are less predictable compared
to standard criteria donors. Expert but subjective assessment at the transplanting centre of
macroscopic appearance and back-table perfusion quality after several hours on ice does not
guarantee graft function or recipient survival. Conversely, there may be significant wastage of
donor livers that are discarded when they are in fact transplantable. During 2014 in the UK,
102 out of 932 procured livers were discarded because of prolonged WIT and CIT, inadequate
perfusion or advanced steatosis.[203].
Machine perfusion is a developing technology that aims to improve preservation of organs prior
to transplantation. Three machine perfusion strategies based on temperature (hypothermic, sub-
normothermic, normothermic) are being investigated, but in all the delivery of oxygen attenu-
ates the detrimental effects of IRI. Several teams have pioneered NMLP using a Packed Red
Cell (PRC) based perfusion fluid at 37oC to achieve near physiological conditions and exposes
the liver to oxygen and nutrients supporting intrinsic metabolic activity.[202, 205, 206] A ran-
domised trial comparing the outcome of transplanted livers having been subjected to NMLP and
SCS is underway as part of a European consortium. This trial utilises Standard Criteria Donor
(SCD) and ECD livers.
NMLP is a novel technology developed to provide superior organ preservation compared to
static cold storage. Over the last decade, NMLP has been developed to attenuate IRI and im-
prove donor organ utilisation. Experimental data and early clinical results using livers suitable
for transplantation have been encouraging.[122, 197, 202, 206, 207, 208, 209, 210, 211, ?] The
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anticipated advantages of NMLP include: (1) Attenuating IRI; (2) Assessment of liver func-
tion before transplantation; (3) Improvement of transplantation logistics and; (4) Potential to
administer therapeutic interventions to repair livers currently considered unusable, to enable
subsequent transplantation.
The aim of this chapter is to test the hypothesis that human ex vivo normothermic machine
liver perfusion can be developed and evaluated using a standardised protocol for functional
assessment with perfusate lactate concentration as a real-time viability test in discarded human
livers that correlates with histopathological analysis.
2.2 Materials & Methods
Development of NMLP commenced in March 2013 with the delivery of the machine perfusion
device. Assessment of the model commenced with the inclusion of 12 consecutively perfused
human discarded donor livers offered for research to the NIHR Birmingham Liver BRU and
Centre for Liver Research between May 2013 and June 2015.
2.2.1 Ethics Statement
The study was approved by University of Birmingham Local Regional Ethics Committee, Uni-
versity Hospitals Birmingham NHS Foundation Trust Novel Therapeutics Committee (NT001/14)
and National Research Ethics Service committee in London-Surrey Borders (reference number
13/LO/1928). Consent to use donor tissues for research was obtained either directly from the
donor when joining the UK Organ Donor Register (ODR) or by a SNOD from the donor’s next
of kin during consent for organ donation. None of the organ donors were from a vulnerable
population and all donors or next of kin freely provided written informed consent.
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2.2.2 NMLP Device and Consumables
Normothermic machine perfusion was performed using the CE marked Liver Assist device and
the single-use set of consumables (Organ Assist, Groningen, The Netherlands) providing dual
perfusion of the Hepatic Artery (HA) and Portal Vein (PV), in a semi-closed circuit, propelled
by two rotatory pumps to produce pulsatile and non-pulsatile flows respectively. Arterial and
portal pressures were regulated to maintain physiological flow through the HA and PV and set
independently. Pressure was limited to a mean of 50 mmHg in the hepatic artery and 10 mmHg
in the portal vein. Measured flow rates and calculated resistances were shown in real-time on a
liquid crystal display. Oxygen was supplied to two polypropylene, rheoparin R©coated, microp-
orous hollow fibre membrane oxygenators with integrated heat exchangers, that also removed
CO2. Oxygen was supplied via a Sechrist air/oxygen blender (S3500CP-G, Inspiration Health-
care Ltd., Leicester, UK). A novel human-based oxygen carrying solution was developed to
permit perfusion of livers on the normothermic device that would be physiologically represen-
tative. The development of the perfusion fluid is detailed in the section 2.3.
2.2.3 Procurement of Human Discarded Cadaveric Donor Livers
All organs were initially procured by the UK NORS using a standardised surgical protocol,
according to NHSBT and British Transplant Society (BTS) guidelines, with the intention of
clinical transplantation. Upon inspection by the retrieval or accepting transplant surgeon, livers
were subsequently declined for transplantation by all UK transplant centres and were offered for
research by the NHSBT co-ordinating office. The decision not to transplant was based on either
suboptimal ex vivo appearance established by the transplanting surgeon, histological findings
or the presence of extra-hepatic donor malignancy. All livers were preserved by University of
Wisconsin preservation fluid and exposed to a period of static cold storage at 4oC.
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2.2.4 Preparation and Initiation of NMLP in Human Discarded Cadav-
eric Donor Livers
Preparation of the liver for NMLP was analogous to clinical transplantation. Redundant tissue
was removed whilst the liver was bathed in cold Ringer’s solution at 4oC with slushed ice. The
inferior vena cava was dissected and the ends left open. The portal vein was cleaned to its
bifurcation and hepatic artery dissected to the gastroduodenal artery. If present, accessory right
hepatic artery was anastomosed to gastroduodenal artery stump. The weight of each liver was
recorded.
Straight and curved 20 French cannulae (Medos) were inserted into the coeliac trunk and portal
vein respectively and secured with ligatures. If the coeliac trunk diameter did not allow direct
insertion of the cannula provided with the perfusion set, an iliac artery interposition graft was
anastomosed to the aortic patch to permit cannulation (Figure 2.1). The cystic duct was ligated
and bile duct cannulated with a transparent plastic tube. Immediately prior to commencing
perfusion, the livers were flushed with 2 litres of 10% dextrose solution at 37oC as per the unit’s
clinical protocol for transplantation. The liver was then placed into the machine reservoir, the
cannulae primed with the perfusion fluid (Results section, Tables 2.4 & 2.5) and connected to
the perfusion circuits.
The perfusion was controlled by setting the perfusion temperature and individual pressures in
the HA and PV circuits, with the device calculating and displaying real-time resistances and
flow rates. Temperature was initially set to 25oC and increased incrementally to 37oC within 30
minutes of starting NMLP. The initial pressure setting of 30 mmHg and 8 mmHg in the arterial
and portal circuits respectively was increased to 50 mmHg and 10 mmHg within 30 minutes of
commencing NMLP. The Fraction of Inspired Oxygen (FiO2) was set at 0.21 with 2L of flow
per minute.
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Figure 2.1: Back-table preparation of donor liver for NMLP. (A) If the vessels of the liver were
unable to accommodate the cannulae provided, resconstruction using an iliac interposition graft;
(B) Flushing the liver with 2L 10%dextrose; (C) Positioning of the vessels at the start of perfu-
sion to ensure uninterrupted flow; (D) Completion of donor preparation and commencement of
NMLP.
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2.2.5 Sample and Data Collection Protocol
Pressure, resistance, flow and temperature were recorded every 30 minutes. A blood gas sam-
ple was collected from the post-oxygenator hepatic arterial circuit and pre-oxygenator hepatic
venous circuit at the start and after every 30 minutes of perfusion. Perfusate samples for the clin-
ical biochemistry laboratory, a 4.5ml pre-oxygenator hepatic venous circuit sample transferred
in a serum separating tube containing silica particles to activate clotting and serum separator
consisting of an inert polymer gel aiding centrifugation, were collected at the same time as
the blood gas samples. A further two 10ml samples from the pre-oxygenator hepatic venous
circuit were collected at the same time as the blood gas samples and immediately snap frozen
in liquid nitrogen for future proteomic and metabolomic analysis. If produced, bile was col-
lected every 30 minutes once perfusion had commenced and subsequently weighed. Both 16G
and 3cm cubed wedge parenchymal biopsies snap frozen in liquid nitrogen and formalin fixed
for paraffin embedding were collected immediately before perfusion and every 3 hours follow-
ing commencement of NMLP. Bile duct samples were taken immediately prior to perfusion
snap frozen in liquid nitrogen and formalin fixated for paraffin embedding as well as 2.5% glu-
taraldehyde followed by embedding in a resin block for electron microscopy. A summary of the
sample collection protocol is demonstrated in Figure 2.2.
2.2.6 Assessment of Physiology for Livers Subjected to NMLP
Arterial and hepatic venous perfusion fluid was samples were assessed immediately using a
Cobas b 221 point of care system (Roche Diagnostics, USA) blood gas analyser measuring
partial pressures of O2, and CO2, pH, base excess, bicarbonate, O2 saturation, haemoglobin,
haematocrit, sodium, potassium, chloride, calcium, glucose and lactate concentrations. Oxygen
consumption per gramme of liver tissue (ml/min/g) and oxygen extraction ratio (O2ER) were
calculated based on perfusate oxygen content, delivery and extraction from the arterial and
hepatic venous elements of the NMLP circuit respectively. Content of oxygen (ml/L) in the






























































































































1. Hb is haemoglobin (g/L).
2. SaO2 and SvO2 are arterial and hepatic venous oxygen saturations (%) repsectively.
3. PaO2 and PvO2 are partial pressures (kPa) of arterial and hepatic venous oxygen repsec-
tively.
4. 1.34 is the direct measurement of the maximum oxygen carrying capacity, known as
Hüfner’s constant.
Oxygen delivery, ḊO2, (L/min) is defined as:
ḊO2 =CO×CaO2 (2.3)
Where CO (L/min) is the combined inflow rate in the arterial and portal venous circuits.
Oxygen consumption, V̇ O2, (L/min) is defined as:
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V̇ O2 =CO× (CaO2 −CvO2) (2.4)
This can then be expressed in millilitres per gramme of liver tissue (ml/min/g)





2.2.7 Structural and Functional Histological Assessment
Biopsies taken at the timepoints above were formalin fixed and embedded in paraffin blocks
for histological evaluation. Slide mounted sections were obtained by cutting the blocks in to
sections of 10µm thickness using a microtome then floating the sections on to a pencil labelled
slide using a water bath. These were then prepared for Haematoxylin & Eosin (H&E) staining
and assessed semi-quantitatively for large and small droplet macrovesicular steatosis (ldMS and
sdMS respectively), coagulative necrosis and intrahepatic bile duct injury (apoptosis, vacuola-
tion and lifting of epithelium from basement membrane), that were recorded as percentages
of cells affected. Additional sections were assessed for polysaccharide (glycogen) content us-
ing Periodic Acid-Schiff (PAS) staining and the mitochondrial Uncoupling Protein 2 (UCP2)
staining. Histological assessment of slides stained with H&E was performed by a qualified
pathologist who was blinded to 5 random fields from each section from the samples.
Period-acid Schiff Staining
Periodic-acid Schiff staining was performed by initially dewaxing batches of sections in Xy-
lene for 3 minutes, then repeated twice. After dehydration in 99% Industrial Denatured Alcohol
(IDA) for 3 minutes, repeated twice, the sections were rehydrated in tap water for 3 minutes,
repeated once. Subsequently, sections were bathed in periodic acid 1% with aqueous (Sigma-
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Aldrich 395132-1L) for 10 minutes then the excess drained, following which they were placed
under running water for 5 minutes. Schiff reagent (Feulgen stain for microscopy, VWR Chem-
icals 351204L) was added for 30 minutes, after which the sections were placed under running
tap water for 10 minutes. Sections were covered with filtered haematoxylin using a pipette for
30 seconds whilst placed on a horizontal rack. Following rinsing in warm tap water, sections
were bathed in Scott’s tap water for 30 seconds then, after rinsing, were bathed in tap water
for 3 minutes, repeated once, to rehydrate them. Sections were bathed in 99% IDA for 3 min-
utes, repeated twice, then xylene for 3 minutes, repeated twice, before mounting in Distyrene
Polystyrene Xylene (DPX) CellPath, UK) using a glass coverslip.
Assessment of Adenosine Triphosphate
Confirmation of maintaining or increasing ATP during NMLP was important to establish thus
demonstrating the amelioration of IRI. Measurement of ATP was performed by immediately
homogenising snap frozen liver tissue in SONOP Buffer using the GentleMacs system. Pro-
tein concentration was determined using a Pierce BCA Protein Assay kit. ATP concentration
determined was performed using the ATP Bioluminescent Kit (Sigma FL-AA). Concentrations
were determined from a calibration curve on the same plate, corrected for amount of protein
and expressed as nmol/g protein.
Staining for Mitochondrial Uncoupling Protein 2
As pertained in the Introduction, it has been demonstrated that UCP2 induces mitochondrial un-
coupling which can be initially protective against IRI but reduces the liver’s capacity to tolerate
further IRI in human and rat models of NASH.[212] It does this by being a negative regulator
of superoxide by increasing respiration.[213] As NMLP can help ameliorate IRI and maintain
ATP content, establishing a relationship between UCP2 and ATP is important. To summarise,
staining for UCP2 was performed by dewaxing, dehydrating and rehydrating batches of slides
as described above. During the second bathing in 99% IDA ethanol, a high pH buffer was
made by adding 10ml of high pH buffer solution in to 1L of distilled water in a large plastic
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tub. After initial rehydration, the slides were transferred to a plastic microwave rack and then
to the tub containing high pH buffer solution. After microwaving for 30 minutes at high power
(800W) followed by cooling for 10 minutes, the plastic rack and slides were extracted from the
microwave, the lid of the tub removed and the slides rinsed in cold tap water. Once cooled,
the slides were transferred to a glass jar and then assembled as part of the Sequenza R©rack and
CoverplateTMsystem (Thermo Scientific, Runcorn, UK), to ensure reproduction staining con-
sistency and reduce error. Each reservoir was filled with Phosphate Buffered Saline (PBS) to
check that even flow rates between the chambers. To each chamber, 100µL (2 drops) of BLOX-
ALL blocking solution (SP-6000, Vector Laboratories, Ltd., Peterborough, UK) was added for
10 minutes, followed by PBS wash buffer for 5 minutes. Whilst 100µL of 2% Casein (SP-5020,
Vector Laboratories, Ltd., Peterborough, UK; 1ml 10x Casein + 4ml distilled water) was added
for 10 minutes, the primary rabbit anti-human polyclonal UCP2 antibody was prepared 1:400
in 2% Caesin. Once completed, 100µL of UCP2 primary antibody (ab203244, Abcam, Cam-
bridge, UK) was pipetted to each chamber and incubated for 1 hour. This was followed by a 5
minute wash buffer step then the addition of 2 drops goat anti-rabbit IgG AmplifierTMAntibody
(MP-7602, Vector Laboratories, Ltd., Peterborough, UK), before incubation for 15 minutes. Af-
ter another wash in PBS buffer for 5 minutes, 2 drops of ImmPRESSTMExcel Amplified Horse
Radish Peroxidase (HRP) Polymer Reagent (anti-goat IgG, MP-7602, Vector Laboratories, Ltd.,
Peterborough, UK) was added and incubated for 30 minutes. This was followed by 2 washes
in PBS buffer, during which equal volumes of ImmPACT DAB EqV Reagent 1 with Reagent 2
(SK-4103, MP-7602, Vector Laboratories, Ltd., Peterborough, UK) were combined and mixed
well. Subsequent to the last incubation, incubated with ImmPACT DAB EqV working solution
for 5 minutes, before another incubation with wash buffer over 5 minutes. Two drops of filtered
Mayers haemotoxylin was pipetted to each slide for 30 seconds, before the reaction stopped by
adding warm tap water. The sections were then brought to Xylene and finally mounted to DPX
using a glass coverslip as described above.
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Spectral Image Analysis of Stained Sections
For PAS and UCP2, photomicrographs of complete sections were obtained using a slide scan-
ner (Axio Scan Z1, Zeiss, GmBH) at 5x objective, with the raw .ZVI images processed using
Zen Blue software (Zeiss, GmBH) and exported as lossless Tagged Image Format (.TIF). Sub-
sequently, spectral image analysis was performed using Fiji.[214] Each image was opened and
colour deconvolution was performed, splitting each image into its Red Green Blue (RGB) chan-
nels, using vectors based upon the histological staining technique incorporated.[215] Using the
‘Colour 2’ image, the default threshold was applied, that uses an iterative procedure based upon
the isodata algorithm.[216] Once the measurements had been set to include the median intensity
density, the image was processed and the data exported as a comma separated file (.CSV).
For ultrastructural examination by Transmission Electron Microscopy (TEM), 2mm segments
of the pre-fixed biopsies, pre-fixed in 2.5% glutaraldehyde and processed to a resin block,
were cut and mounted. Photomicrographs were taken at 13000x magnification of mitochon-
dria within random hepatocytes and examined for signs of injury.[217]
2.2.8 Statistical Analysis
Calculation of Missing Liver Masses
The first three perfused livers were not weighed for logistical reasons. A derived mass for the
missing values was determined by initially calculating the body surface area (BSA) for each






The Calculated Liver Mass (CLM) for each perfused livers was determined using the published
method:[218]
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CLM(g) = 772×BSA (2.7)
A linear regression model was determined, through the origin, for all perfused livers where an
Actual Liver Mass (ALM) was available (Figure 2.3):
ALM(g) = 1.281× (CLM);R2 = 0.981 (2.8)
From this, the derived liver masses for the missing values were obtained. The outliers at each
extreme of liver mass in Figure 2.3 were acknowledged as was the need for any regression
model to intercept at the origin. Whilst the linear regression model could be affected by bias,
particularly with small numbers used to generate the model, the high coefficient of determina-
tion of 0.981 was encouraging as well as the fact that such weights are seen in clinical practice.
A more accurate model, that would minimise any residuals, could be obtained potentially using
the Liver Unit Transplant Database at Queen Elizabeth Hospital. However, although the mass of
720 grafts were available from the database, corresponding donor mass and height were incom-
plete hence could not be added to the linear regression model. Nevertheless, with mean mass of
1535g, standard deviation of 466g and being normally distributed, all the liver masses in Figure
2.3 were within the 95% confidence interval [620g, 2449g] of the database, thus not regarded as
outliers. For these reasons, the linear regression model presented was used for further statistical
analysis.
Initial Analysis of Perfusion Data
All data was analysed using R 3.3.0 within the RStudio 0.99.896 (RStudio Inc., Boston, MA,
USA) Integrated Development Environment.[219] Individual plots of perfusion parameters were
generated using the Stata software programme.
The perfusion parameters were limited to either 6 hours NMLP duration or the end of perfu-
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Figure 2.3: Linear regression model for liver masses. The actual liver mass (ALM) for each
perfused liver, if available, was plotted against its corresponding calculated liver mass (CLM).
From this, a linear regression model with its intercept through the origin was obtained in order
to calculate the derived liver mass of the missing values.
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sion, whichever was shorter. Assessment of which perfusion parameter produced the best two
separate groups for viability testing was determined by cluster analysis using the unsupervised
machine learning Partitioning Around Medoids (PAM) algorithm based on K-Medoids. This
method is robust to outliers compared to K-means clustering.[220]
For grouped graphs, dots represent the individual data points, whilst the blue lines are smoothed,
parabolic, weighted regression curve for the data using the Locally Estimated Scatterplot Smooth-
ing (LOESS) method and shaded areas are the 95% confidence interval for the regression curve.
This provides a graphical representation of local regression to model non-parametric data. Plots
were created using the ‘ggplot2’ and ‘cowplot’ packages for R.
Statistical analysis was performed using the ‘psych’ and ‘exactRankTests’ R packages.Categorical
data is presented as rounded whole numbers and frequencies. Tests of association were per-
formed using Fisher’s exact test. Numerical data are presented as median and range. Data out
of range were assigned the appropriate upper or lower limit value for statistical analysis. One
and two-tailed Mann-Whitney U allowing for ties were performed as appropriate. Two-way re-
peated measures factorial Analysis of Variance (ANOVA) was conducted to determine the influ-
ence of two independent variables (viabililty and perfusion time) using the ‘nlme’ package.[221]
Viability included two levels (Non-viable, viable) and time consisted of three levels (Start, 2 or
3 hours of NMLP, end of NMLP) with post-hoc Friedman’s tests performed if factors or inter-
actions were significant. A p-value of < 0.05 was deemed significant and presented to three
decimal places.
Secondary Analysis of Perfusion Data
Twenty-seven perfusion parameters were measured and recorded over a maximum 6-hour pe-
riod at 30 minute intervals, giving the data a repeated measures structure (Table 2.1). Each
perfusion parameter was evaluated using connected scatter plots. Perfusion measurements were
plotted against time, combining all study livers’ measurements on the same axes for compar-
ative purposes. By giving each liver its own observable trajectory, this enabled any specific,
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Function Parameter Unit Type
Fluid Dynamics
Hepatic arterial flow rate ml/min/100g Actual
Hepatic arterial pressure mmHg Actual
Hepatic arterial resistance mmHg/(ml/min) Derived
Portal flow rate ml/min/100g Actual
Portal pressure mmHg Actual























Oxygen consumption mass ml/min/100g Derived
Oxygen extraction ratio Derived
Bile production g Actual
Table 2.1: Collected NMLP Parameters. All parameters either directly collected or calculated
every 30 minutes for the duration of the NMLP. pCO2, partial pressure CO2; pO2, partial pres-
sure of O2; HCO3, bicarbonate; BE, base excess; Na
+, sodium; K+, potassium; Cl−, chloride;
Ca2+, calcium; O2Hb, concentration of oxygenated haemoglobin; COHb, concentration of car-
boxyhaemoglobin ; MetHb, concentration of methemoglobin; HHb, concentration of deoxy-
genated haemoglobin; SO2, oxygenation saturation; Hct, haematocrit
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common trends to be identified.
Descriptive statistics were obtained for all variables. The median, minimum and maximum
values are presented for continuous variables due to the small sample size and accounts for any
skewed observations in the data. Numbers are reported at initiation of NMLP (T0) and then
after two, four and six hours of NMLP to illustrate performance over time.
Multilevel repeated measures models were employed by a statisitcian (Amanda Kirkham), in
view of the complexity of the method, to investigate response variables over time between two
groups using a limited sample size. To model the data faithfully, the time variable used for mod-
elling consisted of the actual minute at which each perfusion time point was measured. Random
intercept models were constructed with response repeated measures over time and clustered
within each liver. Where linear relationships were not observed, data were transformed as ap-
propriate. Explanatory variables and interactions were tested where applicable and included if
found to be significant at the 5% level. Models were estimated using the method of maximum
likelihood estimation.
2.3 Results
2.3.1 Compilation of Human-Based Oxygen Carrying Solutions for NMLP
The initial fluid was based on PRC and Fresh Frozen Plasma (FFP) described by the Groningen
group.[202] As the volume of fluid within the circuit of the Liver Assist device is 2L, dosage
calculations were based on 40% adult blood volume. Arterial Blood Gases (ABG) and perfusate
samples were taken every 30 minutes during NMLP and informed subsequent interventions.
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Oxygen Carrier
For ethical, financial and logistical reasons, initial perfusions were performed with 3 units of
either group specific or O-negative PRC aged between 35-45 days, the maximum for clinical us-
age in the UK and US respectively. The PRC were provided by Blood Bank at Queen Elizabeth
Hospital Birmingham. Progressive erythrocyte haemolysis was noted and declining oxygen
transport capacity beyond four hours of NMLP was observed. Erythrocyte fragility was associ-
ated with the age of PRC and compounded by sheer stress from the centrifugal pumps, circuit
tubing and the large surface area of the fluid-air interface in the device’s reservoir. After four
NMLPs and with ethical approval, transfer to non-clinical grade group specific or O-negative
PRC of less than 35 days age, where the volume in each bag was in excess of the 15% tolerance
permitted for human transfusion, was instigated. This decreased haemolysis and allowed more
stable NMLP lasting 6-10 hours.
Oncotic Pressure
Three bags of FFP were used for the initial pre-study NMLP, performed with a porcine liver
(data not shown). During the second pre-study NMLP, using a human discarded liver, defrosting
FFP delayed commencement of perfusion, precipitation was observed in the circuit at priming
and overall was associated with very poor oxygenator performance. As FFP exposes the liver to
complement and inflammatory mediators that may intensify IRI and adding clotting factors may
interfere with functional assessment, FFP was replaced with Human Albumin Solution (HAS)
5% (Alburex 5, CSL Behring GmbH, Germany; Na+ 144-160 mmol/L). The first two study
livers were beyond resuscitation and pH was not maintained above 7.20 despite intervention.
The significant sodium rise in these perfusions was a result of additional sodium bicarbonate
administered. To counteract hypernatraemia, the initial fluid was amended to reduce starting
sodium concentration. This was achieved using 250ml HAS 20% (Alburex 20, CSL Behring
GmbH, Germany; Na+ 144-160 mmol/L) and 750ml water for injections (Fresenius Kabi, UK),
supplemented with 12ml 30% sodium chloride (approximately 60 mmol Na+), to achieve the
same oncotic pressure with a lower initial sodium concentration of 110-120 mmol/L. As NMLP
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development progressed, one refrained from perfusing severely steatotic livers, with their asso-
ciated lower initial pH value. Therefore, the need for a low starting sodium was negated and so
reverted to using 5% HAS. This also had the advantage of reducing the pre-NMLP preparation
time.
Concurrently, a perfusion fluid using Gelofusine (B. Braun Medical Limited, UK) as an alter-
native to HAS was developed. The sodium content, cost and preparation time were favourable
however, after observing precipitation in the circuit tubing close to the antibiotic administration
port, Gelofusine was concluded to be incompatible with vancomycin. Reduced oxygenation
during NMLP beyond 8 hours perfusion was also noted with Gelofusine but not HAS 5%.
Maintaining Adequate Flow During NMLP
Heparin
In accordance with national guidance, intravenous heparin was administered to DBD donors
prior to commencing aortic perfusion. In DCD donors, as intravenous heparin administration
prior to life support withdrawal is prohibited, the drug was added to the perfusion fluid bags.
Heparin is essential to prevent microthrombi formation in the NMLP circuit, particularly within
the oxygenators. As suboptimal in-situ organ perfusion is a major reason for declining liv-
ers for transplantation, an initial bolus of 10,000 International Units (IU) of heparin sodium
(Wockhardt, UK) was added, followed by an additional 10,000 IU bolus every 3 hours.
Vasodilators
Adequate arterial flow is essential for liver function. No vasoactive drugs were used by the
Groningen group, whilst the team using the OrganOx R©metraTMdevice considered a vasodilator
to be essential.[202, 222] During the second pre-study perfusion arterial flow reached 200-250
ml/min but decreased to 100-120 ml/min after an hour and was associated with a deterioration
in ABG readings. Increasing arterial pressure alone achieved only a transient improvement.
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A continuous infusion of Glyceryl Trinitrate (GTN) with additional boluses was administrated
after 2.5 hours of NMLP. With this intervention, over 5 hours of NMLP with adequate arterial
flow was achieved.
Increased sodium concentrations of up to 200 mmol/L within 6 hours of NMLP were observed
when administering a GTN infusion in severely steatotic livers. One hypothesised that supra-
physiological perfusate sodium concentrations would interfere with the function of cellular
sodium-potassium ATP transporters and be detrimental to liver physiology. From the first study
perfusion onwards a switch to epoprostenol (Flolan, GlaxoSmithKline, UK) infusion was made,
commencing at 8 µg/hr and increased if HA flow rates sequentially decreased. Except for tech-
nical difficulties in cannulation, HA flow rates of greater than 200 ml/min were achieved. The
half-lives of these vasoactive drugs are short; 1-4 minutes for GTN and approximately 6 minutes
for epoprostenol, hence the need for continuous infusion.
Maintaining Physiological pH
An ABG of the fluid following priming the circuit but prior to connecting the liver was per-
formed. Physiological pH was maintained by administering 30 ml boluses of 8.4% sodium
bicarbonate (B. Braun Medical Limited, UK), containing a sodium ion content of 23 mg/ml,
to achieve a pH of greater than 7.20. Whilst bicarbonate, phosphate, protein or carbonic acid
buffers are contros of physiologcal pH in vivo, bicarbonate was the most straightforward to ma-
nipulate and quantitate, as well as being used clinically hence permitting ease of translation to
practice. Hence it was used for the model. Prior to using non-clinical grade PRC of less than
35 days age as the main oxygen carrier, pH always dropped to less than 7.00 following the start
of NMLP. Severely steatotic livers and those with CIT longer than 10 hours required frequent
30 ml boluses of 8.4% sodium bicarbonate, leading to hypernatremia in 6 NMLPs and resulted
in alterations to the fluid constituents. The alkalinity of epoprostenol (pH approximately 10.5),
increased the overall pH of the fluid and may have reduced the need for further boluses of 8.4%
sodium bicarbonate, therefore attenuating hypernatraemia.
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Promoting Bile Production
Taurocholic acid, a water-soluble bile acid, has been demonstrated to increase bile production
in porcine livers subjected to prolonged NMLP over almost 30 hours.[206] Taurocholic acid
(Sigma-Aldrich, UK) was infused during our NMLP in a 2% solution at a rate of 7 ml/hr,
equivalent to that previously published.[206] As there was no access to clinical grade tauro-
cholic acid, it was omitted as livers were targeted for subsequent transplantation. Bile was
produced without a taurocholic acid infusion when perfusion was limited to 6 hours.
Nutrition and Trace Elements
Insulin and Glucose
A continuous insulin (Actrapid, Novo Nordisk, Denmark) infusion (10 IU/ml) was initially
administered at 5 IU/hour to facilitate glucose uptake and utilisation by hepatocytes, similar to
the Oxford group. As one did not observe a relationship between glucose decrease and insulin
dosage, insulin was removed from the perfusion protocol. If glucose concentration was less
than 10 mmol/L then a 50ml bolus of 10% glucose (Macopharma, UK) was administered to the
circuit.
Amino Acids
Calculating the liver’s energy requirements based on its mass as a proportion of the total energy
requirements of the body is inadequate and it is likely to underestimate the amino acid de-
mands. The liver utilises 25% of total amino acid requirement.[223] Based on a typical adult’s
parenteral nutritional need for 12g nitrogen over 24 hours, an estimate of 25% of this amount
was administered as 50ml (0.8g nitrogen) boluses of Aminoplasmal 10% (B. Braun Medical
Limited, UK; nitrogen content 16g/L) every 6 hours.
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Vitamins
Multivitamins for infusion, containing vitamins A (retinol), D3, E (α tocopherol), C, B1 (thi-
amine), B2 (riboflavin), B6 (pyridoxine), B12, folic acid, pantothenic acid, biotin and vitamin
PP (niacin), were administered with Aminoplasmal every 6 hours as 2ml of Cernevit (Bax-
ter Healthcare Ltd., UK) reconstituted with 5ml water for injections. Additionally, 1mg phy-
tomenadione as Konakion Paediatric MM (Roche Products Limited, UK), was administered to
provide the substrate for potential factor V assays during NMLP. Although typically used in
parenteral nutrition, lipid was not added to the circuit, in an attempt to reduce the metabolic
load on steatotic and severely ischaemic livers.
Antibiotics
Antibiotics were added to minimise bacterial contamination. The Groningen protocol included
cefazolin, a first generation cephalosporin that is not readily available in the UK.[202] For this
perfusion protocol antibiotics would be: (1) Compatible with other constituents of the fluid;
(2) provide adequate broad-spectrum cover without undergoing hepatic metabolism; (3) have
assays available to measure concentration within the fluid; (4) administered to livers that could
be transplanted in to recipients irrespective of penicillin allergy. Dosages were calculated based
on perfusion fluid volume in relation to the circulating volume of an adult human (40-50%).
Compatibility studies to identify precipitation with the non-PRC components were conducted
(Table 2.2).
2.3.2 Compatibility Testing of Perfusion Fluid Components
Compatibility testing of various components of the perfusion fluid demonstrated that either a
combination of vancomycin and meropenem or vancomycin and gentamicin would provide the
most appropriate antimicrobial cover, whilst minimising precipitation when albumin was used
to provide oncotic pressure to the solution. If gelofusine was used to provide oncotic pressure,







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































would be deleterious to the perfusion circuit and the perfused liver (Table 2.3)
2.3.3 Final Regimens
Vancomycin (Wockhardt, UK) 500mg and gentamicin (Cidomycin, Sanofi, UK) 60mg were
identified as the appropriate antibiotics for administration with the HAS based fluid. Cefurox-
ime 750mg was used for the Gelofusine based fluid.
Two perfusion fluids were developed providing the components for successful resuscitation
and subsequent transplantation. The first was demonstrated to be suitable in NMLP directed
at preclinical research and potential clinical transplantation in to patients without penicillin
allergy that required NMLP for longer than 6 hours (Table 2.4). The second was shown to be
appropriate for perfusions resulting in potential clinical transplantation in patients with a known
penicillin allergy and where NMLP is required for less than 6 hours (Table 2.5).
These perfusion fluids achieve oxygenation and adequate flow by using either group specific or
O-negative PRC and the dynamic adminstration of epoprostenol respectively. A range of other
pharmacological interventions provide a near physiological environment that facilitates assess-
ment of viability. The fluids are versatile as they can be applied in both preclinical research
environments and in translational studies, as demonstrated by the successful transplantation of
two livers after NMLP, each using a different fluid. Additionally, the fluids can be stratified
according to the penicillin allergy status of the potential recipient whose donor liver has been
subjected to NMLP. These regimens permit the rapid establishment of NMLP, as PRC and ei-
ther HAS or Gelofusine, supplemented by epoprostenol, are essential for initiating perfusion,
with the remaining drugs being infused after commencement. However, composition of the flu-
ids are reliant on the donation and processing of whole blood to provide PRC, an increasingly
scarce resource associated with potential incompatibility with the donated liver and recipient as
well transfusion-related infection. Although these fluids have accounted for available evidence,
the majority of design has been based on expert rationale.
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Prior to commencing NMLP:
Drug Amount/rate Comments
Human albumin solution 5% 1 litre
Single bolus
Packed red cells 3 units
Heparin 5,000iu/5ml 10,000iu (10ml)
Sodium bicarbonate 8.4% 30ml
Calcium gluconate 10% 10ml






Taurocholic acid 2% 2%, 50ml syringe Continuous infusion at 7ml/hr
Aminoplasmal 10% 50ml Single bolus every 6 hours
Sodium bicarbonate 8.4% 30ml Single bolus if pH <7.20
Glucose 10% 50ml bag Single bolus if perfusate glucose <10 mmol/L
Heparin 5,000iu/5ml 10,000iu (10ml) Single bolus every 3 hours
Table 2.4: Final perfusion fluid regimen. Epoprostenol, in 50ml syringe, according to man-
ufacturers instructions. Aminoplasmal, add 5ml water to a vial of Cernevit and add 2ml &
phytomenadione 1mg (0.1ml) to Aminoplasmal 500 ml bottle. Taurocholic acid for research
livers only.
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Packed red cells 3 units
Heparin 5,000iu/5ml 10,000iu (10ml)
Sodium bicarbonate 8.4% 30ml
Calcium gluconate 10% 10ml
Epoprostenol 2mcg/ml in 50ml syringe Continuous infusion at 4ml/hour
After commencing NMLP:
Drug Amount/rate Comments
Cefuroxime 750mg Single bolus
Taurocholic acid 2% 2%, 50ml syringe Continuous infusion at 7ml/hr; research only
Aminoplasmal 10% 50ml Single bolus every 6 hours
Sodium bicarbonate 8.4% 30ml Single bolus if pH <7.20
Glucose 10% 50ml bag Single bolus if perfusate glucose <10 mmol/L
Heparin 5,000iu/5ml 10,000iu (10ml) Single bolus every 3 hours
Table 2.5: Final perfusion fluid regimen for those with a penicillin allergy. Epoprostenool,
in 50ml syringe, according to manufacturers instructions. Aminoplasmal, add 5ml water to a
vial of Cernevit and add 2ml & phytomenadione 1mg (0.1ml) to Aminoplasmal 500 ml bottle.
Taurocholic acid for research livers only.
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2.3.4 Demographics of Human Livers
A total of twelve livers, eight of which where DCD, were included in the study. The median
donor age was 56 (range 30 - 76) years and the body mass index 30 (23-47) kg/m2. The median
CIT was 483 (range 380 - 797) minutes. Three livers were discarded due to steatosis, two livers
for extrahepatic primary donor malignancy, 2 for excessive CIT and 2 for excessive donor WIT.
Liver fibrosis, prolonged stay on ITU and poor perfusion in the remaining 3 livers precluded
use for OLT (Table 2.6).
There was a significant discrepancy between the subjective assessment of liver quality per-
formed by the organ retrieval or transplant surgeon and the subsequent histological findings.
Microscopic evaluation confirmed only a mild large droplet macrovesicular steatosis in livers
declined for steatosis. Histology did not reveal any fibrosis in the liver declined for this pre-
sumed diagnosis. Two livers (Table 2.6, donors 8 and 9), were declined for unexpected remote
donor malignancy and otherwise had favourable macroscopic appearances and stable perfusion
characteristics during NMLP (Figure 2.4 A). Similar characteristics were observed in another
four livers. The remaining six livers had unsatisfactory macroscopic appearances, including
steatosis and fibrosis, or unsatisfactory perfusion parameters during NMLP (Figure 2.4 B).
2.3.5 Identification and Confirmation of Differentiating Perfusion Param-
eters for Viability Testing of Discarded Human Cadaveric Donor
Livers Subjected to NMLP
Lactate Metabolism Clusters Perfused Livers into Two Distinct Groups
Only the lactate plot for individual NMLPs visually demonstrated clustering in to two dis-
tinct groups (Figure 2.5). Plots for flow parameters (Hepatic artery flow per gramme of liver
tissue, hepatic artery pressure, hepatic artery resistance and congruent portal vein flow param-
eters), acid-base balance (pH, bicarbonate and base excess), oxygen carrying capacity (total
haemoglobin, haematocrit, oxygen consumption per gramme of liver and oxygen extraction ra-























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































haemoglobin graphically appeared to form two clusters, this could not be justified as NMLP 3
terminated after 3 hours of perfusion. Furthermore, PAM cluster analysis confirmed that lactate
concentration in the perfusate could group the data in to two distinct clusters, confirming the
visual representation.
Parameters were then categorised in to two groups based on lactate group, named ‘viable’ and
‘non-viable’, interchangeable with ‘lactate clearing’ and ‘non lactate clearing’ respectively.
There was no difference in the median starting lactate concentration between the viable and
non-viable groups (13.1 mmol/L vs. 13.4 mmol/L, p = 0.411). During NMLP, viable livers
showed significantly higher lactate clearance (Figure 2.18). After 2 hours, the median lactate
concentration in the viable group was 3.1 mmol/L vs. 15.8 mmol/L in the non-viable group (p =
0.004). By the end of NMLP, the median lactate in the viable group was lower compared to the
non-viable group (2.3 mmol/L vs. 15.2 mmol/L, p = 0.001). These were reinforced by greater
reductions in lactate concentrations compared to initial concentration, known as the delta lac-
tate, in the viable group at both 2 hours of NMLP (-9.6mmol/L vs. -0.5mmol/L, p = 0.002) and
at the end (-10.4mmol/L vs. -0.1mmol/L, p = 0.013). Detailed information concerning lactate
clearance is provided in Figures 2.18 and 2.19 as well as in Tables 2.7 and 2.8.
Bile Production
In the non-viable group, only one liver produced bile by the end of the NMLP (2.6g at 6 hours).
A binomial test indicated that the proportion of non-viable livers producing bile during the
perfusion 0.0139 was lower than the expected 0.5, p < 0.001. There was more sustained bile
production in the viable group, although this only occurred in 4 livers. A binomial test indicated
that the proportion of viable livers producing bile during the perfusion 0.486 was similar to the
expected 0.5, p = 0.906. After 2 hours, the median production was similar (viable 0.0g vs. non-
viable 0.0g, p = 0.227), but was significantly higher in the viable group at the end of NMLP






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.18: Lactate concentration (mmol/L) during NMLP based on viability criteria. There
was no difference in the median lactate at the start of perfusion. At 2 hours, viable livers had
lower lactate concentrations than non-viable livers (median viable 3.1 mmol/L vs. non-viable
15.8 mmol/L, p = 0.004) This was maintained at the end of perfusion (median viable 2.3 mmol/L
vs. non-viable 15.2 mmol/L, p = 0.001). Line is the LOESS regression curve, shaded area is the
95% confidence interval for the regression curve. Non-viable, NMLP 1-5,10; Viable, NMLP
6-9,11,12.
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Figure 2.19: Delta lactate concentration during NMLP based on designated viability.The differ-
ence in delta lactate after 2 hours of NMLP between viable and non-viable livers (-9.6mmol/L
vs. -0.5mmol/L respectively, p = 0.002) reinforces the differences seen in absolute lactate con-
centrations despite relatively low n numbers. Line is the LOESS regression curve, shaded area




























































































































































































































































































































































































































































































































































































































































































































Overall Non-Viable Viable p-value
Age (years) 56 (30-76) 58 (46-76) 56 (30-70) 0.485
BMI (kg/m2) 30.2 (23.1 – 47.2) 31.3 (23.1 – 47.2) 27.7 (23.9-44.8) 0.699
Cold ischaemic time (mins) 493 (380 - 797) 523 (380 - 797) 475 (408 - 583) 0.485
Donor risk index 2.373 (1.411 - 3.228) 2.707 (1.411 -3.228) 2.072 (1.612 -3.053) 0.31
Lactate (mmol/L)1 5.1 (0.6 - 20.0) 15.8 (4.4 - 20.0) 3.1 (0.6 - 5.5) 0.004
Change in lactate (mmol/L)1 -.27 (-12.2-7.0) -0.5 (-2.8-7.0) -9.6 (-12.2 - -2.5) 0.002
Lactate (mmol/L)2 5.8 (0.7-20.0) 15.2 (6.9-20.0) 2.3 (0.7-4.6) 0.001
Change in lactate (mmol/L)2 -4.9 (-12.6-12.8) -0.1 (-8.3-12.8) -10.4 (-12.6 - -4.1) 0.013
Trough lactate (mmol/L) 3.3 (0.6 – 13.4) 10.8 (4.4 – 13.4) 1.0 (0.6 – 2.1) 0.001
Bile production (grammes)1 0.0 (0.0 - 10.9) 0.0 (0.0 - 0.0) 0.0 (0.0 - 10.9) 0.227
Cumulative bile production (grammes)2 0.0 (0.0 - 23.0) 0.0 (0.0 - 2.6) 6.5 (0.0 - 23.0) 0.03
Arterial flow (ml/min)1 440 (14 - 727) 266 (14 - 631) 478 (420 - 727) 0.09
Change in arterial flow (ml/min)1 +240 (-302 to +616) +94 (-302 to +420) +331 (+189 to +616) 0.032
Arterial resistance1 0,209 (0.095-4.929) 0.123 (0.055-0.160) 0.047
Portal flow (ml/min.)1 1060 (650 - 1580) 915 (650 - 1250) 1210 (1000 - 1580) 0.051
Change in portal flow (ml/min)1 +505 (+120 to +1230) +195 (+120 to +780) +795 (+410 to +1230) 0.004
Change in portal flow (ml/min)2 +640 (60-1570) +500 (60-850) 840 (600-1570) 0.023
Portal resistance1 0.010 (0.006-0.014) 0.010 (0.007-0.014) 0.008 (0.006-0.010) 0.036
Glucose (mmol/L)1 43.1 (23.3-64.5) 50.0 (39.5-64.5) 40.0 (23.3-59.3) 0.083
Glucose (mmol/L)2 32.1 (8.0-56.2) 32.1 (15.1-56.2) 29.1 (8.0-52.4) 0.393
HCO3 (mmol/L)2 17.9 (9.1-40.7) 28.4 (14.5-40.7) 12.5 (9.1-22.9) 0.026
Haemoglobin (g/L)1 76.8 (64.2-84.0) 70.3 (64.2-81.7) 80.5 (74.0-84.0) 0.032
Haemoglobin (g/L)2 73.7 (46.7-84.8) 59.6 (46.7-84.8) 75.6 (73.6-80.1) 0.032
Sodium (mmol/L)2 139.8 (126.8-196.5) 145.8 (136.6-196.5) 131.9 (126.8-149.5) 0.013
Change in sodium (mmol/L)2 22.6 (-19.4-66.2) 38.0 (26.5-66.2) 13.2 (-19.4-26.5) 0.01
Oxygen Extraction Ratio1 0.270 (0.085-0.831 0.266 (0.181-0.831) 0.245 (0.085-0.460) 0.284
Oxygen Extraction Ratio2 0.280 (0.124-0.645) 0.259 (0.202-0.645) 0.288 (0.124-0.490) 0.457
Note:Values are presented as median with range; *1 parameter measured after 2 hours of perfusion; *2 parameter measured at end of perfusion
Table 2.8: Donor and perfusion parameters comparison between viable vs. non-viable groups.
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Figure 2.20: Bile production by viability group. Bile production was sporadic in both groups
however, cumulative bile production in the viable group was higher than the non-viable group by
the end of NMLP. There was no difference after 2 hours of NMLP when the viability assessment
was made. Line is the LOESS regression curve, shaded area is the 95% confidence interval for
the regression curve. Non-viable, NMLP 1-5,10; Viable, NMLP 6-9,11,12.
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Flow Parameters
There was no difference in the initial hepatic artery flow rates between the groups (Figure
2.21 A; median non-viable 128ml/min vs. viable 114ml/min, p = 0.818). After 2 hours of
NMLP, hepatic artery flow rates had increased more in the viable group (478ml/min, change
+331ml/min vs. 266ml/min, change +94ml/min, p = 0.032). There was no difference in the
arterial flows at the end of NMLP (viable 617ml/min vs. non-viable 376ml/min, p = 0.197).
These differences were maintained when accounting for the mass of liver perfused. Similarly,
there were no differences in initial hepatic artery flow rates per 100 grammes of liver between
the groups (2.22 A; median non-viable 5.689ml/min/100g vs. viable 6.294ml/min/100g, p =
0.699). After 2 hours of NMLP, not only had there been an increase in hepatic arterial flow
rates per 100 grammes of liver between the groups (non-viable +4.458ml/min/100g vs. viable
16.207ml/min/100g, p = 0.026) but also the absolute flow rates was higher in the viable group
(non-viable 14.619ml/min/100g vs. viable 24.690ml/min/100g, p = 0.013). However, absolute
and changes in hepatic arterial flow rates were similar by the end of NMLP.
Portal vein flow rates were similar in both groups at the start of NMLP (Figure 2.21 B; median
viable 470ml/min vs. non-viable 550ml/min, p = 0.288). After 2 hours of NMLP, portal vein
flow rates in the viable group had increased more compared to the non-viable group (viable
1210ml/min, change +795ml/min vs. non-viable 915ml/min, change +195ml/min, p = 0.004).
Portal vein flow rates were higher in the viable group at the end of NMLP (viable 1320ml/min
vs. non-viable 1060ml/min, p = 0.047). Accounting for mass of liver perfused, there were
no differences in portal vein flow per 100 grammes of liver between the two groups at the
start of NMLP (2.22 B; non-viable 29.687ml/min/100g vs. viable 22.230 ml/min/100g, p =
0.394). Again, not only was there an increase in the portal vein flow rates per 100 grammes of
liver between the groups after 2 hours of NMLP (non-viable +10.455ml/min/100g vs. viable
42.362ml/min/100g, p = 0.008), but also the absolute flow rate per 100 grammes of liver in the
portal vein was higher in the viable group (non-viable 43.829ml/min/100g vs. viable 63.621
ml/min/100g, p = 0.032). In comparison to the hepatic arterial flow rates at the end of NMLP,
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absolute and changes to portal vein flow rates per 100 grammes of liver were higher in the vi-
able group (absolute non-viable 57.932ml/min/100g vs. viable 71.387ml/min/100g, p = 0.004;
change non-viable +28.654ml/min/100g vs. viable 43.920ml/min/100g, p = 0.008).
Hepatic artery and portal vein resistances were similar between the two groups at the start of
NMLP (Figure 2.23). After 2 hours of NMLP, hepatic artery resistance was higher in the non-
viable group (Figure 2.23 B); viable 0.123 vs. non-viable 0.209, p = 0.047) but returned to
similar values by the end of NMLP. These differences were reflected in portal vein resistance
after 2 hours of NMLP (Figure 2.23 D); viable 0.008 vs. non-viable 0.010, p = 0.036), but
returned to similar values by the end of perfusion.
Blood Gas Parameters and Glucose Utilisation
Oxygen consumption per 100 grammes of liver was similar in both groups at the start of NMLP
(Figure 2.24, non-viable 1.188ml/mn/100g vs. viable 1.182ml/min/100g, p = 0.914). Subse-
quently, after both 2 hours and the end of NMLP, there were no differences in oxygen con-
sumption between the groups across the timepoints (2 hours non-viable 2.238ml/min/100g vs.
2.211ml/min/100g, p = 0.331; end NMLP non-viable 2.415ml/min/100g vs. 2.926ml/min/100g,
p = 0.535). The curvature seen in the non-viable group is most likely due to outlying values.
The Oxygen Extraction Ratio (O2ER) was similar for both groups at the start of NMLP (Figure
2.25; viable 0.285 vs. non-viable 0.223, p = 0.962). There was a trend for O2ER to be higher
in the non-viable group after 2 hours of NMLP, but this did not reach statistical significance.
There was no difference between the groups at the end of perfusion.
The pH of the perfusion fluid was similar for both groups at the start of NMLP (Figure 2.26
A; viable 7.265 vs. non-viable 7.168, p = 0.762). There was a trend for the non-viable group
to become more acidotic at the end of NMLP, this did not reach significance. Perfusion fluid
acidosis with pH less than 7.20 was corrected throughout NMLP using 20ml boluses of sodium
bicarbonate 8.4% however, both groups received a similar number of boluses.
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Figure 2.21: Arterial and portal flow rates during NMLP based on viability. Flow rates in
hepatic artery (ml/min; A) and portal vein (ml/min; B). Line is the LOESS regression curve,
shaded area is the 95% confidence interval for the regression curve. Non-viable, NMLP 1-5,10;
Viable, NMLP 6-9,11,12.
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Figure 2.22: Arterial and portal flow rates by mass of liver during NMLP based on viabil-
ity.Flow rates in hepatic artery (ml/min/100g; A) and portal vein (ml/min/100g; B). Line is the
LOESS regression curve, shaded area is the 95% confidence interval for the regression curve.
Non-viable, NMLP 1-5,10; Viable, NMLP 6-9,11,12.
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Figure 2.23: Arterial and portal pressures and resistances during NMLP based on viability.
Pressures (mmHg; A, C) and resistances (mmHg/(ml/min); B, D) in the hepatic artery (A,
B) and portal vein (C, D) during NMLP based on designated viability. Line is the LOESS
regression curve, shaded area is the 95% confidence interval for the regression curve. Non-
viable, NMLP 1-5,10; Viable, NMLP 6-9,11,12.
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Glucose concentrations were similar in both groups at the start of NMLP (viable 43.4mmol/L vs.
non-viable 50.8mmol/L, p = 0.258). Glucose utilisation in the viable livers tended to be higher
after 2 hours of NMLP however, this did not reach significance (Table 2.8, viable 40.0mmol/L,
vs. non-viable 50.0mmol/L, p = 0.083). There was no difference in glucose concentration at the
end of NMLP (Figure 2.27).
Histological Findings
Ischaemic type coagulative necrosis was minimal across both groups. Lost cohesion of hep-
atocytes predominantly in zone 3 was observed in the non-viable group (Figure 2.28 B) with
all post-NMLP livers showing variable amounts of hepatocyte detachment (non-viable 15%,
1-40% v viable 1.5%, 0-10%) (Table 2.9 and Figure 2.28).
By pathologist assessment, there was no difference in amount of glycogen depletion pre-NMLP
between the groups (viable 80% depletion, 5-95% vs. non-viable 75% depletion, 5-99%). At
the end of the perfusion, livers in the viable group displaying increased PAS staining (viable
22.5% glycogen depletion, 5-80% vs. non-viable 80% depletion, 10-90%) in the viable group,
indicating that viable livers were able to uptake glucose and store this as glycogen (Figure 2.29).
None of the livers displayed significant large droplet steatosis and at most reached a mild de-
gree (maximum of 15%). Small droplet macrovesicular steatosis was greater in the non-viable
livers (Figure 2.30 and Table 2.9). Liver 5, declined for transplantation based on its macro-
scopic appearance, had a portal hepatitis (Figure 2.30 A) and severe zone 3 cholestasis (Figure
2.30 B). PAS stained section of liver 4 (Figure 2.30 C) which had the most severe large droplet
macrovesicular steatosis (oval), the type of fat considered in evaluating suitability for trans-
plantation. It is mild involving up to 15% of hepatocytes. This liver was turned down on
macroscopic assessment of steatosis. PAS stained section of liver 1 (Figure 2.30 D) pre-NMLP
showed extensive small droplet microvesicular steatosis, where hepatocyte cytoplasm often con-
tains numerous small droplets of fat which do not displace the hepatocyte nuclei. Several large
droplet fat droplets are also present. This liver was turned down due to the macroscopic appear-
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Figure 2.24: Oxygen consumption by mass during NMLP based on viability. No differences
were observed in oxygen consumption per 100 grammes of liver throughout NMLP between
both groups. Line is the LOESS regression curve, shaded area is the 95% confidence interval
for the regression curve. Non-viable, NMLP 1-5,10; Viable, NMLP 6-9,11,12.
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Figure 2.25: Blood gas parameters during NMLP based on viability criteria. Oxygen extraction
ratio (A), pCO2 (kPa; B), haemoglobin concentration (g/L; C) and haematocrit (%; D) during
NMLP based on designated viability. Line is the LOESS regression curve, shaded area is the
95% confidence interval for the regression curve. Non-viable, NMLP 1-5,10; Viable, NMLP
6-9,11,12.
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Figure 2.26: Acid/base and electrolytes during NMLP based on viability criteria. pH (-
log10[H+]; A), bicarbonate (mmol/L; B), sodium (mmol/L; C) and potassium (mmol/L; D)
concentrations during NMLP based on designated viability. There was a trend towards more
stable maintenance of pH and sodium concentration and a more consistent bicarbonate concen-
tration in the group deemed viable. Line is the LOESS regression curve, shaded area is the
95% confidence interval for the regression curve. Non-viable, NMLP 1-5,10; Viable, NMLP
6-9,11,12.
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Figure 2.27: Glucose concentration during NMLP by viability group. Line is the LOESS re-
gression curve, shaded area is the 95% confidence interval for the regression curve. Non-viable,
NMLP 1-5,10; Viable, NMLP 6-9,11,12.
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ance of steatosis, but large droplet steatosis was mild involving only 5% of hepatocytes in the
whole biopsy. It is likely that the small droplet steatosis was also seen macroscopically. This is
not traditionally considered in assessing a liver for transplantation and indicates the requirement
of a liver biopsy to accurately assess the type and amount of both types of fat droplets. H&E
stained section of liver 7 (Figure 2.30 E) turned down because macroscopically thought to have
fibrosis. There is no fibrosis present. There is a normal portal tract (PT) showing no fibrous ex-
pansion. The abnormality present is centred around hepatic veins (HV) consisting of confluent
areas of hepatocyte loss in which there is variable haemorrhage/congestion (red colour of red
blood cells seen) and pigment laden macrophages. Detailed histological findings are shown in
Table 2.9 and Figures 2.28,2.29,2.30.
Graphically, quantitative histological assessment using the described slide scanning technique
suggested that viable livers at the start of NMLP had a higher polysaccharide content compared
to those in the non-viable group and behaves in a hyperbolic manner compared to the parabolic
curve in the non-viable group (Figure 2.31). However statistical analysis revealed no difference
in the starting polysaccharide content (median viable 4.55x107 v non-viable 3.95x105, p = 1.00).
Repeated measures ANOVA demonstrated the main effect for viability yielded a F value of F =
0.597, p > 0.05, indicating that the effect for viability was not significant. The main effect for
perfusion time yielded a F value of F = 1.089, p > 0.05, indicating that the effect for NMLP
time was not significant. The interaction effect was insignificant, F = 1.369, p > 0.05. Overall,
neither viability nor perfusion time influenced polysaccharide content, in contrast to the semi-
quantitiative scoring assessment by a trained clinical pathologist.
Mitochondrial Responses During NMLP With Respect to Viability
The mitochondrial response to NMLP was determined by ATP content and UCP2. Graphically,
there was a trend towards an increased ATP content in viable livers at the end of NMLP (Figure
2.32). However on ANOVA, both the main effect of viability with F = 2.565, p > 0.05, and
perfusion time with F = 2.069, p > 0.05, were not significant. Similarly, the interaction effect
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Figure 2.28: Histological findings pre- and post-NMLP in viable and non-viable livers: H&E
stain. H&E stained sections (A) viable liver number 8 after 6 hours of NMLP showing normal
hepatocyte plate morphology and attachment of hepatocyte plates to the hepatic vein (HV). (B)
non-viable liver number 3, 6 hours after NMLP showing loss of cohesion of hepatocytes from
each other and from the sinusoidal lining (arrows) and from the hepatic vein (HV). (C) Viable
liver number 12, 6 hours post NMLP showing a small area of coagulative necrosis where the
cells become hypereosinophilic (arrows). This was seen to an equal extent in both viable and
non-viable livers pre and post NMLP and was very mild in this series of livers [original objective







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.31: Quantitiative assessment of PAS staining over NMLP time by viability. Repeated
measures ANOVA main effect for viability F = 0.597, p > 0.05. Main effect for perfusion time
F = 1.089, p > 0.05. The interaction effect was insignificant, F = 1.369, p > 0.05. Overall,
neither viability nor perfusion time influenced polysaccharide content.
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was insignificant, F = 1.244, p > 0.05.
In both viable and non-viable liver, there appeared to be reductions in UCP2 after 3 hours of
NMLP followed by an increase by the end of perfusion. The latter increase appeared to be more
pronounced in the viable group. However, on repeated measures ANOVA, both the main effect
of viability with F = 0.110, p > 0.05, and perfusion time with F = 2.677, p > 0.05, were not
significant (Figure 2.33). Similarly, the interaction effect was insignificant, F = 1.146, p > 0.05.
There was no correlation between ATP content and UCP2 staining (Data not shown).
Secondary Analysis of Perfusion Data Using Multilevel Random Intercept and Slope Mod-
els
Due to the complexity of mutliple variables measured repeatedly over time and compared be-
tween two groups using a realtively small sample size, separate models were created for each
response variable as detailed in section 2.2.8: lactate and glucose metabolism, pH, arterial
and portal flow rates, oxygen extraction ratio, oxygen consumption, oxygen consumption per
gramme of liver and haematocrit. Explanatory variables included a dummy variable based on
lactate clearing trajectories, denoted as Lactate Clearing (LC) and Non-Lactate Clearing (Non-
LC), and perfusion time (in hours). To quantify any changes in response variables over time,
multilevel models were created. It was found that the better fitting models with lowest Akaike
Information Criterion (AIC) values, an estimator of the relative quality of statistical models,
included a random intercept and slope, perfusion time duration and lactate clearing dummy
variable.
Model results showed that lactate levels were 10.225 mmol/L (95% CI: 12.745, 7.705) lower on
average for the LC dummy variable in comparison to the Non-LC group, with the LC dummy
variable effect being strongly significant (p<0.0001), holding other model parameters constant
(Figure 2.34). There was on average 2.341 mmol/L (95% CI: 0.806, 3.876) difference in lactate
levels associated with a mmol/L difference in the inverse of time, with the time parameter
requiring transformation, and the time effect being very significant (p = 0.003), holding other
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Figure 2.32: ATP content per gramme of protein in liver during NMLP by viability. The trend
for increased ATP content at the end of NMLP in the viable group was not statistically signifi-
cant on repeated measures ANOVA (see main text).
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Figure 2.33: UCP2 immunohistochemical staining during NMLP based on viability.The trends
in an initial reduction then increase in UCP2 staining, particularly in the viable group, were not
statistically significant on repeated measures ANOVA (see main text).
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model parameters constant. This demonstrates that lactate not only decreases over time but also
can be described as two distinct groups for the purposes of viability assessment.
The model created for glucose as the response parameter found that change in glucose concen-
trations over time had a linear relationship (Figure 2.35). Results indicated that glucose levels
decreased by 2.469 mmol/L (95% CI: 4.246, 0.694) on average per unit change in time, where
the time effect was very significant (p = 0.006). However, the LC dummy variable effect was
found non-significant in this model (p = 0.148). This demonstrates that using this mathemati-
cal technique, whilst glucose concentration decreases over time, it is not a function of lactate
clearance for the purposes of viability assessment.
Individual models for arterial and portal flow rate responses were constructed, with better fit-
ting models having the lowest AIC values containing time, LC dummy variable, pressure and
resistance explanatory variables. Time was log (natural) transformed for the arterial flow rate
model and log (base 10) transformed for the portal flow rate model. The arterial flow rate model
showed that pressure and resistance were necessary for the model and had an important inter-
action, with their effects being strongly significant (p<0.0001). Results indicated that for a unit
increase in pressure, arterial flow rate decreased by 0.003 ml/min/g (95%CI: 0.004, 0.001); and
for a unit increase in resistance, arterial flow rate decreased by 0.391 (95%CI: 0.569, 0.212);
the interaction term indicated that for a unit increase in both pressure and resistance, the ar-
terial flow rate changed by 0.006 ml/min/g (95%CI: 0.003, 0.009), holding other variables in
the model constant. There was on average 0.034 units (95% CI: 0.0003, 0.067) difference in
arterial flow rate associated with a unit difference in the natural log of time, with the time effect
being significant (p = 0.048), holding other model parameters constant. The LC dummy vari-
able effect was found non-significant in this model (p = 0.824) (Figure 2.36). This demonstrates
that arterial flow rate is dependent on pressure and resistance but that although it increases with
time, arterial flow rate does not vary as a function of lactate clearance.
The portal flow rate model differed to the arterial flow rate model by showing that the resis-














































































































































































































































interaction with pressure was found to be strongly significant (p<0.0001) as was the pressure
parameter. For a one-unit increase in pressure, portal flow rate increased by 0.074 ml/min/g
(95%CI: 0.047, 0.100), whereas for a one-unit increase in both pressure and resistance, the
portal flow rate decreased on average by 3.751 ml/min/g (95%CI: 5.762, 1.742), holding all
other model parameters constant. Time was log (base 10) transformed and found to be strongly
significant (p<0.0001). For a one-unit increase in log (base 10) of time, the portal flow rate
changed on average by 0.116 ml/min/g (95%CI: 0.053, 0.179), holding other model param-
eters constant. The LC dummy variable effect was found non-significant in this model (p =
0.500)(Figure 2.37). This demonstrates that portal flow rate was dependent on pressure and
resistance over time but was not a function of lactate clearance.
Oxygen extraction ratio response was modelled including time and LC dummy variable only
(Figure 2.38). Neither explanatory variable was found to be significant in the model: time p =
0.985; LC dummy variable p = 0.07. Similar models were constructed for oxygen consumption
and oxygen consumption per gramme of liver responses (Figure 2.39). On modelling, oxygen
consumption per gramme of liver was found to have a significant (p<0.0001) linear relationship
with time; for a one-unit increase in time, oxygen consumption per gramme increased by 0.002
(95%CI: 0.0008, 0.003). The LC dummy variable was found not to be significant (p = 0.579).
Again, whilst the oxygen extraction per gramme of tissue increased during NMLP, this was not
as a function of lactate clearance so has limited value in viability assessment.
The pH response model contained three additional explanatory variables (HCO3, Partial Pres-
sure of CO2 (pCO2) and Base Excess (BE)) together with time (natural log transformation) and
LC dummy variable (Figure 2.40). Findings showed for a one-unit increase in HCO3, pH sig-
nificantly (p<0.0001) decreased on average by 0.055 units (95%CI: 0.056, 0.053); a one-unit
increase in pCO2, pH significantly (p<0.0001) decreased on average by 0.005 units (95%CI:
0.007, 0.004); and a one-mmol/L increase in BE, significantly (p<0.0001) increased pH on av-
erage by 0.061 units (95%CI: 0.060, 0.062), holding all other model parameters constant. Also,
the LC dummy variable was found to be strongly significant (p<0.0001), with pH being 0.013
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Figure 2.36: Arterial flow rates per gramme of liver during NMLP using multilevel random
intercept and slope model. Arterial flow rate interacted with pressure and resistance as well as
changing over time, but there was no effect of lactate clearance.
Figure 2.37: Portal flow rates per gramme of liver during NMLP using multilevel random in-
tercept and slope model. Pressure and resistance together interacted with portal vein flow rates,
with there being increases in portal flow rates over time. However, in this model the effect of
lactate clearance was not significant.
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Figure 2.38: Oxygen extraction ratios during NMLP using multilevel random intercept and
slope model. Neither perfusion time nor lactate clearance were found to have a significant
effect.
Figure 2.39: Oxygen consumption per gramme of liver during NMLP using multilevel random
intercept and slope model.There was a significant effect of time on oxygen consumption per
gramme of liver perfused. However, lactate clearance did not have an effect.
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units (95% CI: 0.019, 0.006) lower on average for the LC group in comparison to the non-LC
group. There was on average 0.005 units (95% CI: 0.0004, 0.009) increase in pH associated
with a unit difference in the natural log of time, with the time effect being significant (p =
0.031), holding all other model parameters constant. These results are in keeping with Hender-
son–Hasselbalch equation in relation to the physiological Carbon Dioxide (CO2) bicarbonate
buffering system.
Results for haematocrit modelled with the LC dummy variable found a decreasing linear rela-
tionship between haematocrit and time (Figure 2.41). For a one-unit increase in time, haemat-
ocrit decreased on average by 1.612 units (95%CI: 2.374, 0.0850; p<0.0001). The LC dummy
variable was found not significant (p = 0.818). That haematocrit decresaes over time might be
expected using mechanical rotorary pumps in the perfusion device and packed red cells that are
beyond acceptable thresholds for clinical transfusion. However, haematocrit was not a function
of lactate clearance.
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Figure 2.40: pH during NMLP using multilevel random intercept and slope model. Bicarbonate,
pCO2 and base excess all interacted with pH. Not only did pH increase over time, but also was
higher in the non-lactate clearing group.
Figure 2.41: Hct during NMLP using multilevel random intercept and slope model. Hct de-
creased during NMLP but there was no effect of lactate clearance in the model.
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Defining Viability Assessment Criteria
Based upon the results presented above, criteria defining viability to permit transplantation of
livers being subjected to NMLP are proposed. Timing of this assessment has been defined as af-
ter two hours of NMLP which allows for stabilisation in the performance of each perfused liver
to be established. With the normothermic machine used and accounting for the specifications
of the oxygenators which maintain their licenced performance for 6 hours, an assessment after
2 hours of NMLP permitted 4 hours for the sending and arrival of the patient to the operating
theatre department, completion of anaesthesia and recipient hepatectomy. The proposed criteria
are as follows:
1. Absolute Criteria (after 2 hours of NMLP)
(a) Perfusate lactate concentration <2.5 mmol/L
(b) Evidence of bile production
2. Other Considerations (after 2 hours of NMLP)
(a) Arterial flow rate >500 ml/min or >30 ml/min/100g and portal vein flow rate >1250
ml/min or >70 ml/min/100g
(b) Perfusate pH >7.30
(c) Evidence of homogenous perfusion and soft consistency of the liver.
To ensure patient safety during the early stages of the development of NMLP in discarded
human livers, both of the absolute criteria had to be present whilst the other considerations
were highly desirable and would provide reassurance to the perfusion and transplanting team in
the context of meeting the absolute criteria. As devlopment continues, these criteria could be
refined. Validation of the criteria is presented below in the first human allotransplantation of a
human discarded cadaveric donor liver subjected to NMLP.
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2.3.6 Validation of the Model by the First Allotransplantation of a Human
Discarded Cadaveric Donor Liver Subjected to NMLP
The Patient and the Donor
The patient was a 47-year-old man diagnosed with end-stage liver disease secondary to alco-
holic cirrhosis complicated by hepatic encephalopathy. He was placed on the UK liver trans-
plant waiting list in June 2014 with a Model for End-stage Liver Disease score of 17. NMLP
was discussed with the patient during transplant assessment, where he was seen by a surgeon,
anaesthetist, physician and clinical psychologist. NMLP was approved by the Novel Thera-
peutics Committee at the Queen Elizabeth Hospital and the patient provided written informed
consent for the procedure.
A DCD liver from a 29-year-old male donor with Type I diabetes, who sustained an irrecov-
erable hypoxic brain injury following a cardiac arrest and had been admitted to the ITU for 7
days, was initially accepted for transplantation. Withdrawal of life sustaining treatment was
conducted in ITU according to UK standard practice. Donor oxygen saturation was unrecord-
able 3 minutes after withdrawal of treatment. Systolic blood pressure fell to below 50mmHg
after 98 minutes. Asystole ensued 2 minutes later. Dual liver perfusion with University of Wis-
consin (UW) perfusion fluid at 4oC commenced 12 minutes after asystole using the established
super-rapid technique.[120] On back-table inspection, the retrieval surgeon described the liver
as non-steatotic, with soft consistency and normal vascular anatomy but with several areas of
suboptimal perfusion.
The shortest expected CIT on arrival at the Queen Elizabeth Hospital was 7 hours. The liver
was declined for transplantation following static cold storage however, after consideration it
was decided to subject the liver to NMLP for viability assessment.
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Normothermic Machine Liver Perfusion
On arrival at Liver Theatres within Queen Elizabeth Hospital Birmingham, good macroscopic
appearance was confirmed with a frozen histological needle biopsy. The liver was prepared for
transplantation in our usual manner. After a CIT of 426 minutes, NMLP commenced with the
packed red cell based fluid, supplemented with antibiotics and a prostacyclin infusion, at 37oC
using the Liver Assist device (Organ Assist R©, The Netherlands) as described above. Oxy-
genated pulsatile flow at 48 mmHg and non-pulsatile flow at 9 mmHg perfused the liver via
the hepatic artery and portal vein respectively, before recirculating from the hepatic veins via
the open circuit reservoir. During NMLP, flow parameters, perfusate blood gases and bile pro-
duction were assessed every 30 minutes as described previously. After 2 hours, organ function
was assessed by two transplant surgeons and an anaesthetist independent of the clinical and
perfusion teams. Another histological biopsy was taken at the end of NMLP.
The duration of NMLP was 393 minutes. Within one minute of commencing, heterogenous
macroscopic perfusion was noted on the surface of the liver. Homogenous perfusion was
recorded after 3 minutes of NMLP which was maintained until implantation.
At the start of NMLP, arterial and portal venous flow rates were 110 ml/min and 210 ml/min
respectively. Flow rates increased rapidly, reaching zeniths of 727 ml/min (artery) and 1090
ml/min (portal vein) after 90 minutes of NMLP (Figure 2.42 A). Flow rates at the end of NMLP
were 531 ml/min for the artery and 1070 ml/min for the portal vein. Arterial and portal venous
pressures were maintained within physiological thresholds (Figure 2.42 B). After an initial de-
crease, resistances in the artery and portal vein remained low. The initial reservoir temperature
was 20oC, reaching 35oC after 34 minutes of NMLP.
The initial lactate of 13.3 mmol/L decreased rapidly (Figure 2.42 C). After 2 hours of NMLP,
when the suitability for transplantation was assessed, the lactate was 1.2 mmol/L. It continued
to decrease, although more slowly, being 0.4mmol/L at the end of NMLP. Bile production
commenced 30 minutes after starting perfusion (Figure 2.42 D). In total, 27 grammes were
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Figure 2.42: A: Flow parameters. Hepatic artery flow (red) and portal vein flow (blue). B:
Pressure and resistances. Hepatic artery pressure (red), hepatic artery resistance (yellow), portal




Histological assessment demonstrated maintenance of architectural structure on H&E staining
(Figure 2.43 A-D). Sinusoidal vasodilatation was noted at the end of NMLP (Figure 2.43 B&D).
PAS staining highlighted considerable replenishment of hepatocyte glycogen stores (Figure 2.43
E-H). This was accompanied by a reduction in perfusate glucose concentration from a maxi-
mum of 24.3 mmol/L to 11.4 mmol/L without the adminstration of exogenous insulin (Data not
shown).
Surgical Procedure
Implantation was performed using an inferior vena cava preserving, modified piggyback tech-
nique with the creation of a temporary porto-caval shunt. Once the transplanting surgeon was
ready for implantation, NMLP was stopped, the donor liver disconnected and flushed with 2
litres of Histidine-Tryptophan-Ketoglutarate (HTK) solution (Custodiol, Koehler Chemie, Ger-
many). The liver was reperfused using an artery-first anastomosis technique. There was an
attenuated reperfusion syndrome. The operation was uneventful, with 5 units of packed red
cells and 6 units of fresh frozen plasma being transfused. The operation time was 5 hours and 3
minutes.
Postoperative Function and Course
The patient’s post-operative recovery was uneventful. The patient was transferred to ITU and
commenced on the standard immunosuppression regimen utilised at Queen Elizabeth Hospital
Birmingham, including oral tacrolimus, maintaining levels between 4 and 8 ng/mL, azathio-
prine and steroids. These continued on transfer to the ward. Liver and renal function tests
were checked daily. A peak Alanine Aminotransferase (ALT) of 1215 IU/L immediately post-
transplant halved by the 2nd post-operative day and was within the normal range (<41 IU/L)
4 weeks after transplantation (Figure 2.44 A). Aspartate Aminotransferase (AST) returned to
and was maintained within the normal range (<43 IU/L) after 7 days. The initial bilirubin of
124
Figure 2.43: A,C,E,G prior to NMLP. B,D,F,H after NMLP prior to implantation. A-D haema-
toxylin and eosin staining to demonstrate tissue architecture. E-H PAS staining to detect glyco-
gen content. A,B,E,F at 10x magnification. C,D,G,H at 40x magnification.
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45 µmol/L increased to a peak of 110 µmol/L on the 5th post-operative day, but returned to
and continued within the normal range (<22 µmol/L) after 34 days. Renal function remained
stable and within physiological threasholds (Figure 2.44 B). The patient was discharged home
on the 10th post-operative day. At discharge, the patient was reviewed in the out-patient clinic
weekly for 1 month, fortnightly for 2 months and subsequently monthly. Liver function tests
were checked at each visit. There has been no graft rejection since discharge. A Magnetic Reso-
nance Cholangio-Pancreatogram (MRCP) conducted 6 months after transplantation, performed
to assess the biliary tree, revealed normal intrahepatic bile ducts with neither anastomotic nor
non-anastomotic strcturing (Figure 2.45).
2.4 Discussion
This study presents the initial experience of NMLP with a cohort of discarded human livers.
These organs gave the opportunity to assess the full spectrum of liver function on NMLP and
propose criteria to discriminate between viable and non-viable livers.
The present study reveals unique data and novel observations. These are the first criteria to
be successfully tested in clinical practice and subsequently adopted within a clinical study of
viability testing and transplantation of discarded human livers.[224] The criteria are easy to
measure and consist of familiar parameters. Lactate concentration is an important indicator
of graft function in the peritransplantation period, and as such, its inclusion facilitated clinical
adoption of the protocol.[225] This is the first report that includes marginal organs that were so
severely damaged that we were unable to maintain the perfusion for 6 hours, which has enabled
the assessment of the full spectrum of liver function. The proposed criteria appear to correlate
closely with the current gold standard assessment of liver transplantability: histopathological
assessment. It has demonstrated the quite marked variability in the assessment of steatosis by
the retrieving or transplanting surgeon and the histology of the liver. In this era of progressive
organ shortage, such inconsistency may contribute to the waste of potentially usable livers,
further highlighting the urgent need to develop objective assessment methods to improve the
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Figure 2.44: Post transplant results in the recipient. A: Liver function tests. Alanine transam-
inase (ALT), aspartate aminotransferase (AST), alkaline phosphate (ALP) in IU/L. Bilirubin
measured in µmol/L. B: Urea measured in mmol/L and creatinine in µmol/L.
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Figure 2.45: MRCP at 6 months post NMLP assisted transplant.
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relatively low utilization of high risk organs.
The Groningen group was the first to demonstrate the feasibility of NMLP on 4 discarded human
livers.[202] The livers were subjected to 6 hours of NMLP following a median CIT of 6:55
hours with all organs showing recovery of function and being deemed viable.[202] The inferior
outcomes of some livers from this series may be explained in part by CIT being an average of
2 hours longer. A subsequent study from the Groningen group reported a NMLP series on 12
discarded livers, proposing six hours of cumulative bile production greater than 20 grammes
as a marker of a good liver function.[226] A cut-off volume for bile volumes could not be
determined because some viable organs in the series did not produce bile.
The Cambridge group advocated assessment based on perfusate transaminases and bile pH.[227]
The authors observed a significant correlation between the ALT in the perfusate measured after
2 hours’ perfusion and the peak ALT post-transplant levels within the first week.[227] They
also hypothesized that the liver’s capacity to produce an alkaline bile (pH >7.4) might be a
good marker of cholangiocyte function, possibly identifying a selection of organs with a low
risk of developing Ischaemic Type Biliary Lesions (ITBL). If validated, this observation might
revolutionize DCD liver utilization. However, issues with bile collection, such as technical
problems with bile duct cannulation, could lead to discarding usable livers. In concordance
with the Cleveland group, the importance of bile production in the context of NMLP is possibly
overestimated.[228]
Lactate is the intermediate metabolite of pyruvate within the glycolysis metabolic pathway.
Under anaerobic conditions, pyruvate is converted to lactate by lactate-dehydrogenase. In well-
functioning livers, the periportal hepatocytes use lactate as a primary substrate for gluconeoge-
nesis as one part of the Cori Cycle. In NMLP, hyperlactaemia is predominantly due to tissue
hypoxia resulting from impaired liver blood flow and decreased gluconeogenesis. In this setting
lactate production may exceed its clearance and may therefore be an indicator for real-time liver
function monitoring. A method to further elucidate the role of lactate and glucose metabolism in
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NMLP could be achieved via (13)C glucose labelling studies using 2D NMR, that has demon-
strated whole organ glucose metabolism within an hypoxic environment using a porcine model
of hypothermic machine perufsion.[229] If successfully applied to NMLP, a more detailed and
accurate mathematical model of lactate and glucose metabolism within the liver might be gen-
erated, rather than relying on perfusate samples that are more prone to sample and other errors.
Additionally, bile production has generally been accepted to be a simple, yet sensitive, marker
of graft function in liver transplantation. However, as bile production may be frequently absent
at the end of OLT and does not necessarily indicate PNF, lactate concentration maybe a better
primary parameter for assessing liver viability.
There are other advantages to using lactate in preference to bile production in assessing liver
function during NMLP. Firstly, the decrease in lactate in well-functioning livers emerges 30-90
minutes earlier when compared to the bile production. This observation gives lactate concen-
tration a particular advantage for viability assessment and would permit a timely start of LT.
Secondly, lactate concentration can be measured immediately on commencement of NMLP and
repeated as frequently as required to provide a trend. Additionally, the rate of decline in lactate
level concentration (delta lactate) may be a better parameter for characterising the liver func-
tion, offering a semi-quantitative description of organ functional capacity compared to single
values.
Bile production varied not only in quantity but also in quality. Some livers excreted large
volumes of thin, unconcentrated bile whilst some livers excreted haemobilia, though it ws not
possibleto provide detailed analysis of the bile. The lack of bile production in some viable grafts
may have been exacerbated by a technical issue. This had implications for the assessment of bile
production and, on the basis of this study, quality of bile cannot be considered to be a reliable
marker of liver function. One accepts that other studies have shown bile analytes that may
reflect liver function.[227] In contrast, lactate concentration is a simple value, easily obtained
from readily available, standardised and validated point-of-care blood gas analysers. Readings
are simple to interpret and the familiarity with this measure improved the engagement and
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acceptance in the implementation of NMLP when it was proposed for adoption into clinical
practice.
Perfusate liver function tests were also unreliable in providing an assessment of potential via-
bility. Due to haemolysis within the perfusate samples, one was only able to obtain complete
sets of perfusate transaminase levels from four of the latter perfusions (numbers 8, 10, 11 and
12). In each case there was a steady increase in ALT over the course of the 6 hour perfusion.
Although it is difficult to say with these small numbers whether transaminase levels can be used
to determine viability, it is more likely that similar to their use in clinical scenarios, they are
better suited as indicators of liver injury. Haemolysis also accounted for the high potassium
concentrations recorded for the majority of perfusions.
The O2ER in the two groups were similar after two hours and the end of NMLP. These absolute
values in the viable group are in keeping with the normal adult at rest. Graphically higher O2ER
values seen in the non-viable group reflects relative tissue hypoxia and has been noted in livers
subjected to trauma and haemorrhage after a period of warm ischaemia in animal models, in
which more warm ischaemia was associated with higher O2ER levels.
Viability testing are urgently required for high-risk organs where donor under-utilisation is dic-
tated by the risk of PNF and a suboptimal macroscopic appearance of the liver. This data demon-
strated that histological findings rarely reflected the impression of the retrieving or transplanting
surgeon concerning the possible underlying condition of the liver that led to their discard and
these livers are the best organs to be considered for viability testing via NMLP. As a transplant
community, we are yet to fully understand and validate this data, but such an approach does
show increasing promise for adoption into clinical practice. The objective parameters gener-
ated by NMLP technology have the potential to transform the organ selection process and shift
boundaries into using high-risk livers or inappropriately declined organs in the future. Many
parameters assessed over the course of NMLP can be affected by external intervention. Further
research is needed to understand the complexity and the impact of the interventions performed
during NMLP and to discover optimal strategies to maximise or even improve the quality of
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marginal livers.
With patient safety in mind, composite parameters consisting of multiple variables were devel-
oped, based primarily on lactate clearance and bile production. As NMLP attempts to replicate
the in vivo conditions, parameters of macroscopic graft appearance were also included, as they
are generally seen as favourable signs following reperfusion during transplantation of high-risk
organs. These criteria have now been adopted in our unit’s clinical protocol for the functional
assessment of high-risk or discarded livers.
There are limitations to the use of NMLP. There is uncertainty concerning its impact on long-
term post-transplant outcome and is yet to be determined by adequately powered prospective
clinical trials. It may be possible with future research to refine these parameters and include
additional markers that might have an impact on the long-term graft function. The presented
viability criteria represent a reference point with which to base future research in this area.
Patient safety is the highest priority in implementing this novel strategy into the future organ
selection pathway, hence setting an initial target of meeting criteria within 2 hours of starting
NMLP. Some non-viable organs may still be salvaged by delaying the cut-off for viability as-
sessment or by increasing the required trough lactate value. Additional livers might be rescued
from a ‘grey zone’ of organs achieving trough lactate levels of 2.5 – 4 mmol/L within two hours
of NMLP by supplementary therapeutic interventions, as NMLP alone may not be sufficient to
resuscitate their function. This hypothesis clearly requires further research.
These results demonstrate that lactate clearance and bile production are the most significant
parameters. Presence of bile production is widely recognised as a highly sensitive viability
marker following transplantation and it was included in the viability criteria. However, it has
low specificity as the lack of bile production may be contributed to technical factors, such as
cannulae kinking and low pressure in the biliary tree influencing the ability to collect bile, or
lack of bile salts in the perfusate. Lactate clearance was found to be a consistent, responsive
and readily available parameter confirming liver function. For defining clinically usable via-
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bility criteria to assess the high-risk and or discarded livers function, our main objective was
to assure transplant recipient safety. A composite measure consisting of lactate clearance and
or bile production (major criteria) in combination with additional minor criteria of stable ar-
terial and portal flows, perfusate pH and favourable assessment by the transplant surgeon was
designed. Heterogeneous perfusion is a frequent reason for discarding organs. This usually
improves shortly after the liver temperature normalises and vascular flows stabilise. Persistent
segmental hypoperfusion might suggest vascular damage, thrombi or emboli and, if arterial in
origin, it could lead to liver abscess formation and biliary problems. Soft consistency relates
to the clinical observation of very marginal grafts becoming stiff soon after implantation. In
the transplant community’s experience, gradual softening is a reassuring sign observed earlier
than any objective parameters of recovering function. Consistent stiffness of the liver during
perfusion would be seen as a concerning feature.
2.4.1 The Relationship Between NMLP and the Resuscitation & Recon-
ditioning of Livers for Transplantation
There are a number of different machine perfusion strategies for the assessment and recovery
of either ECD or donor livers outside current criteria for transplantation. Despite international
growing expertise in machine perfusion, it is remains unclear whether a physiological temper-
ature of 37oC best promotes initial energy recovery of such livers.[230] Several reports have
suggested Hypothermic Machine Perfusion (HMP) attenuates IRI in preclinical experiments
subsequently translated in to promising clinical outcomes.[200, 231, 232, 233, 234, 235] In
these studies, donor livers are perfused at 4-10oC with a UW or HTK based solution that can
be supplemented with antioxidants and metabolic intermediates.[233, 234] Comparisons with
variations of UW and HTK solutions have been performed by Bae et al and Stegemann et al
respectively in rat models, although the two groups are yet to be directly compared in dis-
carded human livers.[234, 236] Oxygenation in HMP has been demonstrated to improve func-
tional recovery with increased bile production at reperfusion, most notably with 100% oxygen
administration.[237] A combination of α-ketoglutarate, N-acetylcysteine, prostaglandin E1, ni-
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troglyerin, L-arginine and α-tocopherol attenuate transaminases and inflammatory cytokines in
a rat model of HMP, however, it is not clear the extent to which prostaglandin E1 contributes to
this effect in an ex vivo human system.[236]
Normothermic perfusion provides the conditions required to assess donor organ viability, thereby
increasing safety in the use of high-risk livers and preventing PNF.[210, 238] To date, oxy-
genated Williams E media, whole blood or human PRC and FFP have been used in rat, porcine
and discarded human models of NMLP respectively.[202, 222, 239] One study investigated
oxygenated steen as an acellular fluid in porcine NMLP following a period of SCS, concluding
that it enhanced arterial perfusion and reduced bile duct injury compared to SCS alone.[240]
However, the efficacy of PRC compared to an acellular fluid is yet to be determined. The ratio-
nale for the majority of the components in PRC-based NMLP fluids has not been explored until
now. Imber et al have demonstrated that taurocholic acid is essential to maintaining bile output
in a porcine model of NMLP over 20 hours, hence its initial use in the fluid.[206] However,
due to the lack of availability of clinical grade taurocholic acid, it was excluded from NMLPs
with the prospect of transplantation. The Oxford group added prostacyclin to their circuit to
ensure adequate arterial flows, although the Groningen group did not supplement their NMLP
circuits with a vasodilator but still achieved arterial flows of up to 300 ml/min.[202, 222] As
no data existed to compare arterial flow rates with and without vasodilators, epoprostenol was
incorporated into the fluids to permit higher arterial flows. An extension to these strategies is
subnormothermic perfusion, where livers are maintained at 21oC.[241, 242] These circuits to
date incorporate either Williams E or a novel acellular oxygen carrier.[241, 242]
This experience suggests that providing an initially untransplantable liver adequate oxygenation
with PRC, arterial flows and physiological pH increases the chance of successful NMLP to
assess viability. Despite this, some livers are beyond resuscitation with current technology.
These fluids provide a tool for facilitating NMLP over a period of up to 18 hours and the
delivery of beneficial therapies. Understanding and modulating IRI with NMLP is the next step
towards reconditioning currently discarded human donor livers.
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In summary, this study introduces specific composite viability assessment criteria including
lactate concentration, bile production and vascular flow patterns, that if met may define a Ma-
chine Criteria Donor (MCD) which may be integrated into the clinical organ selection pathway.
NMLP may lead to considerable expansion of the donor pool available for OLT. The positive
effect of NMLP on long-term transplant outcomes is yet to be demonstrated.
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CHAPTER 3
EARLY APPLICATIONS FOR THE POTENTIAL
FUTURE DIRECTIONS OF NORMOTHERMIC
MACHINE LIVER PERFUSION.
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3.1 Identification of Novel Hepatic Biomarkers Using Nor-
mothermic Machine Perfusion
3.1.1 Introduction
Chapter 2 detailed how the viability of a liver for transplantation could be predicted after 2
hours of NMLP based on absolute criteria and other considerations. Whilst this may potentially
represent an advancement in expanding the donor organ pool, such an assessment only leaves
a further 4 hours of possible NMLP before the oxygenators reach their maximum specifica-
tion. During this time, the potential transplant recipient needs to be delivered to the operating
theatre complex, anaesthetised along with the insertion of monitoring devices (including but
not limited to: arterial line, central line, Swann sheath, oesophageal doppler probe, epidural,
urinary catheter), transferred to the operating table, draped, equipment placed and the hepatec-
tomy completed. Potentially, this exposes the donor liver, transplant recipient and clinical team
to adverse outcome. Some of these obstacles can be overcome with the upgrading to larger
oxygenators with longer specifications or the use of a different normothermic perfusion device.
However, to an extent these limitations still exist.
Metabolomics has been utiliised in liver transplantation. Initially, high resolution Nuclear Mag-
netic Resonance (NMR) was performed to compare the metabolome in a patient that had re-
ceived a living donor graft that failed which was followed by successful transplantation from
a cadaveric donor.[243] This demonstrated 48 metabalolites of which six were consisitent with
non-function after the first.[243] The difference in expression of metabolites between 27 DBD
and 13 DCD gratfts has been investigated using liver microdialysate samples in both the cold
storage and post-reperfusion phase of transplanation.[244] This reveled the potential important
role of overexpression of kynurenine in DCD and failed graft.[244] This was translated to liver
biopsies taken during static cold storage and post-reperfusion in DBD and DCD liver transplan-
tation, where differences were found between both time points and graft types.[245] Specifi-
cally, typtophan/kynurenine metabolism during the cold phase and S-adenosylmethionine post-
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reperfusion were of significance.[245]
More specifically, metabolomics analysis has been performed on human cadaveric kidneys sub-
jected to hypothermic machine perfusion to identify markers of immediate and delayed graft
function.[246] Furthermore, comparison with human data has demonstrated that porcine kidney
hypothermic machine perfusion is a valid model for further human studies, whilst recognising
that 3-Hydroxybutyrate is greater in human kidney perfusates.[247] Metabolomic profiling of
livers has been documented when subjecting them to subnormic machine perfusion, at tem-
peratures of 21oC.[248] Untargetted metabolomic profiling was able to cluster livers according
to steatosis and severe warm ischaeia in this study focussed mainly on 18 DCD compared to
3 DBD livers.[248] In particular, perfusate lactate had been noted to rise within the first hour
of perfusion followed by a significant decrease over the following two hours.[248] This was
associated with an decrease in glucose-6-phophate and fructose-6-phosphate but an increase in
citrate, α-ketoglutarate and succinate throughout perfusion.[248] These suggest there are signif-
icant changes in the TCA cycle during even subnormothermic mhacine perfusion of discarded
human livers. At the time of this study, metabolomic profiling had not been performed on livers
subjected to NMLP in either the preclinical setting or as part of a clinical trial.
In the transplant setting, their is some evidence for the use of serum proteomics in detecting
and predicting acute T-cell mediated kidney allograft rejection and the effects of post transplant
statin therapy respectively.[249, 250] Within the field of liver transplantation, proteomics on
donor liver tissue has identified 36 proteins which are significantly altered during IRI, whilst
another study revealed that Ras GTPase-activating-like Protein (IQGAP1) had a protective ef-
fect on bile cannuliculi, damage to which is one of the main drivers of post transplant liver
dysfunction, particularly after DCD transplatation.[251, 252] However, as with any technology,
experimental design is key to being able to answer the specific question in mind, something
not even proteomics can overcome even when attempting to identify proteins associated with
PNF or chronic kidney disease after liver transplantation.[253, 254] Nevertheless, with a robust
approach, proteomics has successfully been used to study the dynamics of hepatitis C medi-
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ated liver disease following transplantation, in particular the onset of immune, hepatoprotective
and fibrogenic pathways leading to the increase in proinflammatory activity and the impair-
ment of antioxidant processes.[255] Recently, the urinary chemokines CXCL-9 and CXCL-10
as well as protein kidney injury markers in the urine such as Neutrophil Gelatinase-associated
Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1) is the focus of clinical validation
of proteomics.[256] Ultimately, proteomics may identify novel targets in the pathways leading
towards personalised immunosuppresive regimens or direct therapeuric intervention.
To date, metabolomics and proteomics have not been used in the context of NMLP. The aim of
this section is to test the hypothesis that metabolomic and proteomic profiling can predict the
viability of livers, initially rejected for transplantation, that have been subjected to NMLP prior
to 2 hours of perfusion. This will allow earlier decision making regarding the quality of the
liver and has the potential to reduce transplant risk to recipients.
3.1.2 Methods
The normothermic perfusion machine, the perfusion fluid, the livers perfused and the sampling
protocol are as described in Chapter 2.
Metabolomic Profiling of Perfusates From Discarded Cadaveric Human Donor Livers
Subjected to NMLP
Pre- Sample Preparation
Batches of defrosted perfusates were interrogated for metabolomic analysis from snap frozen
samples collected at the start of NMLP and then after 1 hours, 2 hours and the end of NMLP
as described above. Prior to perfusate sample preparation, Pall Nanosep mwco 3kDa filters
were washed in 500µL of warm (38oC) distilled water before being centrifuged at 3000g for 15
minutes. The flow through was then discarded and a further 500µL of warm distilled water was
added before centrifugation at 3000g for 15 minutes. Washing was repeated another 4 times
and kept damp whilst any samples required defrosting.
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Sample Preparation
For Ultra Performance Liquid Chromatography Mass Spectrometry (UPLC-MS) reversed phase
analysis, 100 µL of sample was diluted in 300 µL of 3:1 water/methanol followed by vortex
mixing (15 seconds) and centrifugation (13,000 g, 15 minutes). The supernatant was trans-
ferred to a glass autosampler vial and analysed within 48 hours. For UPLC-MS Hydrophilic
Interaction Liquid Chromatography (HILIC) analysis 100 µL of sample was diluted in 300
µL of acetonitrile followed by vortex mixing (15 seconds) and centrifugation (13,000 xg, 15
minutes). The supernatant was transferred to a glass autosampler vial and analysed within 48
hours.
Ultra Performance Liquid Chromatography-Mass Spectrometry
All samples were analysed applying a Ultimate 3000 UPLC system interfaced to an electrospray
Q Exactive Focus mass spectrometer (Thermo Fisher Scientific, San Jose, USA). Full scan data
were acquired continuously for 15 minutes at a mass resolution of 70,000 (FWHM at m/z 200).
Each sample was analysed twice, once in positive ion mode followed by re-analysis in negative
ion mode. UPLC-MS reversed phase analysis was performed applying a Hypersil GOLD aQ
(100 x 2.1mm, 1.9 µm) operating at 45oC (Thermo Scientific, Runcorn, UK) with a binary
gradient elution using solvent A (0.1% formic acid in water (v/v)) and solvent B (0.1% formic
acid in acetonitrile (v/v)) operating at a flow rate of 300 µL/min. The following gradient elution
was applied: 99% A at 0 minutes, 50% A at 2 minutes, 1% A at 9 minutes and 99% A at 10.5
minutes. UPLC-MS HILIC analysis was performed applying a Accucore 150 Amide HILIC
(100 x 2.1mm, 2.6 µm) operating at 35oC (Thermo Scientific, Runcorn, UK) with a binary
gradient elution using solvent A (10 mM Ammonium Formate in 95% acetontrile/water + 0.1%
formic acid (v/v)) and solvent B (10 mM Ammonium Formate in 50% acetonitrile/water + 0.1%
formic acid (v/v)) operating at a flow rate of 500 µL/min. The following gradient elution was
applied: 99% A at 0 minutes, 85% A at 3 minutes, 50% A at 6 minutes and 95% A at 10
minutes.
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Proteomic Profiling of Perfusates From Discarded Cadaveric Human Donor Livers Sub-
jected to NMLP
Perfusate samples for proteomic analysis were taken from the pre-oxygenator hepatic venous
circuit immediately at the start of NMLP, after 2 hours of perfusion and at the end of NMLP.
The samples were initially snap frozen in liquid nitrogen before being stored in a -80oC freezer
until required for proteomic profiling. A summary of the proteomic workflow is demonstrated
in Figure 3.1.
Sample Preparation
Perfusate samples were defrosted before 50µL of the haemolysed sample was added 1:8 (400µL)
to HemogloBind (Biotech Support Group, USA) in an Eppendorf and was mixed well for 30
seconds on a vortexer. This sample was further mixed on a rotary mixer for an additional 10
minutes at room temperature, before being centrifuged for 5 minutes at 10,000g. The super-
natant was removed to a clean tube and to it was added 10X volume of 1% TCA/Isopropanol,
before being mixed on a vortexer for 30 seconds. The sample was subsequently centrifuged at
10,000g (4oC) for 15 minutes. The supernatant was carefully decanted to waste before adding
1ml methanol, mixed for 30 seconds and centrifuged again for 15 minutes, 4oC, at 10,000g.
The supernatant was again decanted to waste and the pellets dried at 60oC.
Standard Digestion
The pellet was re-suspended in 50µL 100mM ammonium bicarbonate at 37oC for 10 minutes
to encourage the pellet to dissolve. To this was added 25µL Dithiothreitol (DTT) (10mM
in 100mM ammonium bicarbonate) and incubated at 60oC for 15 minutes. Subsequently it
was cooled to room temperature and 25µL of 2-Iodoacetamide solution (950mM in 100mM
ammonium bicarbonate) was added. After incubation at room temperature for 45 minutes in the
dark, 500ng Promega Trypsin Gold was added and the mixed well. The solution was incubated
overnight at 37oC.
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Figure 3.1: Summary of the workflow for acquisition of label-free proteomic data with NMLP.
Perfusate analysis at 0, 2 hours and end of NMLP was based on viability in 12 livers subjected
to NMLP (n=6 each group). Haemoglobin depletion was completed using HemogloBind.
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C18 Zip Tip Preparation to Clean Peptides
Zip tips were pre-wetted with 10µL wetting solution (100% acetonitrile), dispensed to waste
and repeated. Aspiration of 10µL equilibration solution (0.1% trifluoroacetic acid in purified
H2O) was followed by dispensing it to waste and the process repeated. Aspiration and dis-
pensation through the entire sample was performed 5 times at which point the sample bound
to the matrix. Aspiration of the wash solution (0.1% trifluoroacetic acid in purified H2O) and
dispensation to waste was performed three times. The peptides were eluted by aspirating 10µL
of elution solution (1:1, acetonitrile: 0.1% formic acid in H2O) with repeated pipetting into
a clean tube or well without introducing air. After repeating twice the eluates were pooled
together. Finally, the tip was discarded and the sample completely dried in a speed vacuum.
LC-MS/MS Experiment
UltiMate 3000 HPLC series (Dionex, Sunnyvale, CA USA) was used for peptide concentration
and separation. Samples were trapped on a uPrecolumn Cartridge, Acclaim PepMap 100 C18,
5 µm, 100A 300µm i.d. x 5mm (Dionex, Sunnyvale, CA USA) and separated in Nano Series
Standard Columns 75 µm i.d. x 15cm, packed with C18 PepMap100, 3 µm, 100A (Dionex,
Sunnyvale, CA USA). The gradient used was from 3.2% to 44% solvent B (0.1% formic acid in
acetonitrile) for 30 minutes. Peptides were eluted directly (∼300 nL/min) via a Triversa Nano-
mate nanospray source (Advion Biosciences, NY) into a LTQ Orbitrap Elite mass spectrometer
(ThermoFisher Scientific, Germany). The data-dependent scanning acquisition was controlled
by Xcalibur 2.1 software. The mass spectrometer alternated between a full FT-MS scan (m/z
380-1800) and subsequent Collision Induced Dissociation (CID) MS/MS scans of the 7 most
abundant ions. Survey scans were acquired in the Orbitrap with a resolution of 120 000 at m/z
400 and Automatic Gain Control (AGC) 1x106. Precursor ions were isolated and subjected to
CID in the linear ion trap with AGC 1x105. Collision activation for the experiment was per-
formed in the linear trap using helium gas at normalized collision energy to precursor m/z of
35% and activation Q 0.25. The width of the precursor isolation window was 2 m/z and only
multiply-charged precursor ions were selected for MS/MS.
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The MS and MS/MS scans were searched against Uniprot database using Sequest algorithm
(ThermoFisher PD 1.4). Variable modifications were deamidation (N and Q), oxidation (M) and
phosphorylation (S, T and Y). Carbamidomethyl (C) modification was for fixed modification.
The precursor mass tolerance was 10 ppm and the MS/MS mass tolerance was 0.8Da. Two
missed cleavages were allowed and were accepted as a real hit protein with at least two high
confidence peptides.
Analysis of Metabolomic Data
Data was processed applying XCMS, a technique that incorporates nonlinear retention time
alignment, matched filtration, peak detection and peak matching, to produce a data matrix
of metabolite features (mass-to-charge/retention time pairs) detected in a minimum of one
sample with the integrated chromatographic peak area reported for each metabolite feature in
each sample.[182] Metabolite annotation was performed applying the software PUTMEDID-
LCMS.[257] When the metabolite was not detected NA was reported. The percentage differ-
ence in peak areas for each metabolite feature were calculated as follows:
1. Calculate the percentage difference for each sample when comparing time 0 and time 6
hours. The 25 metabolites showing the largest percentage increase at 6 hours and the 25
metabolites showing the largest percentage decrease at 6 hours are reported.
2. Calculate the percentage difference to time 6 hours between sample 1 (positive outcome)
and sample 2 (negative outcome). The 25 metabolites showing the largest percentage
increase and the 25 metabolites showing the largest percentage decrease are reported.
Analysis of Proteomic Data
Two techniques were used when analysing the perfusate proteomic data, both of which used
label-free proteomics, one of which identified unique proteins within the sample, the other
quantified proteins within the perfusate.
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Unique Proteins Using Label-Free Perfusate Proteomics
Perfusate proteomic data was exported as a spreadsheet from Proteome Discoverer (Thermo
Scientific, Runcorn, UK). Accession numbers were available for each NMLP across the col-
lected timepoints. Using conditional formatting in LibreOfficeTMCalc (version 5.3.7, The Doc-
ument FoundationTM, Berlin, Germany), protein accession numbers in 5 out of 6 livers for both
viable and non-viable livers at each timepoint were elicited. Inverse conditional formatting be-
tween viable and non-viable livers highlighted unique accession numbers at the start of NMLP,
T2 and the end of NMLP. Concurrently, protein accession numbers in the perfusate across all
timepoints for viable and non-viable livers were determined. Output from the unique and com-
mon accession numbers were parsed to the STRING: functional protein association networks
database (version 10.5) for identification and functional expression analysis.[258]
Quantitative Label-Free Perfusate Proteomics
Although the raw mass spectrometer data was not available due to logisitic reasons, a quantita-
tive approach to high throughput label-free perfusate proteomic data was adopted using meta-
data spectral counting, a MS2-level quantitation technique, adapted from statistical techniques
used in the analysis of large set microarray gene data.[183, 259, 260] Although not as robust
as measuring peptide signal intensities using eXtracted Ion Chromatogram (XIC), MS1-level
quatitation techqniue, it can still be used for comparing large datasets.[261] This provided a
dynamic assessment of fluctuations in the amount of proteins in perfusates across different
timepoints between viable and non-viable livers. Perfusate proteomic data was exported to a
spreadsheet as described above. In addition to protein accession numbers, the total number
of identified peptide sequences, known as Peptide Spectrum Matches (PSM), for each protein
accession number were available. These were summarised by NMLP and timepoint in a pivot
table using LibreOfficeTMCalc (version 5.3.7, The Document FoundationTM, Berlin, Germany).
Analysis of these PSM was performed using the ‘R for Proteomics’ packages in Bioconductor.
Specifically, the expression data was from the pivot table, with zeroes for missing values, was
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arranged with phenotypic feature meta-data and sample meta-data, namely viability, to produce
a MSnSet using the ‘MSnbase’ package.[262] The MSnSet was analysed using negative bino-
mial Generalised Linear Model (GLM) regression technique, that incorporates empirical Bayes
methods to share information among features, allowing it to be used with replicates as low
as two, and tends towards the Poisson distribution.[263, 264] This produced protein accession
numbers, the logarithm of the fold change and the p-values for proteins differentially expressed
between viable and non-viable livers at T0, T2 and the end of NMLP. A p-value of less than
0.01 was deemed significant. The output parsed to the STRING: functional protein association
networks database (version 10.5) for identification and functional expression analysis.[258]
3.1.3 Results
Perfusate Metabolomic Profiling
Metabolomics was performed in negative and positive ion mode for all timepoints, at the start
of NMLP, after 1 hours of NMLP, after 2 hours of NMLP and at the end of NMLP. Principle
Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA) was
performed to highlight goodness of fit (R2) and the goodness of prediction (Q2) of the models
(Figures 3.2 and 3.3). The R2 would increase with the number of Partial Least Squares (PLS)
factors. The data demonstrated that, where available, the models accounted for >80% of the
variance (Table 3.1). The Q2 demonstrated more variability, ranging from 0.50 to 0.73. None
of the Q2 reached higher than the accepted 0.8 for adequate prediction. Overall, metabolomic
analysis of NMLP perfusates did not elicit any metabolites that could be used to predict vi-
ability consistnely across all timepoints. This is contrary to blood gas analysis in Chapter 2,
which clearly demonstrated lactate determining viability. This is possibly a result of sampling,
storage and processing techniques including an untargetted metabolomics approach that should
be addressed in future studies. Once completed, the response of lactate to time during NMLP
could be determined using a metabolomics approach.
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Figure 3.2: PCA and PLS-DA of metabolites identified in negative ion mode during NMLP.
PCA, A,B,C,E,G; PLS-DA, D,F,H; Across all timepoints, A; At start of NMLP, B; After 1
hour of NMLP, C,D; After 2 hours of NMLP E,F; At end of NMLP G,H. In A, quality control
(red), sample (green). For remaining plots non-viable (red), viable (green). None of the models
reached the threshold for goodness of prediction (0.8)
147
Figure 3.3: PCA and PLS-DA of metabolites identified in positive ion mode during NMLP.
PCA and PLS-DA of metabolites identified in negative ion mode during NMLP. PCA, A,B,D,F;
PLS-DA, C,E,G; Across all timepoints, A; At start of NMLP, B,C; After 1 hour of NMLP, D,E;
After 2 hours of NMLP F,G. Metabolites at the end of NMLP not shown. In A, quality control
(red), sample (green). For remaining plots non-viable (red), viable (green). None of the models
reached the threshold for goodness of prediction (0.8)
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Negative Ion Mode Positive Ion Mode
#Components R2 Q2 #Components R2 Q2
All NA NA NA NA NA NA
T0 NA NA NA 2 0.98 0.53
T1 2 0.99 0.72 4 0.99 0.70
T2 1 0.85 0.55 4 0.99 0.73
TEnd 4 0.99 0.54 4 0.99 0.50
Table 3.1: Summary of metabolomic analysis in negative and positive ion modes.
R2, goodness of fit, Q2, goodness of prediction. All, across all timepoints; T0, at start of
NMLP; T2, after 2 hours of NMLP; TEnd, at end of NMLP; NA, not available as no valid
model.
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Proteins Identified Using Label-Free Perfusate Proteomics
The list of all proteins identifed during NMLP using a label-free perfusate proteomics approach,
categorised by NMLP, viability and timepoint, can be found at:
https://doi.org/10.5072/eData.bham.00000361
Unique Proteins Identified Using Label-Free Perfusate Proteomics
Label-free perfusate proteomics identified 11 and 13 unique proteins present in the perfusate
across all timepoints for non-viable and viable livers respectively (Table 3.2). There were a
significantly higher number of Protein-Protein Interaction (PPI) than would have been expected
(PPI non-viable 0.00118, viable 0.0336). There were 5 nodal associations in the non-viable
group and 14 nodal associations in the viable group including known and predicted interactions
(Figures 3.4, 3.5, 3.6).
On commencing NMLP, 15 and 27 unique proteins were present in the perfusate for non-viable
and viable livers respectively (Table 3.3). There were a significantly higher number of PPI than
would have been expected (PPI non-viable 0.00010, viable 6.72x10−6). There were 7 nodal
associations in the non-viable group and 27 nodal associations in the viable group including
known and predicted interactions (Figures 3.7, 3.8).
After 2 hours of NMLP, 15 and 16 unique proteins were present in the perfusate for non-viable
and viable livers respectively (Table 3.4). There were a significantly higher number of PPI
than would have been expected in the non-viable group only (PPI non-viable 5.52x10−7, viable
0.134). There were 11 nodal associations in the non-viable group and 16 nodal associations in
the viable group including known and predicted interactions (Figures 3.9, 3.10).
At the end of NMLP, 13 and 35 unique proteins were present in the perfusate for non-viable
and viable livers respectively (Table 3.5). There were a significantly higher number of PPI than
would have been expected in the viable group only (PPI non-viable 0.154, viable 3.47x10−9).


















































































































































































































































































































































































































































































































































































































































































































Figure 3.4: Legend for protein node interactions in STRING.
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Figure 3.5: Associations of unique proteins identified from non-viable livers throughout NMLP.
The 11 identified proteins are unique to non-viable livers and are present at commencing NMLP,
after 2 hours and the end of NMLP. The line colour indicates the type of interaction evidence.
Filled nodes indicates that some 3-dimensional structure is known or predicted.
Figure 3.6: Associations of unique proteins identified from viable livers throughout NMLP. The
13 identified proteins are unique to viable livers and are present at commencing NMLP, after 2
hours and the end of NMLP. The line colour indicates the type of interaction evidence. Filled
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.7: Associations of unique proteins identified from non-viable livers on commencing
NMLP. The 15 identified proteins are unique to non-viable livers and are present at commencing
NMLP only. The line colour indicates the type of interaction evidence. Filled nodes indicates
that some 3-dimensional structure is known or predicted.
Figure 3.8: Associations of unique proteins identified from viable livers on commencing NMLP.
The 29 identified proteins are unique to viable livers and are present at commencing NMLP
only. The line colour indicates the type of interaction evidence. Filled nodes indicates that





















































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.9: Associations of unique proteins identified from non-viable livers after 2 hours of
NMLP. The 18 identified proteins are unique to non-viable livers and are present after 2 hours
of NMLP only. The line colour indicates the type of interaction evidence. Filled nodes indicates
that some 3-dimensional structure is known or predicted.
Figure 3.10: Associations of unique proteins identified from viable livers after 2 hours of NMLP.
The 17 identified proteins are unique to viable livers and are present after 2 hours of NMLP
only. The line colour indicates the type of interaction evidence. Filled nodes indicates that








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.11: Associations of unique proteins identified from non-viable livers at the end of
NMLP. The 15 identified proteins are unique to non-viable livers and are present at the end of
NMLP only. The line colour indicates the type of interaction evidence. Filled nodes indicates
that some 3-dimensional structure is known or predicted.
Figure 3.12: Associations of unique proteins identified from viable livers at the end of NMLP.
The 36 identified proteins are unique to viable livers and are present at the end of NMLP only.
The line colour indicates the type of interaction evidence. Filled nodes indicates that some
3-dimensional structure is known or predicted.
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viable group including known and predicted interactions (Figures 3.11, 3.12).
KEGG Pathways of Unique Proteins Identified on Commencing NMLP
At the start of NMLP, 15 and 27 unique proteins were identified in the non-viable and viable
livers. To highlight which metabolic pathways might be differentially involved at this timepoint,
KEGG pathway analysis was performed. Although both non-viable and viable livers had acti-
vation of different parts of the metabolic pathway and biosynthesis of amino acids, significant
upregulation of the Tricarboxylic Acid Cycle (TCA) cycle, pyruvate metabolism, glyoxylate cy-
cle in peroxisomes and mitchondria as well as fat digestion and absorption were present in the
viable livers (Table 3.6). In contrast, non-viable livers had significant upregulation of glycolysis
and gluconeogenesis, pentose phosphate pathway and galactose as well as tyrosine metabolism.
Identification of Significant Proteins Using Quantitative Label-Free Perfusate Proteomics
Quantitative label-free perfusate proteomics identified 24 significantly expressed proteins with
both negative (non-viable) and positive (viable) log fold changes across all timepoints (Table
3.7). There was a significantly higher number of PPI than would have been expected (PPI =
0.00305). There were 14 nodal associations including known and predicted interactions (Figure
3.13).
On commencing NMLP, 6 significantly expressed proteins were present in the perfusate (Ta-
ble 3.8). The proteins APOA1, HSP90AA1, ACTC1 and GPX1 was associated with viability,
whilst FTH1 and C4B were associated with non-viable livers. There was not a significantly
higher number of PPI than would have been expected (PPI = 0.778). There was 1 nodal asso-
ciation (ACTC1 to HSP90AA1, both attributed to viable livers) including known and predicted
interactions (Figure 3.14).
After 2 hours of NMLP, 4 proteins (LTF, CD163, MPO and ZCCHC14) were significantly
expressed in the perfusate (Table 3.9). There was a significantly higher number of PPI than




















































































































































































































































































































































































































































































































































































































































































































































































































































































attributed to viable livers) including known and predicted interactions (Figure 3.15).
At the end of NMLP, 3 significantly expressed proteins were present in the perfusate (Table
3.10). There was not a significantly higher number of PPI than would have been expected (PPI
= 1). There were no nodal associations (Figure 3.16).
Gene Ontology Pathways of Proteins Identified by Quantitative Analysis on Commencing
NMLP
KEGG pathway analysis of significantly expressed proteins at the start of NMLP did not reveal
any metabolic pathways that were upregulated. Using Gene Ontology (GO) analysis, protein
oxidation and tissue migration matched proteins in the network (APOA1, GPX1, ACTC1), both
had acceptable false discovery rates (Table 3.11). All of these proteins were associated with
viable livers.
3.1.4 Discussion
The use of metabolomics and proteomics in the context of NMLP and predicting viability is
novel. In particular, the developed label free proteomic techniques have identified unique and
quantitatively significant proteins that can be used to predict viability of discarded human ca-
daveric livers subjected to NMLP, earlier than non -omic methods previously demonstrated.
Furthermore, the analytical techniques have highlighted potential metabolic pathways that are
regulated during the phases of ischaemia reperfusion injury in an ex vivo human model. Fluxes
in these proteins and pathways can then be elicited by proteomic profiling throughout the model.
These findings, particularly in proteomics predicting viability, could be translated to clinical
practice even with limited investigation, potentially increasing the donor pool for liver trans-
plantation than even the current use of NMLP has permitted.
The main strengths of these results, especially with respect to proteomics, is the use of a label











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.13: Associations of proteins identified by quantitative analysis throughout NMLP. The
24 identified proteins have the most significant fold changes on commencing NMLP, after 2
hours and the end of NMLP. The line colour indicates the type of interaction evidence. Filled
nodes indicates that some 3-dimensional structure is known or predicted.
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PPI 0.778
Node Annotation LogFC P-value
APOA1 Apolipoprotein A-I 4.392446 0.0003664732
HSP90AA1 Heat shock protein 90kDa alpha (cytosolic), class A member 1 4.334253 0.0007877133
ACTC1 Actin, alpha, cardiac muscle 1 4.629109 0.0011665981
FTH1 Ferritin, heavy polypeptide 1 -2.642914 0.0055252898
C4B Complement component 4B (Chido blood group) -4.550921 0.008651977
GPX1 Glutathione peroxidase 1 3.17337 0.0087903235
Table 3.8: Identity of proteins present in perfusates on commencing NMLP by quantitative
analysis.
Figure 3.14: Associations of proteins identified by quantitative analysis on commencing NMLP.
The 6 identified proteins have the most significant fold changes on commencing NMLP. The line
colour indicates the type of interaction evidence. Filled nodes indicates that some 3-dimensional
structure is known or predicted.
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PPI 0.0312
Node Annotation LogFC P-value
LTF Lactotransferrin 3.332166 0.001773611
CD163 CD163 molecule -1.964989 0.005445518
MPO Myeloperoxidase 2.153964 0.005654576
ZCCHC14 Zinc finger, CCHC domain containing 14 -3.481443 0.008660559
Table 3.9: Identity of proteins present in perfusates after 2 hours of NMLP by quantitative
analysis.
Figure 3.15: Associations of proteins identified by quantitative analysis after 2 hours of NMLP.
The 4 identified proteins have the most significant fold changes after 2 hours of NMLP. The line
colour indicates the type of interaction evidence. Filled nodes indicates that some 3-dimensional
structure is known or predicted.
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PPI 1
Node Annotation LogFC P-value
AHSG alpha-2-HS-glycoprotein -1.902466 0.003648839
HSP90AA1 Heat shock protein 90kDa alpha (cytosolic), class A member 1 3.713159 0.007913096
ELANE Elastase, neutrophil expressed 3.809979 0.008965856
Table 3.10: Identity of proteins present in perfusates at the end of NMLP by quantitative anal-
ysis.
Figure 3.16: Associations of proteins identified by quantitative analysis at the end of NMLP. The
3 identified proteins have the most significant fold changes on commencing NMLP. There are
no interactions. Filled nodes indicates that some 3-dimensional structure is known or predicted.
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Pathway Description Observed Gene Count False Discovery Rate Matching Proteins in your Network (Labels)
protein oxidation 2 0.0104 APOA1,GPX1
tissue migration 3 0.0104 ACTC1,APOA1,GPX1
Table 3.11: Pathways of significant proteins at the start of NMLP by quantitative analysis using
Gene Ontology.
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clinical translation, as well as incorporating two different techniques that have generated related
lists of proteins. The fact that these results have been acquired despite the heterogeneity of
the discarded human livers that have become available, can also be seen as a strength when
considering clinical translation.
Nevertheless, the relatively low number of perfused livers in combination with the use of
HaemagloBind to overcome the effects of haemolysis seen during NMLP can be seen as po-
tential obstacles to future adoption. The commencement of the VITTAL Trial, towards which
results from Chapter 2 onwards generated the preliminary data for the successful Wellcome
Trust grant application, has allowed time to reflect upon and refine the methodology from sam-
ple protocol to analytical techniques. This should have an impact on the identification of po-
tential proteins important for predicting viability using a proteomic approach. This may also
influence the ability to generate significant metabolomic results by using a targetted approach
to lactate and confirm the role of lactate metabolism in the viability assessment of discarded
human livers subject to NMLP over the course of perfusion.
The use of metabolomics and proteomics in NMLP is novel for ischaemia reperfusion models
of the liver. It has been utilised in a pig and discarded human kidney model using hypothermic
machine perfusion.[246, 247] However, although promising, the results of this are awaiting to
be translated to clinical practice.
Future research must include increasing the numbers over a broader range of livers that have
sustained differing amounts of pre-existing injury prior to commencing NMLP, thus ensuring
that these proteomic results are replicated. To overcome technical biases, samples should be
sent to collaborating laboratories to confirm the results, even by the use of different mass-
spectrometry techniques. More detailed and possibly accurate analysis can be performed by
utilising the vast quantities of data within the raw mass-spectrometry data. The sensitivity and
specificity of spectral counting could be increased by incorporating XIC methods to calculate
the area under the curve of raw data files. Once these challenges have been overcome, the
prospect of clinical translation is increasingly promising.
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3.2 Acellular Perfusion Fluid and Its Potential Application in
NMLP
3.2.1 Introduction
The shortage of suitable donor livers remains a limiting factor in the attempt to transplant an
increasing number of patients with end-stage liver disease. This has led to an increase in the use
of ECD that encompass organs from donors of increased age, higher Body Mass Index (BMI)
and DCD. However, ECD livers are at increased risk of graft dysfunction, primary graft non-
function and increased susceptibility to IRI. One potential method of improving the quality of
ECD livers is by the utilisation of machine perfusion, in particular, NMLP. It is well known that
the main injurious agent during liver IRI is the generation of ROS. During NMLP the liver is
exposed to oxygen and nutrients supporting intrinsic metabolic activity. Currently, devices used
for NMLP in pre-clinical and limited clinical settings perfuse the livers with group specific
packed red cells from the blood bank. However, this has disadvantages including potential
immune-mediated phenomena, disruption of the liver micro-circulation, red blood cell mediated
cell death, haemolysis and the logistical planning for gaining access to the crossmatched blood.
Acellular perfusion fluids, such as Hemopure, allow oxygenation of donor livers during NMLP
without the logistic and cell-mediated issues discussed above. Hemopure or HBOC-201 is
a bovine haemoglobin-based oxygen carrier. The aim fo this section is to test the effec of
Hemopure on liver parenchymal cells in vitro and in the NMLP.
3.2.2 Methods & Materials
Isolation of Human Sinusoidal Endothelial Cells
Liver tissue was obtained via the Hepatobiliary and Liver Transplant surgery program at the
Queen Elizabeth Hospital, Birmingham UK, from consenting adult patients undergoing trans-
plantation, hepatic resection for liver metastasis, hepatic resection for benign liver disease or
normal donor tissue surplus to surgical requirements. Ethical approval for the study was grant
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by the Local Research Ethics Committee (LREC) (reference number 06/Q702/61). HSEC were
isolated from human liver tissue as previously described. Briefly, parenchymal cells were col-
lected after collagenase digestion of mechanically disaggregated liver and were further puri-
fied by density gradient centrifugation over Percoll. Endothelial cells were isolated from the
resultant heterogeneous cell mixture by positive immunomagnetic selection using antibodies
raised against CD31 (Clone JC70A, Dako, Denmark) and magnetic beads (Dynal) conjugated
with goat anti-mouse antibody according to the manufacturer’s protocol. All endothelial cells
were maintained in complete media comprising Human Endothelial-SFM basal growth medium
(Invitrogen) containing 104 U/ml penicillin and 10 µL/ml streptomycin, 10 ng/ml epidermal
growth factor (R & D Systems, Abingdon, UK), 10 µg/ml hydrocortisone (Sigma-Aldrich,
UK), and either 10% heat-inactivated human serum (TCS Biologicals). All endothelial cells
were plated out into collagen-coated culture flasks (Sigma-Aldrich, UK) and maintained at 37◦C
in a humidified 5% CO2 incubator until confluent. The endothelial cells were used only up to
passage 6, and phenotypic identity as well as purity were confirmed by staining for endothelial
markers.
Isolation of Biliary Epithelial Cells
Biliary epithelial cells were isolated from liver tissue as described. Liver (30g) was finely diced
and incubated with collagenase type 1A (Sigma, St. Louis, MO). The digest was layered onto a
33% and 77% iso-osmotic Percoll gradient and centrifuged at 500 g for 30 minutes. The inter-
face layer was collected, washed three times in PBS and incubated with the Biliary Epithelial
Cells (BEC)-specific mouse anti-human monoclonal antibody to Human Epithelial Antigen 125
(HEA125) (TCS Biologicals Ltd., Botolph Claydon, Bucks, UK). BEC were positively selected
by incubating with anti-mouse IgG1-coated Dynabeads (Dynal) and by magnetic separation.
The cells were cultured in plating media comprising Hams F12, Dulbecco’s Eagle medium
(Sigma-Aldrich, UK) containing 10% heat-inactivated fetal calf serum (TCS Biologicals), 104
U/ml penicillin, 10 µL/ml streptomycin, 2 mM glutamine, 10ng/ml epidermal growth factor
(R & D Systems), 2 g/ml hydrocortisone (Sigma-Aldrich, UK), 10 ng/ml choleratoxin, 2 nM
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tri-iodo-thyronine, 0.124 iu/ml insulin. After 1–2 days in culture, the medium was exchanged
for media containing 5% fetal calf serum and 10 ng/ml hepatocyte growth factor (R&D Sys-
tems, Abingdon, UK). In all subsequent experiments, cells were used between passage 2 and 5
depending on the initial yield of the primary isolate.
In vitro Model of Ischaemia Reperfusion Injury
Cells were incubated in standard media or 50:50 mix of media with Hemopure. In experiments,
HSEC and BEC were grown for 2 days at 37oC, 5% CO2 in the media described above in 6-well,
rat type 1 collagen-coated plates. We utilised a model of warm in vitro IRI that described previ-
ously. HSEC and BEC were either incubated in normoxia, or hypoxia (0.1%) for 24 hours, or in
hypoxia for 24 hours followed by 24 hours of reoxygenation, known as Hypoxia-Reperfusion
(H-R). Hypoxia was achieved by placing cells in an airtight incubator (RS Mini Galaxy A in-
cubator, Wolf Laboratories, UK) flushed with 5% CO2 and 95% N2 until oxygen content in
the chamber reached 0.1%, as verified by a dissolved oxygen monitor (DOH-247-KIT, Omega
Engineering, UK). Media was pre-incubated in the hypoxic chamber in a sterile container, al-
lowing gas equilibration, for 8 hours before experiments were conducted. This resulted in a
final oxygen concentration of <0.1%. Where appropriate, after 24 hours of hypoxia media was
aspirated and replaced with fresh, warmed, oxygenated medium, with the cells subsequently
returned to normoxic conditions. This was defined as the beginning of reoxygenation.
Assessment of ROS Production, Apoptosis and Necrosis
ROS production, apoptosis and necrosis were determined using a three-colour assay. Apopto-
sis was determined by labelling cells with Annexin-V (Molecular Probes, Paisley, UK) which
detects exposed phosphatidylserine on the cell membrane. ROS accumulation was determined
using the fluorescent probe 2’,7’-Dichlorodihydrofluorescein (DCF) diacetate (Merck, Notting-
ham, UK,). This probe is cell permeable and once intracellular, is cleaved by intracellular
esterases to 2’,7’-DCF that is then rendered cell impermeable. DCF is then able to react with
intracellular ROS, specifically hydrogen peroxide, to give a fluorescent signal detectable on the
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Fluorescein Isothiocyanate (FITC) channel. The signal is directly proportional to the level of
intracellular ROS present. 7-Aminoactinomycin D (7-AAD) (Molecular Probes, Paisley, UK)
only enters cells once the cell membrane is disrupted during necorsis and is a vital dye that
intercalates with high affinity to GC-rich regions of Deoxyribose Nucleic Acid (DNA).
To ensure consistency of flow cytometric data, each human preparation was labelled with DCF
alone, Annexin-V alone and 7-AAD alone to ensure that cells had become labelled and that the
flow cytometry data could be compensated for crossover of fluorophore emission spectra. The
same flow cytometer protocol, including voltages for all markers, was used for all experiments
shown in the study, ensuring internal consistency of experiments.
Following appropriate treatment of cells, media was aspirated and replaced with HBSS (Gibco)
without calcium and magnesium. DCF (30 µM) was added and the cells were incubated for 20
minutes in the dark at 37oC. Cells were then trypinsed and washed extensively in FACs buffer
(Phosphate-buffered saline pH 7.2) with 10% heat inactivated foetal calf serum (Gibco). Cells
were subsequently labelled with Annexin-V and 7-AAD for 15 minutes whilst on ice before
immediate flow cytometry. At least 20,000 events were recorded within the gated region of the
flow cytometer for each human cell preparation in each experimental condition. Only the cells
within the gated regions were used to calculate Median Fluorescent Intensity (MFI).
Preparation of the Donor Liver
Two human livers deemed not suitable for clinical transplantation were included in the study.
They were procured by one of the teams from UK NORS, with the intention of transplantation
using nationally agreed surgical protocols. In-situ ice cooling and perfusion via the hepatic
artery and portal vein was performed using University of Wisconsin (UW; SPS-1, Organ Re-
covery Systems, USA or Belzer UW Cold Storage Solution, Bridge to Life, USA) preservation
fluid at 4oC. Donor livers were packed in preservation fluid filled sterile bags and placed on
crushed ice immediately prior to transportation.
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Consent for academic research was granted either directly by the donor when joining the UK
ODR or by the donor’s family during consent for procurement utilising a SNOD. Ethical ap-
proval was granted by University Hospitals Birmingham NHS Foundation Trust, as well as
Loco-Regional and NHSBT Ethics Committees.
Each liver was initially prepared for NMLP analagous to clinical transplantation. The inferior
vena cava was dissected and the phrenic veins ligated. The portal vein was dissected to its bifur-
cation. The aortic patch was trimmed and the hepatic artery was dissected to the gastroduodenal
artery. Curved and straight Medos cannulae were inserted in to the coeliac trunk and the portal
vein respectively before being secured with silk ligatures. Livers were then flushed with 2 litres
of 10% dextrose solution. The cannulae were primed with perfusion fluid and connected to the
normothermic perfusion machine.
Normothermic Machine Liver Perfusion
Upon arrival at the transplant centre, the cold preserved liver was prepared on the back table
as described previously [13]. NMLP was initiated using a CE marked (Liver Assist, Organ
Assist b.v., Groningen, The Netherlands) device that enables dual perfusion via both the hepatic
artery and the portal vein in a semi-closed circuit. Two rotary pumps provided pulsatile flow
to the hepatic artery and a continuous flow to the portal vein. The pressure for each system
was set independently. Measured flow rates and calculated resistances were shown in real-time
on a liquid crystal display. Oxygen was supplied to two polypropylene, rheoparin R© coated,
microporous hollow fibre membrane oxygenators with integrated heat exchangers, that also
removed CO2. Pressure was limited to a mean of 50 mmHg in the hepatic artery and 10 mmHg
in the portal vein. The temperature was set to 37oC. Before connecting the liver to the device,
the perfusion fluid was primed with the addition of an 8.4% sodium bicarbonate solution to
obtain a stable physiological pH. The liver was perfused for 6 hours with Hemopure or PRC.
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Assessment of Hepatobiliary Injury Using Histological Evaluation
Biopsies were obtained from the donor liver immediately before as well as after 3 and 6 hours
of NMLP. Biopsies were fixed in formalin for histological evaluation. Paraffin-embedded slides
of liver biopsies were prepared for H&E staining and assessed in a semi-quantitatively for the
presence of endotheial and biliary ductule apoptosis and necrosis using light microscopy.
Statistical Analysis
All data was analysed using R version 3.3.0 within RStudio version 0.99.896 (RStudio Inc.,
Boston, MA, USA) Integrated Development Environment. Graphs were compiled using the
‘ggplot2’ package whilst statistics were performed using the ‘stats’ and ‘psych’ packages. Nu-
merical data is presented as median and range with data assumed to be homoscedastic. Factoral
2-way (2x3 design) ANOVA was performed to compare the effect of culture media, oxygenation
and their interaction on MFI. A p-value of < 0.05 was deemed to be significant.
3.2.3 Results
Hemopure Does Not Alter ROS Production in HSEC and BEC During In Vitro IRI
There was no significant effect of Hemopure on ROS production in HSEC in vitro, F(1,30) =
0.046, p = 0.831 (Figure 3.17 A). There was also no effect of oxygenation on ROS production,
F(2,30) = 0.075, p = 0.928. Similarly, there was no effect of either Hemopure, F(1,18) = 0.717,
p = 0.408, or oxygenation, F(2,18) = 1.722, p = 0.207, on ROS production in BEC in vitro
(Figure 3.17 B).
Hemopure Does Not Increase Apoptosis or Necrosis in HSEC and BEC Necrosis During
In Vitro IRI
Previous work has shown that increases in intracellular ROS increase cell death in parenchymal
liver cells primarily via apoptosis but also necrosis. There was no effect of Hemopure on apop-
tosis in HSEC in vitro, F(1,30) = 0.319, p = 0.712 (Figure 3.18 A). Whilst there was a trend for
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Figure 3.17: ROS production in HSEC (A) and BEC (B) using Hemopure and PRC during in
vitro IRI. There was no significant effect of either Hemopure or oxygenation on ROS production
in either HSEC (A) or BEC (B) in vitro.
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more apoptosis with hypoxia (M = 5.1, SD = 1.3) compared to normoxia (M = 4.4, SD = 0.5)
and H-R (M = 4.3, SD = 0.5), this did not reach significance, F(2,30) = 2.53, p = 0.096. In BEC,
there was no effect of either Hemopure, F(1,18) = 0.00, p = 1.000, or oxygenation, F(2,18) =
0.00, p = 1.000, on apoptosis in vitro (Figure 3.18 B). When cultured in either standard media
or Hemopure, HSEC and BEC did not undergo necrosis (data not shown).
Hemopure Does Not Increase Cell Death During NMLP
In the present study, the liver used for NMLP using PRC infusion was procured from a 60
year old female with a BMI 36.4. CIT was 491 minutes and the liver was discarded due to
macroscopic steatosis. The liver used for NMLP using Hemopure was retrieved from a 70
year old male. The CIT was 359 minutes and the liver was also discarded due to macroscopic
steatosis. Both donor livers showed mild to moderate steatosis onH&E staining prior to NMLP
(Figure 3.19). After 6 hours of perfusion, the liver perfused with PRC showed a slight reduction
in steatosis and showed very little cell death with maintenance of liver architecture and intact
biliary cells. In comparison, the donor liver perfused with Hemopure also did not demonstrate
any increased hepatocellular cell death and also maintained biliary and endothelial cell integrity.
Hemopure Does Not Adversely Affect Perfusion Parameters During NMLP
The duration of NMLP was 431 minutes. Homogenous perfusion was noted on the surface of
the liver after 3 minutes of NMLP which was maintained throughout perfusion.
At the start of NMLP, arterial and portal venous flow rates were 386 ml/min and 980 ml/min
respectively. Flow rates increased rapidly, with an arterial zenith of 650 ml/min after 120 min-
utes whilst the portal flow increased more steadily, reaching 1270 ml/min after 230 minutes of
NMLP (Figure 3.20 A). Flow rates at the end of NMLP were 575 ml/min for the artery and 1300
ml/min for the portal vein. Arterial and portal venous pressures were maintained within physi-
ological thresholds. After an initial decrease, resistances in the artery and portal vein remained
low. The initial reservoir temperature was 32oC, reaching 36oC after 36 minutes of NMLP.
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Figure 3.18: Apoptosis in HSEC (A) and BEC (B) using Hemopure and PRC during in vitro
IRI. There was no effect of either Hemopure or oxygenation on apoptosis in HSEC (A) or BEC
(B) in vitro. When cultured in either standard media or Hemopure, HSEC and BEC did not
undergo necrosis (data not shown).
178
Figure 3.19: H&E staining before and at the end of NMLP using Hemopure and PRC. After 6
hours, PRC perfusion showed a slight reduction in steatosis, very little cell death and mainte-
nance of liver architecture and intact biliary cells. The liver perfused with Hemopure did not
demonstrate any increased hepatocellular cell death and also maintained biliary and endothelial
cell integrity.
179
The initial lactate of 8.1 mmol/L decreased steadily (Figure 3.20 B). After 3 hours of NMLP,
the lactate was 3.8 mmol/L. There was an increase to 6.2 mmol/L by 4.5 hours, after which
it decreased to 5.3 mmol/L at the end of NMLP. The liver utilised glucose during NMLP,
commencing at 37.2 mmol/L and reaching 19.0 mmol/L at the end of perfusion (Figure 3.20
C). Bile was produced throughout perfusion. These results are comparable to similar livers
subjected to NMLP in Chapter 2.
3.2.4 Discussion
Machine perfusion of donor livers is receiving increasing attention as experimental studies have
suggested that this method can afford protection from IRI and improve allograft function. One
of the putative protective mechanisms of NMLP is the reduction in IRI. There is clear evidence
that during IRI, ROS accumulation is central to the necro-apoptosis observed in allografts after
liver transplantation. In addition, NMLP allows the possibility of viability testing of a donor
organs prior to transplantation. However, one potential barrier to the widespread clinical adop-
tion of NMLP is the requirement for group-specific PRC with which to perfuse the donor liver.
This has clear logistical and potential safety implications. The use of an acellular perfusion
fluid, such as Hemopure, would negate many of these issues and potentially increase the wider
clinical application of NMLP by obviating the need for PRC in the perfusion fluid. Its use is
particularly attractive in the NMLP setting given the potential risk of patient sensitisation and
disruption of the liver micro-circulation from red cell trapping. There are some reports in ani-
mal models purporting to the advantage of acellular fluids in models of trauma, brain injury and
haemorrhage.[265, 266, 267] Unfortunately, these promising pre-clinical results with acellular
fluids have not translated into improved patient outcome when used clinically.[268] The effects
upon cardiovascular system, including nitric oxide scavenging and subsequent higher vascular
resistance, have been suggested to underlie the adverse effects seen in patients although more
recent randomized studies suggest there no increased risk with acellular fluids.[269] Limited
studies have assessed the use of acellular perfusion fluids in the setting of liver injury. In a
porcine model of liver injury Hemopure improved early mortality and in rodent models of IRI
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Figure 3.20: A: Hepatic arterial and portal venous flow parameters during NMLP with Hemop-
ure. B: The decrease in lactate concentration during NMLP with Hemopure. C: Utilisation of
glucose during NMLP with Hemopure. These results are comparable to those presented in the
previous chapter.
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Hemopure improved oxygenation in post-reperfusion liver tissue.[270, 271]
This in vitro data shows that under normoxia, hypoxia and H-R HSEC and BEC have a high
basal intracellular ROS content. Exposure to Hemopure in vitro IRI did not alter intracellular
ROS levels in BEC or HSEC significantly. Furthermore, during in vitro IRI neither HSEC
nor BEC show increases in either apoptosis or necrosis. When HSEC and/or BEC cultured
in Hemopure are exposed to the same in vitro model of IRI they did not alter intracellular
ROS production significantly. Interestingly, there was no reduction in intracellular ROS when
using Hemopure during IRI. The reasons for this remain the focus of on-going research in
the laboratory. Importantly Hemopure did not induce cell death in HSEC or BEC during IRI.
These observations suggest that in vitro Hemopure is not toxic to human liver cells. When
used in the NMLP setting, Hemopure demonstrated no increase in hepatocellular apoptosis and
necrosis when compared to PRC perfusion. In this study both donor livers showed maintenance
of biliary duct integrity and relatively normal liver morphology. Although Hemopure has been
used in only one perfusion, the results from this suggest that adequate levels of oxygen can be
delivered the liver tissues in the absence of packed red cells.
In conclusion, this preliminary study suggests that there is potential to expand the use acellular
perfusion fluids in the setting of NMLP. Haempoure both in vitro and in vivo does not appear
to be toxic to liver cells and further studies are required to assess fully the potential for its use
in clinical setting of NMLP.
3.3 Proof of Concept: Liver Splitting During Normothermic
Machine Perfusion
3.3.1 Introduction
Each year 15% of patients on the liver transplant waiting list in the UK either have died or
been removed.[107] One strategy to increase numbers of available livers is splitting, performed
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either in situ or ex situ. The most common approach is the “classical” left lateral + right triseg-
mentectomy split providing left grafts for children. The less frequently performed full left-right
split can provide livers for two adults but this is technically complex and questions remain over
vascular and biliary outcomes.[272]
Normothermic machine perfusion of the liver was developed to attenuate IRI and improve organ
utilisation, early data are encouraging. A viability protocol was developed and subsequently
validated by transplantation.[224, 273] Here, viability testing and resuscitation of a donor liver
followed by left lateral + right trisegmentectomy splitting with concurrent NMLP is reported.
3.3.2 Methods
Donor
A DCD liver from a 69 year-old female with a body mass index of 34.3 kg/m2 and DRI of 3.053,
who sustained an irrecoverable hypoxic brain injury following an out-of-hospital cardiac arrest
and had been admitted to the ITU for 7 days, was initially accepted for transplantation. With-
drawal of life sustaining treatment was conducted in ITU according to UK standard practice and
34 minutes later dual arterial and porto-venous liver perfusion commenced with UW perfusion
fluid at 4oC, using the established super-rapid technique. On back-table inspection the liver was
described as being mildly steatotic with an iatrogenic 2.5cm superficial laceration to the left
lobe and atherosclerosis to the coeliac patch. There was normal extrahepatic vascular anatomy.
The liver was deemed unsuitable for transplantation by the initial allocated transplanting centre,
was offered to the national pool but rejected, and then accepted by the Liver Unit at the Queen
Elizabeth Hospital Birmingham for reseach.
After transportation on static cold storage, the liver experienced a CIT of 9 hours 43 minutes. It
was inspected but subsequently declined for transplantation. It was decided to subject the liver
to NMLP for viability testing.
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Normothermic Machine Liver Perfusion
The liver was prepared for modified piggyback transplantation. The IVC was dissected to permit
unobstructed drainage, portal vein to its bifurcation, hepatic artery to the gastroduodenal artery
and the common bile duct was identified. NMLP commenced with a PRC based fluid at 37oC
using the Liver Assist device (Organ Assist, The Netherlands) via hepatic artery and portal vein
cannulae. Oxygenated pulsatile flow (pressure 50 mmHg) and non-pulsatile flow (pressure 10
mmHg) perfused the liver via hepatic artery and portal vein respectively, before recirculating
via the open circuit reservoir.
During NMLP, flow parameters, blood gases and bile production were assessed every 30 min-
utes. Homogenous perfusion, stable flow parameters, lactate concentration of < 2.0 mmol/L
and evidence of bile production after 2 hours fulfilled criteria for viability.
Splitting
‘Classical’ left lateral + right trisegmentectomy split was performed with an integrated bipolar
and ultrasonic device (Thunderbeat, Olympus, UK) for dissection with simultaneous ligation.
Splitting was conducted in the reservoir with concurrent NMLP throughout (Figure 3.21 A &
B), maintaining inflow and outflow for both ‘grafts’.
Flow parameters and perfusate analysis were recorded during post-hilar and post-parenchymal
phases from left and right hepatic arteries, portal veins and IVC. Post-procedure blood flow
was confirmed using Doppler ultrasound (CX50 CompactXtreme, Philips, The Netherlands), in
each lobe.
Histology
Specimens taken 3 hourly and on completion of NMLP from each lobe were examined by H&E




The liver weighed 1650g. Duration of pre-splitting NMLP was 6 hours 28 minutes. Within
3 minutes of commencing NMLP, homogenous perfusion was noted. At the start of NMLP,
arterial and portal venous flow rates were 116 ml/min and 630 ml/min respectively. Flow rates
increased rapidly, reaching of 573 ml/min (artery) and 1500 ml/min (portal vein) after 3 hours
of NMLP (Figure 3.21 A). Flow rates at the end of NMLP prior to splitting were 500 ml/min
for the artery and 1510 ml/min for the portal vein. Arterial and portal venous pressures were
maintained within physiological thresholds. After an initial decrease, resistances in the artery
and portal vein remained low. The initial reservoir temperature was 26oC, reaching 36oC after
47 minutes.
Prior to NMLP, lactate concentration of the perfusion fluid was >20.0 mmol/L. The initial lac-
tate of 13.9 mmol/L decreased rapidly (Figure 3.21 B). After 2 hours of NMLP, when viability
was assessed, lactate concentration was 1.0 mmol/L. It continued to decrease to 0.9 mmol/L at
2 hours 30 minutes, after which it increased to 3.0 mmol/L by the end of pre-splitting NMLP.
Bile was initially collected 2 hours 30 minutes after starting perfusion (Figure 3.21 C) and in
total 11 grammes were excreted. NMLP was associated with a reduction in perfusate glucose
concentration from a maximum of 46.9 mmol/L to 16.5 mmol/L without the adminstration of
exogenous insulin (Figure 3.21 D).
Pre-Parenchymal, Post-Hilar Dissection and Post-Parenchymal Transection
The duration of splitting with concurrent NMLP was 71 minutes. Total duration of NMLP was 8
hours 22 minutes. No additional PRC were required for the circuit during NMLP. The splitting
procedure resulted in a dry transection surface and extrahepatic vasculature.
During the pre-hilar phase, flow in the hepatic arteries and portal veins decreased despite main-
taining the pre-splitting pressures (hepatic arterial median pressure 55 [53-56] mmHg, flow
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Figure 3.21: (A) Hepatic arterial and portal venous flow rates; (B) Lactate concentrations; (C)
Cumulative bile production; (D) Glucose concentrations.
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447 [441-448] ml/min; portal venous median pressure 10 [10-11] mmHg, flow 750 [720-770]
ml/min). After parenchymal splitting and maintaining previous differential pressures (median
54 [54-55] mmHg), total hepatic arterial flow remained just below pre-hilar rates (median 429
[424-450] ml/min). The total portal venous flow rate increased to near pre-splitting rates (me-
dian 1250 [1230-1260] ml/min) whilst maintaining physiological pressures (median 9 [8-10]
mmHg).
Lactate concentrations at the end of the hilar phase were similar in the left and right hepatic
arteries and portal veins as well as in the effluent from the IVC (Table 3.12). Post-parenchymal
phase lactate concentrations in the hepatic arteries and portal veins were unchanged. Lactate
concentration in the inferior vena cava increased by 0.3 mmol/L compared to the pre-hilar phase.
Bile production continued throughout splitting. Doppler ultrasound demonstrated expected hep-
atic arterial, portal venous and inferior vena cava waveforms in both lobes after splitting (Figure
3.22).
Histological Assessment
Moderate sinusoidal vasodilatation, equivalent to one hepatocyte width, was noted throughout
NMLP although it was milder after splitting (Figure 3.23 A, C, E, G). There was no evidence
of hepatocyte necrosis during the first 3 hours of NMLP (Figure 3.23 A, C). Mild periportal
necrosis (Figure 3.23 E, < 20%) was noted only in the left lobe after 6 hours of NMLP however,
there were no necrotic hepatocytes after parenchymal splitting (Figure 3.23 G). Macrovesicular
steatosis was low (< 10%) on the biopsy taken immediately prior to NMLP (Figure 3.23 A).
The distribution of both macro- and microsteatosis remained the same at completion of splitting
(Figure 3.23 G). There was no evidence of intrahepatic bile duct injury either before or after
splitting. There was patchy PAS staining throughout NMLP prior to and on completion of
splitting as we frequently observe with donor organs initially thought to be un-transplantable
(Figure 3.23 B, D, F). Nevertheless, there was a trend for increasing PAS staining by the end of
splitting (Figure 3.23 H).
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HA PV HA PV HA PV HA PV
pH 7.439 7.432 7.442 7.448 7.387 7.416 7.405 7.439 7.403 7.369
pCO2 (kPa) 4.04 4.22 4.1 4.06 4.83 3.96 4.29 3.74 4.32 4.93
pO2 (kPa) 10.07 6.8 9.47 7.02 4.67 7.94 5.83 10.21 6.28 3.48
BE (mmol/L) -3.6 -3.2 -3.1 -2.9 -3.3 -5.2 -4.5 -4.9 -4.4 -4
HCO3- (mmol/L) 20 20.6 20.5 20.6 21.3 18.7 19.7 18.6 19.8 20.9
tHb (g/L) 76.5 78.2 76.7 77.5 81 78.1 78.4 79.5 79 76.1
Hct (%) 17.2 17.6 17.6 17.4 18.3 16.6 17 16.8 17 16.8
Glucose (mmol/L) 13.7 14 14.1 13.8 14.4 15.3 15.8 16.6 15.8 15.6
Lactate (mmol/L) 2.7 2.7 2.8 2.6 2.6 2.6 2.7 2.8 2.7 2.9
Table 3.12: Table of flow rates and blood gas results prior to, during and after completion of
splitting with concurrent NMLP.
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Figure 3.22: (A) Hepatic arteriolar waveform; (B) Portal venous waveform; (C) Hepatic venous
waveform.
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Figure 3.23: Representative histological samples to assess architectural integrity and necrosis
by H&E staining (A,C,E,G) as well as glycogen content using Periodic acid-Schiff staining
(B,D,F,H). Samples taken prior to commencement of NMLP (A,B), after 3 hours of NMLP




This is the first study demonstrating that splitting a liver with concurrent NMLP throughout is
feasible and viability is maintained. Furthermore, this has been achieved in a liver unsuitable
for transplantation. No studies to date have investigated liver splitting with concurrent NMLP
throughout splitting using either normothermic, subnormothermic or hypothermic strategies.
This technique presents advantages over existing ex situ or in situ methods. There is no increas-
ing temperature and rewarming under ischaemic conditions seen with cold ex situ splitting.
Whilst possible during in situ splitting, concurrent NMLP provides ex situ direct visualisation
of perfused segments. Throughout and after splitting the cut surface can be inspected and ves-
sels ligated to ensure haemostasis. Continuation of NMLP permits continuous viability assess-
ment. This may contribute to recipient selection, aid informed decision-making and facilitate
logistics of transplanting two grafts by preventing long CIT. This study has shown that ex situ
splitting is feasible in extended criteria donor livers performed in combination with NMLP, and
results in pre-transplant biochemical, histological and Doppler findings that are compatible with
transplantation.
Liver splitting during NMLP has been described using the OrganOx metra R© device. Due to the
closed circuit, a hanging procedure was implemented to facilitate dissection whilst minimising
fluid loss from the cut surface. Here perfusion was paused for six minutes to separate the grafts
and yielded only an extended right segment still perfused.[274] Specific advantages of an open
circuit include: Superior manipulation; reduced risk of compromised flow; potential to perform
and assess integrity of vascular reconstruction; the ability to perform the complete splitting
procedure with concurrent NMLP.
Ex-situ splitting with NMLP allows exploration of splitting ECD livers and may increase the
donor pool enabling two recipients to be transplanted from a single donor. This apparatus also
could facilitate training in liver splitting and providing controls for experimental research.
In summary, classical left lateral + right trisegmentectomy liver splitting entirely with concur-
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rent NMLP is feasible, maintaining viability of both lobes, combining ‘normal’ physiological
conditions with reduced CIT with the ease of ex situ splitting, without impacting on organ re-
trieval. Future work will allow improved monitoring and facilitate logistics of liver splitting.
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CHAPTER 4
TWEAK/FN14 IN HUMAN DISEASED LIVER




The potential role of Fn14 in the liver was initially described at the start of the millennium. Fn14
expression was mapped to chromosome 16 by fluorescent in situ hybridisation and its pres-
ence was demonstrated in both human and murine models of hepatocellular carcinoma.[275]
Fn14 is highly expressed in the developing murine foetal liver and up-regulated during murine
and rat adult hepatic injury.[84, 85, 276] Fn14 is expressed on Liver Progenitor Cell (LPC),
hepatocytes and cholangiocytes in human and murine models.[84, 85, 276] Fn14 is expressed
on murine CD 24+, Sca-1 high, Thymocyte Differentiation Antigen-1 (Thy-1) low progeni-
tor cells and its activation results in proliferation and the formation of duct-like structures in
foetal rat liver.[277] Further evidence of Fn14 on LPCs has been provided by a more direct
evaluation of Fn14 and TWEAK in a survey of human liver and their role in HSCs.[278] Re-
cently, transcription of Fn14 in human hepatocellular carcinoma may be mediated by alpha-
fetoprotein.[279] Translational studies have focussed on Fn14 being a potential therapeutic
target in alcoholic hepatitis.[280, 281] TWEAK expression was shown to be up-regulated in
human and murine models of hepatocellular carcinoma and detected on Thy-1+ cells in the re-
generating liver.[282, 283] More recently, in a murine model of fibrosis, macrophage-derived
TWEAK promoted liver progenitor population expansion and improvements in fibrosis.[284]
Translational studies of TWEAK therapy are yet to be conducted and to date, there are no
studies investigating the role of Fn14 and TWEAK subsequent to liver transplantation.
The presence of high levels of Fn14 on cholangiocytes in areas of ductular regeneration and the
presence of surrounding myeloid cells expressing high levels of TWEAK during inflammation
would be consistent with a major role for this receptor-ligand pair in ductular remodelling. The
aim of this chapter is to test the hypothesis that the Fn14/TWEAK receptor-ligand systems plays
a role in intra-hepatic biliary epithelial cell biology using established in vitro modelling.
The aim of this chapter is to test the hypothesis that the Fn14/TWEAK receptor-ligand systems
plays a role in intra-hepatic biliary epithelial cell biology using established in vitro modelling.
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4.2 Materials & Methods
4.2.1 Ethical Approval
Human tissue sections and cultured primary human cholangiocytes were isolated from slices of
normal donor tissue not required for transplantation and explanted diseased livers obtained from
the Queen Elizabeth Hospital Birmingham liver transplant programme. The study was granted
ethical approval by the University of Birmingham Local Regional Ethics Committee (reference
number 06/Q702/61). Consent to use donor tissues for research was obtained by SNOD from
the donor’s next of kin during consent for organ donation. None of the organ donors were
from a vulnerable population. All donors, next of kin freely or liver transplant recipients freely
provided written informed consent.
4.2.2 Determining Fn14 in the Liver by Immunohistochemistry & Im-
munofluorescence
Immunohistochemistry was performed using standard techniques on human tissue sections ob-
tained from blocks of snap frozen tissue that had been stored at -80oC. Briefly, sections were cut
using a cryostat by an experienced laboratory scientist on to poly-L-lyseine coated glass slides
before being fixed in acetone for 5 minutes. Sections were washed in PBS prior to being stored
at -20oC. When required, sections were defrosted in a humidifying chamber, the tissue demar-
cated with a wax pen, labelled and washed in PBS. The peroxide activity of the tissue sections
was quenched by bathing the sections in 0.3% hydrogen peroxide before further washing in
PBS then immunoglobulin blocked with 10% normal horse serum (S2000, Vector Laboratories
Ltd., Peterborough, UK) for 30 minutes. In all immunohistochemical and immunofluorescent
experiments, no primary and relevant concentration-matched isotype immunoglobulin controls
were used. The primary antibodies Fn14 (mP4A8, kindly supplied by Dr. Linda Burkley,
Biogen Idec.) and HEA125 were diluted to their appropriate concentrations, 37 ng/ml and 5
µg/ml respectively, in 10% normal horse serum buffer and incubated at room temperature for
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1 hour. Sections were washed in PBS before rabbit anti-mouse secondary antibody (MP7500,
Vector Laboratories Ltd., Peterborough, UK) was applied and incubated for a further 1 hour.
After further washing in PBS, the sections were incubated with either ImmPACT AEC (3-
amino-9-ethylcarbazole, SK4205, Vector Laboratories Ltd., Peterborough, UK) for 30 minutes
or ImmPACT DAB (diaminobenzidine, SK4105, Vector Laboratories Ltd., UK) for 3 minutes.
Washing in PBS was followed by haematoxylin counterstaining for 30 seconds before washing
and mounting in aqueous mountant.
Immunofluorescence was performed in a similar manner however the blocking and antibody
buffer used was PBS with 10% foetal calf serum and 1% sodium azide. Washes were perforemd
twice in PBS for 10 minutes each time. The secondary and substrate steps were replaced by a
single application of fluorescent secondary conjugates incubated in the dark. These were either
FITC or Texas Red (TXRD). The counterstain used 4’,6-diamidino-2-phenylindole (DAPI) that
had been incubated with the slides for 2 minutes. Sections were mounted using an immunoflu-
orescent mountant and stored in foil at 4oC. Images of fluorescent stained sections were taken
using an fluorescent microscope (Axioskope 40, Carl Zeiss Ltd., Cambridge, UK) within 7
days.
4.2.3 Isolation of Human Cholangiocytes
Primary human cholangiocytes were isolated from donor tissue either not required for transplan-
tation or from the hepatectomy during transplantation. Specimens were processed by a Univer-
sity Hospital Birmingham Pathology Department approved scientist. The method to isolate
human cholangiocytes was commenced within 24 hours of the specimen becoming available
to the laboratory. In summary, the isolation involved a collagenase digestion for 30 minutes
followed by serial centrifugation before purification with a 77%:33% Percoll 25 minute cen-
trifugation step. This was followed by extraction of the pellet and further centrifugation before
immunomagnetic separation using mouse-antihuman HEA125 and Dynal beads. Once sepa-
rated the cholangiocytes were plated on to rat-tail collagen-coated 25cm3 flasks and fed with
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sterile supplemented Dulbecco’s Modified Eagle’s Medium (DMEM):Ham’s-F12 based media.
Flasks were incubated at 37oC and the media changed every other day. Once at least 70% con-
fluent, cholangiocytes were passaged using trypsin to a 75cm3 rat-tail collagen-coated flask for
further incubation to expand the cholangiocyte population.
4.2.4 Human Cholangiocyte Cell Lines
The viability of primary human cholangiocytes is known to be dependent upon the liver disease
from which the cholangiocytes were isolated. For this reason contiguous experiments were
conducted on non-malignant and malignant cell lines. None of these cell lines are Simian Vac-
uolating Virus 40 (SV40) transformed. The Andreas K Nussler-1 (AKN-1) cell line, initially
described in 1999, was derived from a 10 year old boy and characterises non-malignant bil-
iary epithelial cells.[285] The CC-LP-1 and CC-SW-1 cell lines, described together in 1992,
were derived from moderately differentiated adenocarcinomae and characterise intrahepatic
cholangiocarcinoma.[286] All of the cell lines are plastic adherent and do not require the flasks
to be coated with rat-tail collagen. Cells were incubated with a supplemented DMEM media.
4.2.5 Phenotyping of Cultured Human Cholangiocytes and Cell Lines
Once primary human cholangiocytes or the cell lines became at least 70% confluent in the
75cm3 flasks, the cells could be trypsinised and cultured in a 24 well plate at 5x104 cells
per well. Once these were 70% confluent the cells could be phenotyped by either immuno-
histochemistry/immunofluorescence after being cytospun to poly-L-lysine coated slides or by
flow cytometry using standard techniques. The cellular phenotype was determined using a
variety of different antibodies including but not exclusively the following: Epithelial Cell Ad-
hesion Molecule (EpCAM), also known as HEA125, a surface cholangiocyte marker; Cytok-
eratin (CK)18, an intracellular hepatocyte and cholangiocyte marker; CK19, an intracellular
cholangiocyte marker); CD 31 also known as Platelet Endothelial Cell Adhesion Molecule-1
(PECAM-1), a surface endothelial cell maker; CD 90, also known as Thy-1, surface fibroblast
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marker. Additionally, no primary and relevant concentration matched immunoglobulin isotype
control samples were tested to ensure specificity of the phenotyping antibodies.
4.2.6 Determining Trypsin Sensitivity of Fn14
Trypsin can disrupt the glycocalyx immediately surrounding the cell. The use of trypsin to dis-
sociate cells from flasks or culture plates may therefore cleave the extracellular domains of Fn14
and render it inactive. The sensitivity of the cultured cell lines to trypsin was investigated by
subjecting the cells to either trypsin or cell dissociation buffer immediately prior to preparation
for flow cytometry to determine Fn14 expression. For each dissociation method, the experiment
was repeated three times.
4.2.7 Determining Expression of Fn14 on Cultured Cholangiocytes and
Cell Lines
Cholangiocytes and cell lines were cultured in a 24 well plated at 50x105 cells per well. After
incubation for 24 hours cells were either left to continue being cultured in standard media or
were stimulated with either TNF-α (10 µg/ml), IFN-γ (50 ng/ml) or Fibroblast Growth Factor-
basic (FGF-b)(0.05 ng/ml) for 24 hours. Cells were then trypsinised off the 24 well plate and
either cytospun for immunohistochemistry/immunofluorescence or prepared for flow cytometry
using standard methods. Fn14 was determined by FITC emission on the 488 nm laser.
4.2.8 Determining Expression of Fn14 on Cultured Cell Lines Using Cell
Surface Proteomics
This method was developed over 6 months to maximise on yield of peptides from the cell
surface proteome being was delivered to the mass spectrometer. The final experiment was
performed three times once the protocol was optimised.
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Biotinylation
Four T75 flasks 95% confluent with CC-SW-1 intra-hepatic cholangiocarcinoma cell line were
used for determining Fn14 expression by cell surface proteomics. The T75 flasks were placed
on ice, the media removed before being washed twice with 8ml of ice-cold PBS per flask. The
PBS was quickly removed to prevent rounding and detachment of the cells. The contents of one
vial of EZ-Link Sulfo-NHS-SS-Biotin (Thermo Scientific, UK) was dissolved in 48ml of ice-
cold PBS, before 10ml of the biotin solution was added to each flask. The EZ-Link Sulfo-NHS-
SS-Biotin is a sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate that has accessible
lysine residues which can covalently bind to primary amines at the sulfo end (Figure 4.1).
Subsequently, the flasks were placed on a rocking platform or an orbital shaker and gently
agitated for 30 minutes at 4oC to ensure even coverage of the cells with labelling solution. The
flasks were washed three times with ice-cold PBS to remove all labelling solution, after which
500µL of Quenching Solution was added to each flask to stop the reaction. The cells were
subsequently scraped gently in to solution and transferred to a single 50ml conical tube. This
was centrifuged at 500x g for 3 minutes and the supernatant discarded. Finally, 5ml of Tris
Buffered Saline (TBS) was added to the cell pellet to suspend it before centrifugation at 500x g
for 3 minutes with the supernatant again discarded.
Cell Lysis
The supplied protease inhibitor was added to 500µL of lysis buffer and added to the cells and,
after gentle suspension, disrupted by sonicating on ice for 1-second bursts. The cells were
then incubated on ice, vortexing every 5 minutes for 5 seconds. Additional sonications were
performed during incubation as necessary. The lysate was then centrifuged at 10,000x g for 2
minutes at 4oC after which the clarified supernatant was transferred to a new tube.
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Figure 4.1: Biotinylation of cell surface proteins in preparation for cell surface proteomics. The
EZ-Link Sulfo-NHS-SS-Biotin covalently binds to primary amines of cell surface proteins at
(A), with the attached Biotin captured on a NeutrAvidin gel (B). The disulfide bridge (C) is
cleaved to release the proteins for peptide processing. Figure adapted from Thermo Scientific
EZ-Link Sulfo-NHS-SS-Biotin product information.
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Isolation of Labelled Proteins
An even suspension of the supplied NeutrAvidin Agarose was added to a collecting column
that had been capped. This was centrifuged for 1 minute at 1000x g and the flow-through
discarded before being repeated twice. The bottom cap was applied, the clarified cell lysate
added to the gel and the top cap applied. The capped column was incubated for 60 minutes
at room temperature with end-over-end mixing using a rotator. The column was uncapped and
centrifuged for 1 minute at 1000x g before 500µL of 1M sodium chloride was added. Following
two further centrifugations, 25µL of the supplied protease inhibitors was added to 2.5ml of
wash buffer, from which 500µL was added to the column that had been placed in the collection
tube. Centrifugation for 1 minute at 1000x g was conducted 4 times before the bottom cap was
replaced.
Protein Elution
A 0.5M preparation of DTT was prepared by weighing 77.1mg of DTT in a 1.5ml Eppendorf,
adding 900µL of Chromanorm H2O and 100µL of Tetraethylammonium Bromide (TEAB). To
450µL of a 2% solution of Sodium-deoxycholate (SDC) in 100mM of TEAB, 23.7µL of 0.5M
DTT was added to make sample buffer. From this, 400µL of the sample buffer was pipetted
to the gel and the column capped. Incubation of the reaction occurred for 60 minutes at room
temperature with end-over-end mixing on a rotator. The sample was then centrifuged in to a
new column for 2 minutes at 1000x g to yield the eluted protein.
Protein Digestion
To defrosted 20µg of sequencing grade trypsin (Promega UK, Southampton, Hampshire, UK),
100µL of 100mM TEAB was added and mixed thoroughly. From this 50µL was added to the
protein solution which was then placed on a shaker overnight at room temperature to complete
digestion of the eluted cell surface proteins.
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Peptide Enrichment
To the peptide solution, 50µL of pure Trifluoroacetic Acid (TFA) was added to precipitate the
SDC. After vortexing for 1 minute, the sample was cetrifuged for 3 minutes at 13,000g. A 50µL
aliquot of 1M iodoacetamide in 100mM of TEAB was added to 500µL of the peptide solution.
This was incubated at room temperature for 60 minutes in the dark.
Purification of Labelled Peptides
To a 15ml conical tube, a SUPEL C18 cartridge was inserted and subsequently washed with 1ml
of acetylnitrile/1% TFA, leaving a disc of fluid following low pressure suction to the cartridge.
The SUPEL C18 cartridge was then washed with 1ml Chromanorm/1% TFA, again leaving a
disc of fluid following low pressure suction. The peptide samples were rolled, added to the
SUPEL C18 cartridge and allowed to drip in to a new 15ml conical tube. Any residual sample
was washed with 1ml Chromanorm/1% TFA for 5-10 minutes. The purified peptides were
eluted by adding 1ml acetylnitrile/1% TFA to the C18 cartridge. Sample quality was checked
by taking 100µL from the peptide sample for SDS-PAGE banding. The remaining purified
sample was dried over 1-2 hours and stored as appropriate at -20oC.
Peptide Fractionation and Mass Spectrometry
The dried sample was reconstituted in 105µL of 0.03% Triethylamine in water before being
fractionated in to 22 low-binding Eppendorfs, each being a 3 minute fractionation. The frac-
tionated samples were then dried for 2 hours with centrifugation. After drying, 40µL pf 1%
formic acid was added to each fraction, sonicated for 2 minutes, vortexed then centrifuged for
3 minutes. Finally, 20µL of each reconstituted fraction was placed in to a microvial and trans-
ferred to the cooling rack in preparation for fragmentation in to the 8 most abundant peptides per
fraction by tandem mass spectrometry (MS/MS) with an Electrospray Ionisation (ESI) interface
using a maXis impact UHR-TOF mass spectrometer and its associated software ProteinScape
(both Bruker Daltonics, Bremen, Germany). Subsequent analysis of collision induced dissoci-
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ation was performed against NCBInr using the Mascot search algorithm to generate Swiss-Prot
accession numbers to identify corresponding proteins using the STRING: functional protein
association networks database (version 10.5) for functional expression analysis.[258] Immuno-
histochemistry was performed on paraffin-embedded sections with a peroxidase detection tech-
nique, with 3,3’-Diaminobenzidine (DAB) as the substrate, previously described.
4.2.9 Determining Functional Outcome of Fn14 Activation by TWEAK
To determine the functional outcome of Fn14 activation by TWEAK, unstimulated and stim-
ulated cells as described above were exposed to either no TWEAK, a low concentration of
TWEAK (10 ng/ml) or a high concentration of TWEAK (100 ng/ml) for a further 24 hours.
Cells were then prepared for flow cytometry to determine apoptosis, autophagy, ROS and necro-
sis activity using a 4 colour assay developed by the Afford Group. In summary, apoptosis was
tested using Annexin-V (Molecular Probes, Paisley, UK) emitting in the pacific blue channel on
the 405 nm laser. Autophagy was investigated using Monodansylcadaverine (MDC) (Sigma-
Aldrich, UK),that binds to autophagic vacuoles and emits in the pacific orange channel on the
405 nm laser. The ROS production was determined using DCF diacetate (Merck, Nottingham,
UK,) that recognises a number of species including peroxides, super oxides and nitric oxide,
with emission is via the FITC channel on the 488 nm laser, once cleaved by intracellular es-
terases to 2’,7’-DCF whichrenderd it cell impermeable. Necrosis was quantified using 7-AAD
(Molecular Probes, Paisley, UK) that intercalates with high affinity to GC-rich regions of DNA,
with emission in the PE-Cy-5 channel on the 488 nm laser. Appropriate compensation of the
4 colour assay was determined by permeabilising the cells of 4 wells and attaching the fluo-
rochromes in the above channels to CK19. The compensation matrix was calculated prior to the
4 colour assay being conducted on different experiments.
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4.3 Results
As determined by immunohistochemistry, using DAB as the substrate, Fn14 is expressed mainly
on diseased tissue (Figure 4.2). There is a very low expression of Fn14 in donor tissue not re-
quired for transplantation (Figure 4.2 A), whilst the diseased tissues stain at a stronger intensity.
In ALD (Figure 4.2 B) Fn14 expression is limited to the ductular reactive regions around the
Canals of Hering as located by the arrow. In PBC (Figure 4.2 C), overall there is a more
widespread ductular reaction which stains with a higher intensity for Fn14 compared to ALD.
In contrast, Fn14 expression in chronic rejected organs is more widespread and is seen not only
in areas of ductular reaction, as demarcated by the arrows, but also on hepatocytes peripheral to
the stroma.
4.3.1 Phenotyping of Cultured Human Primary Cholangiocytes and Cell
Lines
Phenotyping of the cultured human primary cholangiocytes and cell lines is used to determine
if the cells cultured are adequate model of those seen in tissue. Representative gating strategies
for primary cholangiocytes (Passage 4 PBC) and the AKN-1 cell line are shown (Figure 4.3 A
& B respectively). The forward:side scatters of the primary cholangiocytes are more diverse
compared to the AKN-1 cell line suggesting a more heterogeneous population. The forward
scatter:pulse width of the primary cholangiocytes are more tightly grouped, demonstrating that
a higher proportion of the primary cells are singlets compared to the AKN-1.
Quantitatively, the differences between the different cell types are shown in Figure 4.4. The
primary cells are cholangiocytes from: passage 2 (P2) NASH; P4 PBC; P5 PBC; P5 ALD; P6
ALD; P6 Donor. Generally, all cell types are CD31 low, CD90 low, CK18 high and CK19
high. However, there are differences between cell types or each marker. There is a higher
amount of CD31 in the primary cells compared to the AKN-1 cell line (MFI Primary 11.54 cf.
AKN-1 7.81, p < 0.05), however there is no such difference between the primary cells and the
cholangiocarcinoma cell-line CC-SW-1. Additionally, there is a higher amount of CD90 in the
204
Figure 4.2: Expression of Fn14 in normal and diseased tissue by immunohistochemistry. (A)
Donor tissue, (B) ALD, (C) PBC, (D) chronic rejection. Staining uses DAB as a substrate and
haematoxylin as the counterstain. Arrows indicate areas of ductular reaction around the Canals
of Hering.
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Figure 4.3: Phenotype of cultured human cells by flow cytometry. (A) Passage 4, primary
cholangiocytes from a PBC liver, (B) AKN-1 cell line, N = 4 for each cell type. Gating strategy:
R1, Forward:Side Scatters gating to R2, Forward Scatter:Pulse Width. Histograms are log
fluorescent intensity versus event count gated from R2, Forward Scatter:Pulse Width. R3, Cells
only; R4, 2% positive cells for IgG1; R5, CD31; R6, CD90; R7, CK18; R8, CK19. R5-8 same
FITC Log as R4.
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primary cells compared to the AKN-1 cell line (MFI Primary 26.20 cf. AKN-1 7.98, p < 0.05).
Again, no difference exists between the primary cells and the CC-SW-1 cell line. There appears
to be differences in the CK18 and CK19 contents between cell types but this is not statistically
different.
4.3.2 Fn14 Expression In Vitro by Immunohistochemistry and Immunoflu-
orescence
Using immunohistochemistry, primary human cholangiocytes (P6 ALD) that were cytospun on
to poly-L-lyseine coated slides are a heterogeneous group of cells as shown by the variability
in cellular size on haematoxylin staining (Figure 4.5). CK19 staining, demonstrating mature
cholangiocytes, is expressed at a higher intensity on the smaller diameter cells. In contrast,
Fn14 is expressed on these cells at a higher intensity on the larger cells.
Immunofluorescence on cytospun primary cholangiocytes demonstrates Fn14 is present on the
majority of the cholangiocytes (Figure 4.6). Fn14 is distributed across the plasma membrane of
cholangiocytes and within the cytoplasm. Additionally, there are areas of much higher intensity
within the cytoplasm, suggesting storage of Fn14.
4.3.3 Determining Optimum Concentration of Fn14 Antibody for Flow
Cytometry
The optimum concentration of the Fn14 antibody is demonstrated using the titration by doubling
dilutions (Figure 4.7). The overlay histograms generated by flow cytometry in the AKN-1 cell
line show a decrease in the percentage positivity of the cells with low concentrations of the
Fn14 mouse anti-human antibody (Figure 4.7 A). A 2% positivity for the IgG1 isotype control
antibody was used to ensure that positivity of the Fn14 antibody was more than two standard
deviations away from the mean of the isotype control, hence this could not be a result of chance.
Quantitatively, the percentage of AKN-1 cells positive for Fn14 was 79.02%, 78.03%, 74.97%,
65.73%, 59.16% and 37.32% when titrated to 1:25 (148 ng/ml), 1:50 (74 ng/ml), 1:100 (37
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Figure 4.4: Phenotype of primary cholangiocytes, AKN-1 cell line and CC-SW-1 cell line ex-
pressed as MFI. Left to right CD31, CD90, CK18, CK19. AKN-1 represented by grey bars,
cholangiocarcinoma cell line CC-SW-1 represented by tight hatched bar, primary cholangio-
cytes represented by wide hatched bars, N = 4 for each cell type. Error bars indicate standard
error. * and ** indicate statistical difference from AKN-1 cell line using two-tailed students’
T-test, with p < 0.05.
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Figure 4.5: Fn14 expression on primary cholangiocytes by immunohistochemistry. Cytospun
primary human cholangiocytes (P6 ALD) stained for CK19 and Fn14, imaged with 20x and 40x
objective. No primary and concentration matched isotype controls also shown. Counterstaining
with haematoxylin.
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Figure 4.6: Fn14 expression on primary cholangiocytes by immunofluorescence. Cytospun
cholangiocytes stained using DAPI nuclear stain (blue) and isotype control (left), Fn14 (centre,
FITC) and cholangiocyte marker CK19 (right, TXRD).
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ng/ml), 1:250 (14.8 ng/ml), 1:500 (7.4 ng/ml) and 1:1000 (3.7 ng/ml) respectively (Figure 4.7
B). A similar pattern in the decrease of percentage positive cells at different dilutions was seen
in the CC-LP-1 and CC-SW-1 cholangiocarcinoma cell lines. For further flow cytometry a
dilution of 1:100 (37 ng/ml) was considered to be appropriate.
4.3.4 Trypsin Sensitivity of Fn14
Although the smallest of the TNF receptor superfamily, the extracellular domains of the Fn14
receptor exist in the extracellular glycocalyx. The forward:side scatters demonstrate that the
AKN-1 cells dissociated from the coated flasks using Cell Dissociation Buffer (CDB) generated
more debris compared to using trypsin (Figure 4.8 A1 & B1). Using CDB prevented the AKN-
1 cells from forming couplets or triplets, as shown by a higher proportion of cells within the
singlet gate on the forward scatter: pulse width compared to cells dissociated with trypsin
(Figure 4.8 A2 & B2). However, there was no difference between Fn14 expression using the
different dissociation methods (Percentage postitive cells Trypsin 80.33% cf. CDB 73.39%, p
= 0.239)(Figure 4.8 A3 & B3). Similar results are seen with the other cell lines CC-LP-1 and
CC-SW-1.
4.3.5 Surface and Intracellular Expression of Fn14
Surface and intracellular expression of Fn14 by different cell types was investigated quantita-
tively (Figure 4.9). The primary cells were cholangiocytes from: P2 NASH; P4 PBC; P5 PBC;
P5 ALD; P6 ALD; P6 Donor. The AKN-1 and CC-SW-1 cell lines were also used. Gener-
ally, for all models there was a higher expression of Fn14 intracellularly compared to the cell
surface. There was a higher amount of Fn14 intracellularly compared to the cell surface for
CC-SW-1 cholangiocarcinoma cell line (Percentage positive cells Intracellular 81.48% cf. Sur-
face 69.02%, p < 0.05). Although there was a trend for the intracellular expression of Fn14 to
be higher compared to the surface in the primary cells (Percentage positive cells Intracellular
80.54% cf. Surface 53.57%) and the AKN-1 cell line (Percentage positive cells Intracellular
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Figure 4.7: Determining optimum Fn14 antibody concentration by doubling dilutions. Overlay
histograms demonstrating Fn14 expression in cultured AKN-1 cholangiocytes by flow cytome-
try (A). Unfilled histogram represents IgG1. Other histograms, from left to right, represent ex-
pression using progressively higher Fn14 antibody concentrations, 1:1000, 1:500, 1:250, 1:100,
1:50 and 1:25. Region R4 based on 2% positivity for IgG1 cells. Percentage positive cells for
different concentrations of Fn14 antibody based on region R4 (B).
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Figure 4.8: Determining the trypsin sensitivity Fn14. Flow cytometry of AKN-1 cell line disso-
ciated from collagen coated flasks using trypsin (A) and CDB (B). From left to right, Forward
v side scatter (1), forward scatter v pulse width (2) and log FITC v event count (3). MFI for
trypsin and CDB dissociated cells not statistically different. Figure representative of N = 4
experiments.
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Figure 4.9: Surface and intracellular expression on Fn14. Summary of quantitative flow cytom-
etry for surface and intracellular expression of Fn14 on primary cholangiocytes (wide hatched
bars), AKN-1 cell line (grey bars) and CC-SW-1 cholangiocarcinoma (narrow hatched bars)
cell line. N=4 for each cell type. Error bars indicate standard error. Line indicates higher
intracelleular expression of Fn14 from cell surface in the CC-SW-1 cell line expression using
two-tailed students’ T-test, with p < 0.05.
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85.41% cf. 79.60%), it does not reach statistical significance.
4.3.6 Expression of Fn14 Stimulation After 24 Hours of Cytokine Stimu-
lation
The expression of Fn14 changed when the different models were exposed to cytokine stimu-
lation for 24 hours (Figure 4.10). In the AKN-1 cell line, Fn14 expression, based upon MFI
increased after exposure to TNF-α stimulation (1.07; 95% CI=1.05-1.09; p < 0.05) and FGF-b
(1.29; 95% CI = 1.25-1.34; p < 0.01) relative to no stimulation at 24hrs. There was no decrease
in Fn14 expression after 24 hours of IFN-γ stimulation in the AKN-1 cell line. Again, the pri-
mary cells are cholangiocytes from: P2 NASH; P4 PBC; P5 PBC P5 ALD; P6 ALD; P6 Donor.
Although there was a decrease in Fn14 surface expression at 24 hours of IFN-γ stimulation
(0.84; 95% CI = 0.76-0.91; p < 0.05), there was no decrease in Fn14 expression after 24 hours
of TNF-α and FGF-b stimulation.
4.3.7 Expression of Fn14 on Cholangiocarcinoma Is Confirmed by Mass
Spectrometry
Confirmation of extraction of the cell surface proteome was confirmed by gel electrophoresis
using SDS-PAGE (Figure 4.11). The intensity of the cell surface peptides in the gel was in
keeping as a proportion of the whole cell peptides that demonstrated a greater intensity on the
gel. Mass spectrometry yielded spectra that highlighted abundant peptides (Figure 4.12). In
total, 862 cell surface enriched proteins were common to all three of the final samples that had
maximised their yield over the course of the protocol development (Figure 4.13). Further anal-
ysis revealed that of the 862 proteins identified, 271 (31.4%) were components of the plasma
membrane, with gene products having a moiety embedded in the membrane. Most (135 pro-
teins) were integral to the plasma membrane, having gene products that penetrate at least one
leaflet of the bilipid layer (Figure 4.14). The cell surface proteins could also be categorised
according to their preclinical and clinical applications. From this, it could be seen that mark-
ers used in the clinical staging of cholangiocarcinoma, such as CK19, as well as cancer stem
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Figure 4.10: Surface expression of Fn14 after 24 hours of cytokine stimulation on cholangio-
cytes. Flow cytometry for surface expression of Fn14 after 24 hours of cytokine stimulation
on primary cholangiocytes (narrow hatched bars) and AKN-1 cell line (grey bars). Results ex-
pressed as median fluorescent intensity relative to unstimulated cells for each cell type (N=6).
Error bars indicate standard error. Asterisk and double asterisk indicates statistical difference
from expression on unstimulated cells using two-tailed students’ T-test, with p < 0.05. NS = no
stimulation.
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cell markers (EpCAM, Neural Cell Adhesion Molecule (NCAM)) in addition to differentiation
markers (Frizzled-2, -6 and NOTCH-2, -3) and Fn14, also kown as TNFRSF12A (Figure 4.15).
Further verification of the presence of Fn14 in cholangocarcinoma was provided by immuno-
histochemical staining of tissue as well as that of CK19 (Figures 4.16 & 4.17). A list of all
cell surface proteins identified in the cholangiocarcinoma cell line for each experiment, those
that were shared with all experiments and categorised by cellular location can be found at:
https://doi.org/10.5072/eData.bham.00000362
4.3.8 Functional Outcome of Fn14 Activation by Recombinant TWEAK
The gating strategy adopted for investigating the functional outcome of Fn14 activation by
TWEAK on the CC-LP-1 cholangiocarcinoma cell line is shown in Figure 4.18. After 24 hours
of cytokine stimulation, followed by a further 24 hours of cytokine stimulation and exposure to
TWEAK, the forward:side scatter and forward:pulse width are similar to that of unstimulated
cells. There is a demarcated population of cells, the majority of which form singlets.
The quantitative summary of the functional outcome of Fn14 activation by TWEAK in the CC-
LP-1 cholangiocarcinoma cell line is shown in Figure 4.19. In general, the apoptosis response
and ROS production are similar as are the autophagy and necrosis responses. For each cy-
tokine stimulation, the sum of the percentage positivity for the different functional outcomes
approaches 100%. In all cytokine stimulation models, the majority of the response to Fn14
activation is apoptosis and is at least 60%.
In the unstimulated, TNF-α stimulated and IFN-γ stimulated cells, exposure to TWEAK in-
creases ROS production and apoptosis whilst decreasing autophagy and necrosis. However, in
the FGF-b stimulated cells that up-regulates Fn14 receptor expression, exposure to TWEAK de-
creases apoptosis but increases autophagy and necrosis. Despite graphical appearances, statisit-
cally this is not proven, with the exception of autophagy, where all values are less (p < 0.05)
than the reference of no stimulation and no TWEAK.
217
Figure 4.11: Gel electrophoresis confirming presence of the cell surface proteome. From left
to right, surface peptides, whole cell peptides, standard ladder. The extent of the cell surface
peptides is in keeping as a proportion of the whole cell peptides (middle).
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Figure 4.12: Typical spectrum obtained during ESI tandem mass spectrometry of cell surface
peptides. The 8 most abundant peptides from the top spectrum were fragmented to enable
analysis of collision induced dissociation against NCBInr using the Mascot search algorithm.
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Figure 4.13: Venn diagram of cholangiocarcinoma cell surface proteins by cell surface pro-
teomics. Each circle represents a single experiment of N=3. Despite optimising the yield of cell
surface proteins, there was considerable disparity between the number of proteins detected on
the cell surface proteome between each experiment. A total of 862 proteins were common to
the three experiments, the basis of further analysis.
220
Figure 4.14: Location of identified proteins by cellular component. 135 of the 271 plasma
membrane proteins identified from three experiments were integral components of the plasma
membrane, having at least one gene product penetrating one leaflet of the bilipid membrane.
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Figure 4.15: Categorisation of CC-SW-1 cell surface enriched proteins by application. Selected
proteins categorised according to preclinical and clinical use. KRT = Cytokeratin; EPCAM
= Epithelial Cell Adhesion Molecule; NCAM = Neural Cell Adhesion Molecule; PROM =
Promonin; FZD = Fizzled; TNFRSF = Tumour Necrosis Factor Receptor Superfamily; TNFSF
= Tumour Necrosis Factor Superfamily.
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Figure 4.16: Confirmation of presence of CK19 on cholangiocarcinoma by immunohistochem-
istry. Immunohistochemistry of formalin fixed paraffin embedded an intrahepatic cholangiocar-
cinoma specimen for CK19, used to clinically stage disease, by DAB staining photographed at
10x objective.
Figure 4.17: Confirmation of presence of Fn14 on cholangiocarcinoma by immunohistochem-
istry. Immunohistochemistry of sections from same formalin fixed paraffin embedded specimen
as Figure 4.16 for Fn14, by DAB staining using earlier described method, photographed with
40x objective.
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With the exception of unstimulated cells, a higher concentration of TWEAK results in lower
ROS production and a decrease in apoptosis. In contrast and again with the exception of un-
stimulated cells, a higher concentration of TWEAK is associated with increased autophagy and
necrosis.
4.4 Discussion
The principal findings of this project investigating the role of the Fn14/TWEAK receptor ligand
in ductular reactive cell differentiation and bile ductule neogenesis during hepatic inflammation
and repair are that:
1. Fn14 is expressed in diseased liver tissue and that the extent of expression is dependent on
liver pathology.
2. Isolated and cultured primary human cholangiocytes from various liver diseases as well as
the non-malignant AKN-1 cholangiocyte cell line and the cholangiocarcinoma CC-LP-1 and
CC-SW-1 cell lines express Fn14.
3. Fn14 is not cleaved by trypsin but it remains to seen the functional impact that typsin has on
Fn14.
4. Fn14 not only exists on the cell surface but also that considerable amounts of Fn14 exist
within the cytoplasm of the different cholangiocyte models.
5. The expression of Fn14 is dependent on the inflammatory cytokines to which the cultured
cholangiocyte are exposed and that the response varies depending on the cholangiocyte model
used.
6. In FGF-b stimulated cholangiocarcinoma cell line, exposure to TWEAK decreases apoptosis
but increases autophagy and necrosis in contrast to other cytokine stimulations.














































































































































































































































































































































































































































































































































































































apoptosis but is associated with increased autophagy and necrosis.
A particular strength is the use of cultured cholangiocytes isolated from human diseased livers.
This is only possible as a result of the availability of human liver tissue from the adjacent Queen
Elizabeth Hospital liver transplantation programme that has the highest transplant activity in the
United Kingdom. Clearly, this is a highly valuable resource without which much of the project
would not be possible.
Additionally, this project makes use of the non-malignant non-SV40 transformed AKN-1 cell
line. The availability of the AKN-1 cell line means firstly that experiments can be optimised
prior to investigations on the primary human cholangiocytes that are regarded as a precious
commodity. Secondly, by demonstrating that the AKN-1 cell line is an appropriate model for
primary isolated human cholangiocytes, these results can inform other groups to conduct ex-
periments that would not otherwise be possible without access to human tissue. This ultimately
means that data and knowledge can be assimilated more quickly that allow for translational
research to be conducted earlier so that therapies may become available for the treatment of
patients.
Confirming the presence of Fn14 on the cell surface proteome was designed to demonstrate
improvements over more traditional methods such as Western Blotting, especially by reducing
potential errors in processing. The fact that there was considerable variation in the number
of proteins in the experiments demonstrates that in its current state, although it has a role in
protein discovery, cell surface proteomics is still prone to significant errors using this particular
cell surface enrichment technique. Other stages of the experimental design are more established.
As the enrichment technique evolves, hopefully the variation in the end result will be attenuated.
There is potential for this technique to contribute towards the construction of the protein atlas
especially for relatively rare diseases, such as cholangiocarcinoma, where access to primary
human tissue is limited.
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Finally, by demonstrating that the phenotype of the cell lines CC-LP-1 and CC-SW-1 are not
dissimilar to that of primary human cholangiocytes, further investigation may inform of the role
of the Fn14/TWEAK receptor-ligand system cholangiocarcinoma, a disease that also has a high
morbidity and mortality for which there are very few treatment options for patients. Detailed
investigation of the differences in Fn14 expression between the primary cells and cell lines
after 24 hours of cytokine expression needs to be conducted in the context of similar broad
phenotype. The results from this data may be a funcion of the elements of the phenotype not
investigated or an issue with the cell lines themselves. More detailed phenotype analysis is
warranted.
Currently, there are a number of weaknesses in the data presented from this project to date. Most
notable are the experimental numbers for the primary human cholangiocytes. Importantly, al-
though the total number is adequate, experiments have been conducted on a number of different
diseases, ranging from NASH, PBC, ALD and donor livers. The expression of Fn14 varies
considerably between these diseases and therefore increases the standard deviation for these ex-
periments. This subsequently influences any of the statistics that are conducted on the primary
cholangiocytes and largely explains the lack of significance that might be expected from the
results presented. This is a considerable sample bias. By stratifying Fn14 expression by type of
liver disease, a true indication of Fn14 expression will be revealed.
A further issue with the use of the primary cholangiocytes is the variability in the passage
number for the samples, ranging from P2 to P6. It is not known if Fn14 expression changes
with passage number per disease type and therefore must be considered a considerable bias that
also contributes to the high standard deviation values seen in results for experiments conducted
on the primary cholangiocytes. This could be overcome by investigating Fn14 expression on
cells in serial passages.
Although the activation of Fn14 by TWEAK has been investigated at 10 ng/ml and 100 ng/ml,
further elucidation of the response should be investigated at the 1 ng/ml and 1000 ng/ml con-
centrations to allow for the formation of a dose-response curve. There have been reports of a
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bipotent response (Burkly, unpublished data) at different concentrations of TWEAK however,
this requires further clarification. Statistical analysis is further hampered by the low experimen-
tal number when investigating the effect of different doses of TWEAK on functional outcome
of already cytokine stimulated cells. Due to the high number of variables, a student’s T-test
or even non-parametric equivalent are not robust enough to accept or reject any hypothesis us-
ing an experimental number of three, despite the graphical representations. The solution, is
to use factorial ANOVA, ideally incorporating time as a factor to provide a repeated measures
approach.
Following on from the above, it is not clear from the data at what time point TWEAK initiates
its effect and if the cellular response is dependent on the prolonged activation of the Fn14
receptor. Evaluating the response to TWEAK using repeated serial time course experiments
in the cholangiocytes and the various cell lines may provide further evidence of the reported
bipotent response. This would give insight to the potential signalling mechanisms that could
be investigated. This requires considerable numbers of samples within the experimental design
and should include positive controls for apoptosis, such as the use of hydrogen peroxide or
etoposide.[287, 288]
The functional outcome of Fn14 activation by different concentrations of TWEAK has been in-
vestigated by flow cytometry for apoptosis, autophagy, ROS production and necrosis. However,
the extent of cellular proliferation after Fn14 activation by TWEAK has not been investigated.
This is due to delays in developing the technique for the consistent assessment of proliferation
by flow cytometry. Such issues are now almost overcome and further functional experiments
will include proliferation as an output, so as to provide a more complete assessment. Addi-
tionally, the stage of the cell cycle after exposure to TWEAK could be investigated by flow
cytometry.
There is a paucity of publications investigating the role of Fn14 in the liver. Those that exist re-
late mainly to the role of Fn14 in either murine and human models of hepatocellular carcinoma
or its potential role in murine liver progenitor cells.[84, 85, 275, 282, 284] Additionally, Fn14
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has been suggested to be a potential therapeutic target after transcriptome analysis revealed that
it was up-regulated in patients with alcoholic hepatitis and predicted 90-day mortality and the
severity of portal hypertension.[280] However, to date there are no publications directly ad-
dressing the role of Fn14 either cholangiocytes or cholangiocarcinoma or the cholangiopathies.
Studies in other organ systems have provided some insight in to the function of the Fn14/TWEAK
receptor-ligand system. These show highly variable effects in renal, cardiac and rheumatic dis-
eases. There has been some work investigating the signalling pathways involved in these other
systems. Pathways implicated include JAK-STAT, EGFR, JNK and NF-kappa-B.[79] As yet
my data neither addresses the intracellular signalling pathways involved nor the role that the
scavenger receptor CD163 plays nor the effect of blocking the FGF-b signalling pathway on
the Fn14/TWEAK receptor-ligand system. Currently, it is not clear if these signalling pathways
are conserved between organ systems. Therefore, it would be disingenuous to speculate on the
mechanisms through which Fn14 signalling in the liver is occurring.
Furthermore, despite some studies published purporting to investigate the role of this receptor-
ligand system on murine liver progenitor cells, as yet there are no published techniques to isolate
a pure liver progenitor cell populations in either the murine or the human models. Once this
methodological technique has been established, the role of the Fn14/TWEAK receptor-ligand
system in ductular reactive cell differentiation in human liver can be characterised.
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CHAPTER 5
THE ROLE OF FN14/TWEAK DURING
NORMOTHERMIC MACHINE LIVER PERFUSION
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5.1 Introduction
To date, studies in to the role of Fn14 and TWEAK both in vivo and in vitro, as with many other
systems, have been limited by the model used or the methods incorporated. In vivo, this includes
but is not limited to the of use animal models that may not truly reflect the human biological
system, whilst in vitro the cellular isolation technique and microenvironment might not result in
a representative phenotype, despite best efforts.[85, 278, 289, 290] One approach that has been
gaining traction is the use of microfluidic devices, in which cultured cells have a culture medium
perfused over them in an attempt to mimic the in vivo environment.[291] Whilst this approach
was oringially conceived to allow more accurate investigation of human physiology, it has since
developed into a drug discovery tool as organ/body-on-a-chip.[292] This has been expanded
to the development of bioreactor systems that have been assessed in human tumour models,
an example being in breast cancer.[293] Direct comparison within the same microfluid chip
based culture system of both animal and human tissue concurrently further allows assesment of
potential drug candidates and towards the goal of personalised medicine.[294] Examples exist
of bioprinted liver-on-a-chip systems for drug screening that incorporate hepatocyte organoids
withina hydrogel scaffold to model the 3-dimensional environment of the liver.[295] [296] [297]
[298] To date, this has been scaling up development from in vitro cell culture systems. Since the
time of commencing this thesis, although a number of groups are reporting to be investigating
the role of NMLP in studying liver disease, published data is awaited. It could be anticipated
that relatively helathy donor livers, still rejected for transplantation, would be good candidates
for such testing prior to attempts at perfusing resected liver specimen containing, for example,
cancer. Nevertheless, NMLP might provide a more robust model to study disease and modulate
biological systems, including the ability to administer novel therapeutics, whilst overcoming
the potential issues surrounding animal testing. As a means that, one tested the hypothesis that
NMLP could be used to investigate the role of the Fn14/TWEAK receptor ligand system in an
ex vivo human model.
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5.2 Materials & Methods
The normothermic machine, the perfusion fluid, the 12 livers used, the sampling protocol, spec-
tral analysis and the machine, fluids, livers, sampling protocol, slide scanner methodology,
spectral analysis and statistical techniques using 2-way repeated measures factorial ANOVA
have been described in Chapter 2. The rabbit anti-human Fn14 antibody and the method for im-
munohistochemical staining of generated specimens using the semi-automated Sequenza R©rack
and CoverplateTMsystem (Thermo Scientific, Runcorn, UK) have been described in Chapters 4
and 2.
The rationale for using Van Gieson (VG) was to demonstrate collagen within with the speci-
mens. Once batches of sections had been taken to water, they were stained with Celestine Blue
(Sigma Aldrich, Gillingham, UK) for 5 minutes. After washing in a water bath for 2 minutes,
repeated twice, they were stained in Harris Haematoxylin (PFM Medical, Poynton, UK) for 4
minutes, followed by a further wash in water for 2 minutes. Subsequently, slides were dipped
in 1% Acid Alcohol for 30 seconds followed by a water bath for 2 minutes. Following a wash
in Scott’s Tap Water Substitute for 30 seconds and another wash in water for 2 minutes, slides
were stained with VG solution (PFM Medical, Poynton) for 3 minutes. Excess stain was rinsed
off using alcohol before slides were taken back to Xylene and mounted in DPX using glass
coverslips as previously described. Any collagen in the tissue would then be seen as bright red,
nuclei blue or black and cytoplasm yellow.
A one-way Analysis of Covariance (ANCOVA) was performed to determine a statistically sig-
nificant difference between intensity density staining of Fn14 and VG, controlling for viability




Titrations of the anti-human Fn14 antibody were performed to confirm the correct dilution to
be used. Sections from the same PSC specimen were used with dilutions ranging from 1:50 to
1:400, N = 3 for each dilution, after which sections were subjected to spectral analysis via the
slide scanner (Figure 5.1). This confirmed that 1:100 was the most appropriate dilution, balanc-
ing adequate chromagen staining, whilst ensuring that a range of chromagen intensities across
the section could be observed (Figures 5.2 and 5.3) This was congruent with the concentration
of the anti-human Fn14 antibody utilised for manual staining as described in Chapter 4.
Sections stained with anti-human Fn14 antibody were categorised according to viability across
different NMLP timepoints (Figure 5.3). Both non-viable (n=5, Figure 5.3 A,C,E) and viable
(n=3, Figure 5.3 B,D,F) appeared to have higher intensity staining at the end of NMLP (Figure
5.3 E & F respectively), with non-viable at the start of NMLP higher than viable livers (Figure
5.3 A & B respectively). At higher resolution, the differences between viable and non-viable
livers becomes more apparent, with increased staining in the viable group and a possible mor-
phological ductular reaction noted at 3 hours of NMLP and beyond (Figure 5.4).
Spectral analysis of intensity density against perfusion time and viability was performed (Figure
5.5). Graphically, there appeared to be a trend towards higher intensity density in viable livers
towards the end of NMLP compared to non-viable livers. However, repeated measures ANOVA
demonstrated the main effect for viability yielded a F value of F = 0.162, p > 0.05, indicating
that the effect for viability was not significant. The main effect for perfusion time yielded a F
value of F = 2,574, p > 0.05, indicating that the effect for NMLP time was not significant. The
interaction effect was insignificant, F = 0.952, p > 0.05.
Sections stained with VG were categorised according to viability across different NMLP time-
points (Figure 5.6). Viable livers (n=3, Figure 5.6 B,D,F) appeared to have higher intensity
staining at the end of NMLP compared to non-viable (n=5, Figure 5.6 A,C,E) Viable livers ap-
peared to have less staining intensity for VG at the start of NMLP compared to non-viable livers
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Figure 5.1: Representative immunohistochemistry of Fn14 antibody titrations for use with the
slide scanner. Sections from the same PSC specimen subjected to titrations of anti-human Fn14
antibody as previously described. A, control; B, 1:50; C, 1:100; D, 1:400
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Figure 5.2: Titrations of Fn14 antibody for use with the slide scanner. Sections from the same
PSC specimen were subjected to titrations of anti-human Fn14 antibody as previous described,
to ascertain the best concentration to use for slide scanning.
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Figure 5.3: Fn14 staining in livers subjected to NMLP by viability. A,C,E non-viable; B,D,F
viable; A,B at start of NMLP; C,D after 3 hours of NMLP; E,F at end of NMLP. All photographs
using the Axio Scan Z1 (Zeiss, GmBH).
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Figure 5.4: Higher resolution Fn14 staining in livers subjected to NMLP by viability. A,C,E
non-viable; B,D,F viable; A,B at start of NMLP; C,D after 3 hours of NMLP; E,F at end of
NMLP. All photographs using the Axio Scan Z1 (Zeiss, GmBH). Arrows in D and F indicate
morphological ductular reaction asociated with intense Fn14 staining.
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Figure 5.5: Intensity density of Fn14 staining by perfusion time in livers subjected to NMLP
by viability. Graphical representation is made by combining dot and box plot to demonstrate
sample results. Horizontal bar within box plot is median intensity density.
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(Figure 5.3 A & B) and so a more pronounced increase in VG staining with longer perfusion
time.
Spectral analysis of intensity density against perfusion time and viability was performed (Figure
5.7). Graphically, there appeared to be a trend towards higher intensity density in viable livers
towards the end of NMLP compared to non-viable livers, with a more marked increase over
NMLP time. However, repeated measures ANOVA demonstrated the main effect for viability
yielded a F value of F = 0.162, p > 0.05, indicating that the effect for viability was not signif-
icant. The main effect for perfusion time yielded a F value of F = 2.142, p > 0.05, indicating
that the effect for NMLP time was not significant. The interaction effect was insignificant, F =
1.048, p > 0.05.
Intensity density of Fn14 and VG across all timepoints of NMLP was performed to ascertain
if there was any correlation (Figure 5.8). This demonstrated a reasonable positive association
between Fn14 and VG with a R2 of 0.775. However, when interrogating if any relationship
was present according to viability, a stronger positive correlation was seen in the viable group
(R2 of 0.938) compared to the non-viable group (R2 of 0.600)(Figure 5.9). Analysis using one-
way ANCOVA with Fn14 as the dependent variable confirmed a significant effect of VG on
Fn14 F(1,21) = 73.159, p < 0.001 after eliminating the effect of viability. Viability was not
a significant covariate F(1,21) = 0.250, p = 0.623. Replacing VG as the dependent variable
confirmed a significant effect of Fn14 on VG F(1,21) = 73.159, p < 0.001 after eliminating the
effect of viability. Again, viability was not a significant covariate F(1,21) = 0.739, p = 0.400
however, there did exist an interaction between Fn14 and viability F(1,21) = 5.425, p = 0.030.
5.4 Discussion
This is the first study to demonstrate Fn14 in human cadaveric donor livers rejected from trans-
plantation and subjected to NMLP. The results suggest that Fn14 content changes over time
and that there is possibly a more positive correlation between Fn14 and collagen deposition in
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Figure 5.6: Van Gieson staining in livers subjected to NMLP by viability. A,C,E non-viable;
B,D,F viable; A,B at start of NMLP; C,D after 3 hours of NMLP; E,F at end of NMLP. All
photographs using the Axio Scan Z1 (Zeiss, GmBH).
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Figure 5.7: Intensity density of Van Gieson staining by perfusion time in livers subjected to
NMLP by viability. Graphical representation is made by combining dot and box plot to demon-
strate sample results. Horizontal bar within box plot is median intensity density.
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Figure 5.8: Correlation between intensity density of Fn14 and VG staining across all perfusion
times. Regression analysis revealed a positive correlation with a R2 of 0.779.
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Figure 5.9: Correlation between intensity density of Fn14 and Van Gieson staining by viability
across all perfusion times. Regression analysis revealed positive correlations for both non-
viable and viable livers with R2s of 0.600 and 0.938 repsectively.
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viable livers compared to non-viable livers. The reason for any increase is yet to be determined.
One possibilty is that it is a response to inflammation associated with non-resident immune cells
however, as the model employs a perfusion circuit, it would be expected for these immune cells
to be washout. Addition of a leukocyte filter to the circuit would remove these cells from the
circuit and help ascertain an explanation. An alternative is that Fn14 is upregulated as part of a
regenerative response on either HSCs or epithelial cells of the liver including the bipotent liver
progenitor cells. This would seem less likely given the duration of NMLP however, early mor-
phological evidence associated with Fn14 staining in the viable group after 3 hours of NMLP.
Further extensive studies are required.
The main strengths of these results are that this is an ex vivo human model of ischaemia reperfu-
sion injury and so more likely to represent biological action in humans compared to other animal
models. The method presented also provide the advantage of reducing technical, assessor and
interpretation bias during immunohistochemistry, as each section is subjected to the same light
intensity during scanning, there is an assessment of the whole slide rather than possibly random
areas within each section and the output is a numerical intensity density.
Despite these advantages, a number of weaknesses still exist. Each of the sections were scanned
at a 5x objective rather than standard 20x or 40x objective due to the file sizes involved. Conse-
quently, the resolution available for spectral analysis was lower, so might have missed variations
in intensity that otherwise exist. this is particularly important for the VG staining which het-
erogenously distributed in the liver and is dependent on the specimen of tissue sampled. To
overcome this would require repeated sectins to be scanned within the same block of tissue.
Additionally, the size of the section scanned influenced the quality of the image. Some of the
sections, particularly in the viable group, were small as the livers were destined for transplanta-
tion. In these livers only 16G needle biopsies were performed to reduced the risk of haematoma
and bile leak in the transplant recipient. Sections from these biopsies were especially susceptible
to light washout in which the slide scanner was unable to differentiate between different intensi-
ties of staining on the section. Immunohistochemical staining makes a number of assumptions
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regarding antibody binding to antigen, particularly the Beer-Lambert law of intensity of stain
is directly proportional to amount of antigen present. However, it is known that is not the case
when using chromagens such as DAB.[299, 300]. Finally, although the Sequenza R©rack and
Coverplate R©system reduces technical bias compared to manual immunohistochemical tech-
niques, a fully automated system, subject to calibration, would provide an advantage.
The results demonstrate that there is a positive correlation between Fn14 and collagen deposi-
tion over perfusion time for all livers, independent of viability. Whilst statistically not signifi-
cant, the positive correlation between VG as a function of Fn14, including an interaction with
viability, is in keeping with data demonstrating that Fn14 is upregulated in acute human liver
injury and that Fn14 gene expression is significantly upregulated in CCl4 murine models of hep-
atic injury.[278]. That the interaction with viability occurs when VG is the dependent variable
suggests, in this small series of relatively short perfusions, a mechanism in which increases in
ECM and collagen deposition is a result of activation of Fn14 in stellate cells rather than the
commencement of a cellular regenerative response and that this is more pronounced in viabile
livers.
Future research should initially start with improving this ischaemia reperfusion injury model.
This would include increasing the numbers and length of perfusions, improving the staining
techniques possibly by the use of fluorescent microscopy to adhere more closely to the Beer-
Lambert law, as well as incorporating better slide scanner and spectral analysis workflows.
Further studies understanding the distribution and mechanism of Fn14 activation, including the
role of its cognate ligand by extraneous administration of TWEAK and the role of circulat-
ing immune cells, in this exciting new model of ischaemia reperfusion injury, especially with






The initial aim of the project was to identify the functional significance of the Fn14/TWEAK
system in cholangiocytes and ductular reactive cells during hepatic inflammation and repair. Al-
though it could be established that Fn14 is present on cholangiocytes and ductular reactive cells
as well as cholangiocarcinoma demonstrated by existing immunohistochemical and a newly
established cell surface proteomic technique there are clearly severe limitations in the in vitro
modelling that was available at that time. The issue largely revolves around the micro envi-
ronment of cell culturing which is not representative of its in vivo environment. Differentiators
between the two models include: The extracellular matrix onto which cells isolated from human
liver; whether resected, explanted or surplus to transplantation are cultured; the constituents of
the culture media itself; the relative hyperoxia that cells are exposed to when being incubated.
This is before considering that in vivo cells are within a three-dimensional environment com-
pared to in vitro where they are largely within a two-dimensional plane. This is assuming one
has prospectively isolated, or isolated with a media selective technique, the specific cells that
are of structural and functional significance to ones research.
Considering the previous paragraph, the opportunity became available to establish, evaluate
and validate a new ex vivo human model. Not only could this system be used for the origi-
nal intention of viability testing ex vivo human livers using normothermic machine perfusion
and, specifically for this project, livers that had been declined for transplantation by all UK
Transplant Centres that has helped to define the MCD, but also it could be used for transla-
tional and clinical research. To this end, this model of normothermic machine liver perfusion
has been used to make an early evaluation of a bovine-based artificial oxygen carrier instead
of the standard packed red cells, which are expensive and of limited resource, and that poten-
tially it can be used to expand the donor pool, by evaluating livers that may be split with a left
lobe being transplanted into either a child or small adult and the right lobe being transplanted
into an adult. Furthermore, there has been an early demonstration of this ex vivo model being
established in preclinical research as a novel ischaemia-reperfusion injury model, which will
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not only help directly with interrogating existing adjuncts to transplantation but also to evaluate
novel therapies. This would establish NMLP as a method of improving the efficiency of the
current bench to bedside translational research pathways. Excitingly, this project has allowed
for the significant development and establishing of a number of new techniques many of which
are still in their early phases. As NMLP becomes more widely accepted, hopefully the scientific
community will see this as a valuable resource.
6.2 Future Work
1. Development of existing in vitro modelling and prospective isolation of small popula-
tions of resident hepatic cells are of paramount importance. It is quite possible that there
is a different role for more immature cells, for example the bipotent liver progenitor cells
compared to more mature intra-hepatic cholangiocytes, when exposed to the correct con-
ditions. Furthermore there needs to be an evolution of cell surface proteomics. In its
current form the requirement for large numbers of cells for the assay to work limits its
application defining small populations of cells where its application would be most appre-
ciated. Additionally there needs to be better in vitro modelling as elicited in the overview.
2. In its current format normothermic machine perfusion could be improved. Defining the
mechanism of viability is key to the future of all normothermic machine liver perfusion
strategies. Additionally, further work can be conducted on perfusion fluid design such
as artifical oxygen carriers, temperature strategies for specific donor organs for example
DCD and steatotic livers, as well as understanding the potential role for interventions by
drugs for defatting, viral vector or cellular therapy. These studies are currently being
undertaken. Further studies can be conducted on splitting for clinical and preclinical
research purposes as described above and with regards to using explanted and resected
specimens.
3. Overall this would allow for a much better comparison of the specific role of the Fn14/TWEAK
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receptor ligand system both in vivo and ex vivo allowing for more rapid, safe translation
of future work.
For ex vivo NMLP to be a success it is absolutely imperative that there is intellectual, preclin-
ical, translational, clinical and moral robustness and integrity in the design and application of
research projects utilising this valuable resource. There must be rigour in definitions of via-
bility assessment, resuscitation and reconditioning in addition to the use of controls, whether
scientific or clinically orientated, specifically when using NMLP to intervene with drug, viral,
cellular, vesicular or nucleic acid therapy. To that end the splitting of livers with concurrent
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A, Hübscher SG, Mirza DF, Afford SC, Mergental H. The use of an acellular oxygen carrier in a
253
human liver model of normothermic machine perfusion. Transplantation. 2017 Nov;101(11):2746-
2756.
Mergental H, Perera MT, Laing RW, Muiesan P, Isaac JR, Smith A, Stephenson BT, Cil-
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ture and Dynamics of the Fenestrae-Associated Cytoskeleton of Rat Liver Sinusoidal
Endothelial Cells. Hepatology (Baltimore, Md). 1995 Jan;21(1):180–189.
261
[19] Fraser R, Dobbs BR, Rogers GW. Lipoproteins and the Liver Sieve: The Role of the
Fenestrated Sinusoidal Endothelium in Lipoprotein Metabolism, Atherosclerosis, and
Cirrhosis. Hepatology (Baltimore, Md). 1995 Mar;21(3):863–874.
[20] Braet F, Spector I, De Zanger R, Wisse E. A Novel Structure Involved in the Formation
of Liver Endothelial Cell Fenestrae Revealed by Using the Actin Inhibitor Misakinolide.
Proceedings of the National Academy of Sciences of the United States of America. 1998
Nov;95(23):13635–13640.
[21] Shetty S, Weston CJ, Adams DH, Lalor PF. A Flow Adhesion Assay to Study Leuco-
cyte Recruitment to Human Hepatic Sinusoidal Endothelium under Conditions of Shear
Stress. Journal of Visualized Experiments: JoVE. 2014 Mar;(85).
[22] Sakamoto S, Okanoue T, Itoh Y, Sakamoto K, Nishioji K, Nakagawa Y, et al. Inter-
cellular Adhesion Molecule-1 and CD18 Are Involved in Neutrophil Adhesion and Its
Cytotoxicity to Cultured Sinusoidal Endothelial Cells in Rats. Hepatology (Baltimore,
Md). 1997 Sep;26(3):658–663.
[23] Wise C, Pilanthananond M, Perry BF, Alpini G, McNeal M, Glaser SS. Mecha-
nisms of Biliary Carcinogenesis and Growth. World Journal of Gastroenterology. 2008
May;14(19):2986–2989.
[24] Gaudio E, Franchitto A, Pannarale L, Carpino G, Alpini G, Francis H, et al. Cholan-
giocytes and Blood Supply. World Journal of Gastroenterology. 2006 Jun;12(22):3546–
3552.
[25] Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F, et al. Notch Signaling
Controls Liver Development by Regulating Biliary Differentiation. Development (Cam-
bridge, England). 2009 May;136(10):1727–1739.
[26] Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ, et al. Intrahepatic Bile
Ducts Develop According to a New Mode of Tubulogenesis Regulated by the Transcrip-
tion Factor SOX9. Gastroenterology. 2009 Jun;136(7):2325–2333.
[27] Blomhoff R, Wake K. Perisinusoidal Stellate Cells of the Liver: Important Roles in
Retinol Metabolism and Fibrosis. FASEB journal: official publication of the Federation
of American Societies for Experimental Biology. 1991 Mar;5(3):271–277.
262
[28] Pinzani M. Liver Fibrosis. Springer Seminars in Immunopathology. 1999;21(4):475–
490.
[29] Gaça MDA, Zhou X, Issa R, Kiriella K, Iredale JP, Benyon RC. Basement Membrane-
like Matrix Inhibits Proliferation and Collagen Synthesis by Activated Rat Hepatic Stel-
late Cells: Evidence for Matrix-Dependent Deactivation of Stellate Cells. Matrix Biol-
ogy: Journal of the International Society for Matrix Biology. 2003 May;22(3):229–239.
[30] Sica A, Invernizzi P, Mantovani A. Macrophage Plasticity and Polarization in Liver
Homeostasis and Pathology. Hepatology (Baltimore, Md). 2014 May;59(5):2034–2042.
[31] Martinez FO, Sica A, Mantovani A, Locati M. Macrophage Activation and Polarization.
Frontiers in Bioscience: A Journal and Virtual Library. 2008 Jan;13:453–461.
[32] Liaskou E, Zimmermann HW, Li KK, Oo YH, Suresh S, Stamataki Z, et al. Monocyte
Subsets in Human Liver Disease Show Distinct Phenotypic and Functional Characteris-
tics. Hepatology (Baltimore, Md). 2013 Jan;57(1):385–398.
[33] Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M. Extracellular Matrix:
A Matter of Life and Death. Connective Tissue Research. 2008;49(3):203–206.
[34] Roskams T. Different Types of Liver Progenitor Cells and Their Niches. Journal of
Hepatology. 2006 Jul;45(1):1–4.
[35] Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver
Cirrhosis Mortality in 187 Countries between 1980 and 2010: A Systematic Analysis.
BMC medicine. 2014 Sep;12:145.
[36] Koyama Y, Brenner DA. Liver Inflammation and Fibrosis. The Journal of Clinical In-
vestigation. 2017 Mar;127(1):55–64.
[37] Burt AD. Primary Biliary Cirrhosis and Other Ductopenic Diseases. Clinics in Liver
Disease. 2002 May;6(2):363–380, vi.
[38] Desmet VJ. Histopathology of Chronic Cholestasis and Adult Ductopenic Syndrome.
Clinics in Liver Disease. 1998 May;2(2):249–264, viii.
263
[39] Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, et al.
Nomenclature of the Finer Branches of the Biliary Tree: Canals, Ductules, and Ductular
Reactions in Human Livers. Hepatology (Baltimore, Md). 2004 Jun;39(6):1739–1745.
[40] Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate Tracing
Reveals Hepatic Stellate Cells as Dominant Contributors to Liver Fibrosis Independent
of Its Aetiology. Nature Communications. 2013;4:2823.
[41] Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Se-
lective Depletion of Macrophages Reveals Distinct, Opposing Roles during Liver Injury
and Repair. The Journal of Clinical Investigation. 2005 Jan;115(1):56–65.
[42] Ding BS, Cao Z, Lis R, Nolan DJ, Guo P, Simons M, et al. Divergent Angiocrine
Signals from Vascular Niche Balance Liver Regeneration and Fibrosis. Nature. 2014
Jan;505(7481):97–102.
[43] Michalopoulos GK, DeFrances MC. Liver Regeneration. Science (New York, NY). 1997
Apr;276(5309):60–66.
[44] Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al.
TLR4 Enhances TGF-Beta Signaling and Hepatic Fibrosis. Nature Medicine. 2007
Nov;13(11):1324–1332.
[45] Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural Killer Cells Ame-
liorate Liver Fibrosis by Killing Activated Stellate Cells in NKG2D-Dependent and
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Dependent Manners. Gas-
troenterology. 2006 Feb;130(2):435–452.
[46] Hellerbrand C, Jobin C, Licato LL, Sartor RB, Brenner DA. Cytokines Induce NF-
kappaB in Activated but Not in Quiescent Rat Hepatic Stellate Cells. The American
Journal of Physiology. 1998 Aug;275(2):G269–278.
[47] Friedman SL. Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of
the Liver. Physiological Reviews. 2008 Jan;88(1):125–172.
[48] Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, et al. Kupf-
fer Cell Engulfment of Apoptotic Bodies Stimulates Death Ligand and Cytokine Expres-
sion. Hepatology (Baltimore, Md). 2003 Nov;38(5):1188–1198.
264
[49] Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, et al. Phagocytosis of
Apoptotic Bodies by Hepatic Stellate Cells Induces NADPH Oxidase and Is Associated
with Liver Fibrosis in Vivo. Hepatology (Baltimore, Md). 2006 Mar;43(3):435–443.
[50] Syal G, Fausther M, Dranoff JA. Advances in Cholangiocyte Immunobiology. American
Journal of Physiology Gastrointestinal and Liver Physiology. 2012 Nov;303(10):G1077–
1086.
[51] He Y, Wu GD, Sadahiro T, Noh SI, Wang H, Talavera D, et al. Interaction of
CD44 and Hyaluronic Acid Enhances Biliary Epithelial Proliferation in Cholestatic
Livers. American Journal of Physiology Gastrointestinal and Liver Physiology. 2008
Aug;295(2):G305–312.
[52] Xie G, Wang X, Wang L, Wang L, Atkinson RD, Kanel GC, et al. Role of Differentiation
of Liver Sinusoidal Endothelial Cells in Progression and Regression of Hepatic Fibrosis
in Rats. Gastroenterology. 2012 Apr;142(4):918–927.e6.
[53] Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver Fibrosis and Repair:
Immune Regulation of Wound Healing in a Solid Organ. Nature Reviews Immunology.
2014 Mar;14(3):181–194.
[54] Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, et al. Anti-Fibrotic
Activity of NK Cells in Experimental Liver Injury through Killing of Activated HSC.
Journal of Hepatology. 2006 Jul;45(1):60–71.
[55] Jeong WI, Park O, Suh YG, Byun JS, Park SY, Choi E, et al. Suppression of Innate
Immunity (Natural Killer Cell/Interferon-γ) in the Advanced Stages of Liver Fibrosis in
Mice. Hepatology (Baltimore, Md). 2011 Apr;53(4):1342–1351.
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‘One learns three axioms during research: The subject to which you are
fundamentally dedicating intellectual perseverence; oneself as the conduit of this
endeavour, in particular one’s resilience and self-determination; chiefly, you learn
the most about other people.’
— Barney Stephenson, December 2017
‘Illegitimis non carborundum.’
— Anon, during The Great War
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